🏷

Classifications

IUIS Category

ISDS Skeletal Nosology

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

CHH is autosomal recessive, arising from biallelic variants in RMRP. Heterozygous carriers are asymptomatic and do not show the cellular proliferation defect, although telomerase activity is reduced in carriers in a gene-dose-dependent manner, so the carrier state is not entirely silent at every molecular level. Each sib of an affected individual has a 25% recurrence risk.

Autosomal recessive inheritance

Show evidence (4 references)

PMID:32506568 SUPPORT Human Clinical

"Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."

States the autosomal recessive mode of inheritance alongside the defining multisystem phenotype.

PMID:22420014 SUPPORT Human Clinical

"If both parents are known to be heterozygous for an RMRP pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."

GeneReviews recurrence risks used in counselling families.

PMID:42170584 SUPPORT Human Clinical

"humans carrying pathogenic variants in a single allele remain asymptomatic (8, 64) and do not demonstrate cell proliferation defects (42)"

Establishes that heterozygous carriers are unaffected at both the clinical and the cellular proliferation level.

+ 1 more reference

?

Discussions and Knowledge Gaps

5

By what route does deficiency of a ubiquitously expressed non-coding RNA produce failure of enteric neural crest colonization, and why does this manifest as Hirschsprung disease in only a minority of patients?

KNOWLEDGE GAP OPEN gap_chh_hirschsprung_mechanism

Attached to

pathophysiology#Gastrointestinal and Enteric Nervous System Involvement pathophysiology#Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay

Hirschsprung disease is one of the best-established comorbidities of CHH, occurring far above population background, yet it is the single feature for which no candidate mechanism has been offered; the review literature states this absence explicitly. A proliferation defect is an attractive general explanation, since enteric neural crest colonization of the gut is a proliferation-and-migration process on a developmental deadline, but that account is untested and would predict far higher penetrance than the observed 9% to 25%. The zebrafish knockout shows a hypoplastic gut, but that is epithelial hypoplasia rather than aganglionosis, so it does not fill the gap. Resolving this matters practically because Hirschsprung disease is itself a reported risk factor for early death, so a shared upstream determinant of severity may exist.

Proposed experiments

Enteric neural crest colonization under graded RMRP deficiency

exp_chh_enteric_crest_colonization

Track enteric neural crest cell proliferation, migration velocity and terminal colonization of the distal gut across a graded allelic series of RMRP deficiency, using the zebrafish model and patient-derived enteric neural crest-like cells, and test whether the colonization front fails to reach the hindgut within the developmental window. Measure Cyclin B2 turnover in the migrating population to test the cell-cycle account specifically.

Decision criterion

If colonization failure tracks the degree of cell-cycle impairment in enteric neural crest specifically, the proliferation account is supported; if colonization is normal despite comparable cell-cycle impairment, a distinct mechanism must be sought.

Supporting outcome

A generalized cell-cycle defect acting on migrating enteric neural crest explains the Hirschsprung association

Refuting outcome

Enteric neural crest colonization is unaffected by RMRP deficiency, implicating a separate mechanism

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"Hirschsprung's disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown."

Explicit statement in the review literature that this mechanism is unknown, which is what makes it a knowledge gap rather than an omission.

Is the lymphoma excess in CHH driven by loss of immune surveillance, or by the cell-cycle and telomere lesions acting cell-autonomously within the transforming B-cell clone?

KNOWLEDGE GAP OPEN gap_chh_cancer_surveillance_versus_cell_autonomous

Attached to

pathophysiology#Impaired Immune Surveillance and Lymphomagenesis pathophysiology#Impaired Telomere Maintenance pathophysiology#Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay

The surveillance account is conventional and is how the original cohort studies framed their finding, but they offered it as probable rather than demonstrated. Three observations sit awkwardly with it. Over half of non-skin cancers in prospective follow-up arose in patients with no preceding clinical symptoms of immune defect, and other CHH manifestations poorly predict lymphoma. Every cell in the patient carries a cell-cycle lesion and shortened telomeres, both established routes to genomic instability in their own right. And the malignancy spectrum is narrow, dominated by B-cell lymphoma and basal cell carcinoma, which suggests specific lineage vulnerability more than a general failure to police tumours. The distinction is not academic: if the driver is substantially cell-autonomous, correcting immunity by transplantation would not be expected to abolish residual risk in the recipient's own surviving lymphoid tissue, and surveillance would still be needed after transplant.

Proposed experiments

Genomic and clonal characterization of CHH-associated lymphomas

exp_chh_lymphoma_clonal_origin

Sequence CHH-associated lymphomas for mutational signatures of replication stress and telomere crisis, quantify telomere length and cyclin dysregulation within the malignant clone against the patient's own non-malignant lymphocytes, and determine Epstein-Barr virus status systematically rather than opportunistically. Compare against sporadic diffuse large B-cell lymphoma and against lymphomas arising in non-CHH immunodeficiencies.

Decision criterion

If CHH lymphomas carry genomic signatures of replication stress or telomere crisis exceeding those of immunodeficiency-associated lymphomas generally, a cell-autonomous contribution is supported; if they are indistinguishable from other immunodeficiency-associated lymphomas, the surveillance account suffices.

Supporting outcome

The cell-cycle and telomere lesions contribute cell-autonomously to lymphomagenesis

Refuting outcome

CHH lymphomas are genomically typical of immunodeficiency-associated lymphoma, supporting pure surveillance failure

Show evidence (2 references)

PMID:10064668 SUPPORT Human Clinical

"This study confirms an increased risk of cancer, especially non-Hodgkin's lymphoma, probably attributable to defective immunity, among patients with CHH."

The surveillance attribution is offered as probable, not demonstrated, which is the opening this gap addresses.

PMID:31379817 SUPPORT Human Clinical

"Of the 15 patients with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency."

The observation that makes a purely surveillance-based account uncomfortable: most cancers arose without clinical immune failure.

How does loss of RMRP reduce telomerase activity when telomerase gene transcript levels are normal?

KNOWLEDGE GAP OPEN gap_chh_telomerase_post_transcriptional_mechanism

Attached to

pathophysiology#Impaired Telomere Maintenance

This is a well-posed gap rather than a vague one, because the simplest explanation has already been excluded by measurement: telomerase activity is reduced in patient lymphocytes in a gene-dose-dependent manner, yet the transcript levels of the telomerase genes are normal relative to endogenous controls. The defect is therefore post-transcriptional, and the authors say outright that the mechanism is unidentified. Candidate routes exist and are testable, including the reported TERT-RMRP complex and its RNA-dependent RNA polymerase activity, and a general ribosome-synthesis ceiling limiting translation of telomerase components; distinguishing them would also determine whether the telomere arm is a genuinely separate mechanism or a downstream consequence of the ribosome arm.

Proposed experiments

Localizing the post-transcriptional telomerase defect in CHH lymphocytes

exp_chh_telomerase_assembly_step

In patient lymphocytes across an allelic series, quantify TERT protein abundance, TERC levels, telomerase holoenzyme assembly and trafficking, and TERT-RMRP complex formation, and test whether restoring TERT protein alone rescues telomerase activity. Run the same panel in cells where ribosome synthesis is limited independently of RMRP, to separate a specific TERT-RMRP effect from a general translational ceiling.

Decision criterion

If telomerase activity tracks holoenzyme assembly or TERT protein abundance and is not reproduced by independent ribosome limitation, a specific RMRP-telomerase mechanism is supported; if independent ribosome limitation reproduces it, the telomere arm is downstream of the ribosome arm.

Supporting outcome

A specific post-transcriptional RMRP-telomerase mechanism independent of general ribosome limitation

Refuting outcome

Reduced telomerase activity is a downstream consequence of limited ribosome synthesis

Show evidence (2 references)

PMID:28126377 SUPPORT Human Clinical

"Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."

Excludes the transcriptional explanation, which is what makes this gap specific rather than generic.

PMID:28126377 SUPPORT Human Clinical

"These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism."

The authors state directly that the mechanism is unidentified.

Does haematopoietic stem cell transplantation ever rescue linear growth in CHH, and if so, what distinguishes the patients in whom it does?

KNOWLEDGE GAP OPEN gap_chh_hsct_effect_on_linear_growth

Attached to

pathophysiology#Growth Plate Chondrocyte Differentiation Failure pathophysiology#Multilineage Bone Marrow Progenitor Failure

This entry treats the skeletal phenotype as chondrocyte-autonomous, and the strongest support for that is the observation that transplantation corrects immunity while growth failure remains unaffected. The literature is not unanimous. The same review that states skeletal features are not altered by transplantation also records two patients who normalized their growth afterwards, both carrying promoter-region duplications. That is a small number, but it is not obviously noise, because promoter variants act by reducing transcription rather than by perturbing RNA structure and might therefore behave differently. If growth rescue is real in any subgroup, the chondrocyte-autonomous framing needs qualifying and there would be a case for transplanting earlier on skeletal grounds, which is currently never an indication. The alternative reading, that these two patients reflect conditioning-era effects, catch-up from chronic illness, or ascertainment, is equally live and would leave the framing intact.

Proposed experiments

Genotype-stratified growth trajectories before and after transplantation

exp_chh_growth_trajectory_after_hsct

Assemble the transplanted CHH cohorts and plot height standard deviation scores against CHH-specific growth curves before and after transplantation, stratified by RMRP variant class (promoter-region versus transcribed-region) and by conditioning regimen and age at transplant. Include untransplanted genotype-matched patients as the comparison, since the question is whether transplant changes the trajectory rather than whether growth continues.

Decision criterion

If post-transplant growth trajectories improve specifically in promoter-variant patients relative to genotype-matched untransplanted controls, growth rescue is real and variant-class dependent; if trajectories are indistinguishable once genotype and age are accounted for, the two reported cases are best read as ascertainment.

Supporting outcome

Transplantation rescues linear growth in a definable RMRP variant subgroup

Refuting outcome

Growth trajectories are unchanged by transplantation across all variant classes, upholding the chondrocyte-autonomous model

Show evidence (2 references)

PMID:20375313 SUPPORT Human Clinical

"allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected"

The observation this entry's chondrocyte-autonomous framing rests on.

PMID:42170584 SUPPORT Human Clinical

"Skeletal features are not altered by HSCT (68); however, two patients normalized their growth after HSCT, one homozygous and another compound heterozygous for promoter region duplications"

Carries both sides of the discrepancy in one sentence, including the variant class shared by the two exceptional patients; PARTIAL because two cases cannot settle the question either way.

Can conclusions about CHH pathogenesis be validated in a mammalian whole-organism system, given that Rmrp knockout mice die before embryonic day 6.5 while heterozygotes are healthy?

HUMAN MODEL MISMATCH OPEN mismatch_chh_no_viable_mouse_model

Attached to

pathophysiology#RMRP Non-Coding RNA Loss of Function pathophysiology#Growth Plate Chondrocyte Differentiation Failure

This is a structural, not incidental, gap in the evidence base. Complete loss of the RNA is embryonic lethal in mouse and lethal in yeast, while mice carrying one null allele are healthy with 50% expression, so the mouse offers neither a null nor a graded hypomorphic model in the range where human disease lives. Every mammalian result in this entry therefore comes from cell culture, and the only whole-organism data come from zebrafish, whose cartilage development is architecturally different from the mammalian endochondral growth plate and whose ossification phenotype is directionally mixed. The consequence is that the most therapeutically interesting claim available, partial rescue of chondrodysplasia by beta-catenin inhibition, rests on a single non-mammalian model and cannot currently be tested in a mammal at all.

Proposed experiments

Hypomorphic and conditional Rmrp mouse alleles reproducing patient variants

exp_chh_hypomorphic_mouse_knockin

Generate knock-in mice carrying the founder n.71A>G variant and a promoter-region insertion allele, plus a chondrocyte-conditional deletion, and characterize growth-plate architecture, limb proportion, immune reconstitution and erythropoiesis. Test whether beta-catenin inhibition rescues the skeletal phenotype in a mammalian growth plate as it partially does in zebrafish.

Decision criterion

If a hypomorphic allele is viable and reproduces the skeletal and immune phenotype, mammalian mechanistic and preclinical work becomes possible; if all hypomorphic alleles are either lethal or normal, the murine dose window does not overlap the human one and non-mammalian models remain the only whole-organism option.

Supporting outcome

A graded mammalian model of RMRP deficiency is achievable and can validate the zebrafish rescue

Refuting outcome

The murine RMRP dose-response has no window corresponding to human disease

Show evidence (3 references)

PMID:42170584 SUPPORT Model Organism

"Mouse model for RMRP deficiency has never been established, as Rmrp knockout by insertion of DNA elements upstream the promoter was lethal early in embryonic development before embryonic day (E) 6.5"

Establishes the absence of a viable mouse null, the core of this mismatch.

PMID:42170584 SUPPORT Model Organism

"Hemizygous mice missing one RMRP allele showed 50% decrease of RMRP expression in embryonic fibroblasts and were healthy"

Establishes that the surviving murine genotype is unaffected, so no graded mammalian model currently spans the human disease range.

PMID:31237961 SUPPORT Model Organism

"in addition, there are no viable animal models for CHH"

Independent statement of the same absence, from the group that built the zebrafish model in response to it.

⚙

Pathophysiology

13

RMRP Non-Coding RNA Loss of Function

RMRP is a 269-nucleotide gene encoding the untranslated RNA subunit of RNase MRP, a nucleolar ribonucleoprotein endoribonuclease. The lesion is one of RNA dosage and RNA folding rather than of a protein coding sequence, and the two classes of pathogenic variant act by different routes: insertions and duplications between the TATA box and the transcription start site silence or reduce transcription, while variants inside the transcribed region leave transcription intact and instead perturb conserved nucleotides and stem pairings. Notably the variants do not prevent the protein subunits binding the RNA; what the common founder allele does is reduce the amount of intact complex assembled. Complete absence of the RNA appears incompatible with life, so every recognized patient is a partial loss of function and the disease is graded rather than all-or-none.

RMRP hgnc:10031

Downstream

Impaired Pre-rRNA Processing and Ribosome Biogenesis Loss of RNase MRP activity on its pre-ribosomal RNA substrate compromises ribosome synthesis.

Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay Loss of activity on the messenger-RNA substrate that licenses mitotic exit dysregulates cell-cycle progression.

Impaired Telomere Maintenance RMRP partners with TERT, so loss of the RNA also perturbs telomerase activity and telomere length.

Loss of RMRP-Derived Small RNA Gene Silencing The RNA is itself processed into gene-silencing small RNAs, and several disease-causing variants fall within them.

Gastrointestinal and Enteric Nervous System Involvement Hirschsprung disease and enteropathy occur at increased frequency in RMRP-deficient patients. The edge is drawn from the genetic lesion directly because no intermediate mechanism has been identified; it records an established association of the biallelic state, not a known route.

Show evidence (6 references)

PMID:11207361 SUPPORT Human Clinical

"We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype."

The original identification of RMRP as the CHH gene and of the gene product as an untranslated RNA.

PMID:11207361 SUPPORT In Vitro

"Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not."

Establishes the two mechanistically distinct classes of pathogenic variant, promoter-silencing versus structure-perturbing.

PMID:11207361 SUPPORT In Vitro

"The association of protein subunits with RNA appears unaltered."

Rules out failure of protein binding as the mechanism, which is what makes the later finding of reduced intact complex abundance informative rather than redundant.

+ 3 more references

Impaired Pre-rRNA Processing and Ribosome Biogenesis

The first substrate arm, and the one that earns CHH the ribosomopathy label. RNase MRP cleaves pre-ribosomal RNA in the internal transcribed spacer 1 region during ribosome synthesis. Engineering the common founder allele into human cells specifically impairs that step, reducing mature rRNA and, more tellingly, lowering the ratio of cytosolic to mitochondrial ribosomes; the same processing delay is seen in patient-derived fibroblasts, so this is not an artefact of engineered or immortalized cells. Because activating a naive T cell requires roughly a tenfold increase in per-cell ribosome abundance, a ceiling on ribosome synthesis is felt first by exactly the cells that must build ribosomes fastest, which is the unifying logic of the whole disease. The magnitude of residual rRNA cleavage tracks skeletal severity across the CHH-AD spectrum, and CHH sits where enough activity is retained to avoid the anauxetic skeleton but not enough to build a normal growth plate.

rRNA processing GO:0006364 ↓ DECREASED ribosome biogenesis GO:0042254 ↓ DECREASED

Downstream

Growth Plate Chondrocyte Differentiation Failure Reduced ribosome synthesis strikes hardest at the most biosynthetically demanding cells of the growth plate.

Defective Lymphocyte Proliferation and Combined Immunodeficiency T cell activation demands a large increase in ribosome abundance, so a ceiling on ribosome synthesis limits the activation programme directly.

Show evidence (6 references)

PMID:35115551 SUPPORT In Vitro

"Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes."

The most specific available molecular statement of this node: the founder allele impairs pre-rRNA processing and shifts ribosome composition.

PMID:35115551 SUPPORT In Vitro

"Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay."

Confirms the processing delay in primary patient cells rather than only in engineered or cancer-derived lines.

PMID:35115551 SUPPORT In Vitro

"Together, these results indicate that CHH is a ribosomopathy."

The authors' explicit conclusion, which is the strongest direct support for the ribosomopathy framing this node adopts.

+ 3 more references

Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay

The second substrate arm, and the one that carries the extraskeletal disease. RNase MRP cleaves Cyclin B2 messenger RNA at the end of mitosis, so losing that activity leaves mitotic cyclin turnover dysregulated. Patient fibroblasts followed by pulse-labelling and time-lapse microscopy are delayed specifically at the G2-to-mitosis transition, and their transcriptomes show coordinated downregulation of cell-cycle genes together with effects on apoptosis, bone and cartilage formation and lymphocyte function. Residual mRNA cleavage activity, not rRNA activity, predicts hair hypoplasia, immunodeficiency and haematological abnormality across the spectrum, which is why CHH is the end where those features are expected rather than conditional.

regulation of cell cycle GO:0051726 ↓ DECREASED G2/M transition of mitotic cell cycle GO:0000086 ↓ DECREASED

Experimental models

CHH patient-derived fibroblast cell-cycle and transcriptome model PRIMARY CELL CULTURE Directly measures cell-cycle progression and transcriptome changes in patient-derived cells carrying the disease genotype.

Animal models

rmrp knockout zebrafish Zebrafish recapitulates Reproduces inhibited proliferation and increased apoptosis with dysregulation of cell-cycle and apoptosis genes.

Downstream

Defective Lymphocyte Proliferation and Combined Immunodeficiency Rapidly dividing lymphoid populations are least able to tolerate a cell-cycle block.

Multilineage Bone Marrow Progenitor Failure Marrow progenitors, likewise proliferation-dependent, fail to form colonies.

Hair Follicle Hypoplasia Hair hypoplasia tracks the messenger-RNA cleavage arm specifically.

Growth Plate Chondrocyte Differentiation Failure Chondrocyte proliferation in the growth plate is subject to the same cell-cycle constraint, and bone and cartilage formation genes are among those dysregulated in patient cells.

Abnormal spermatogenesis Spermatogenesis is among the proliferation-dependent processes the generalized cell-cycle defect has been invoked to explain.

Show evidence (6 references)

PMID:31551465 SUPPORT In Vitro

"Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."

Direct measurement in patient-derived cells localizing the block to the G2-to-M transition, which is what this node asserts.

PMID:31551465 SUPPORT In Vitro

"Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle."

Transcriptomic support that the cell cycle is the dominant affected programme in patient cells.

PMID:31551465 SUPPORT In Vitro

"Multiple other pathways, involving regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as well as PI3K-Akt signaling."

Shows the same lesion touching the bone and lymphocyte programmes, which is the transcriptomic counterpart of the clinical pleiotropy.

+ 3 more references

Impaired Telomere Maintenance

A third arm, and the one that aligns CHH with the telomere biology disorders it clinically resembles. RMRP binds telomerase reverse transcriptase, and patient lymphocytes show both shortened telomeres and reduced telomerase activity, the latter scaling with gene dose between carriers and patients. The mechanism is not simply reduced telomerase gene expression: transcript levels are normal, so the defect is post-transcriptional and remains unidentified. Population-level telomere shortening is real but does not correlate with genotype or with any clinical or laboratory feature within CHH, so this arm should not be read as explaining an individual patient's course.

telomere maintenance GO:0000723 ↓ DECREASED

Downstream

Short telomere length Connects the molecular arm to its directly measured clinical correlate.

Defective Lymphocyte Proliferation and Combined Immunodeficiency Impaired telomere homeostasis limits the replicative capacity of the lymphocyte compartment.

Show evidence (4 references)

PMID:28126377 SUPPORT Human Clinical

"Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH."

Direct measurement of both telomere length and telomerase activity in patient lymphocytes.

PMID:28126377 SUPPORT Human Clinical

"Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."

Negative result excluding the simplest explanation and establishing that the defect is post-transcriptional.

PMID:27986801 SUPPORT Human Clinical

"Compared with age-matched and sex-matched healthy controls, median RTL was significantly shorter in patients with CHH (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10, p=0.224)."

Independent quantification of telomere shortening in a larger patient cohort.

+ 1 more reference

Loss of RMRP-Derived Small RNA Gene Silencing

A fourth arm that is easy to overlook and is the best available explanation for the hair phenotype specifically, which the ribosome arm accounts for poorly. The RMRP transcript is itself processed into at least two short RNAs, RMRP-S1 and RMRP-S2, that behave as microRNAs, and several disease-causing variants map inside them. Both are markedly reduced in cells from patients. Their regulatory targets are enriched for skeletal development, hair development and haematopoietic differentiation programmes, naming PTCH2 and SOX4 among others, so the disease may be as much a disorder of lost small-RNA regulation as of lost cleavage activity.

miRNA-mediated post-transcriptional gene silencing GO:0035195 ↓ DECREASED

Downstream

Hair Follicle Hypoplasia Loss of small-RNA regulation of hair development programmes is the most direct available route to the hair phenotype.

Growth Plate Chondrocyte Differentiation Failure Skeletal development genes are among the programmes these small RNAs regulate.

Show evidence (4 references)

PMID:24009312 SUPPORT In Vitro

"We show that the 268-nt non-coding RNA component of mitochondrial RNA processing endoribonuclease, (RNase MRP), is the source of at least two short (∼20 nt) RNAs designated RMRP-S1 and RMRP-S2, which function as miRNAs."

Establishes the existence and microRNA function of the RMRP-derived small RNAs on which this node rests.

PMID:24009312 SUPPORT In Vitro

"Point mutations in RNase MRP cause human cartilage-hair hypoplasia (CHH), and several disease-causing mutations map to RMRP-S1 and -S2."

Links the disease alleles physically to the small RNAs, which is what makes this arm disease-relevant rather than incidental biology.

PMID:24009312 SUPPORT In Vitro

"RMRP-S1 and -S2 are significantly reduced in two fibroblast cell lines and a B-cell line derived from CHH patients."

Demonstrates loss of the small RNAs in patient-derived cells.

+ 1 more reference

Growth Plate Chondrocyte Differentiation Failure

Chondrocytes in the growth plate are among the most biosynthetically demanding cells in the developing skeleton, which is why a ceiling on ribosome synthesis strikes them first. RNase MRP is itself expressed in the growth plate, with the RNA and its protein subunits co-clustering to the hypertrophic zone, so this is tissue-specific expression rather than a purely quantitative demand argument. Loss of function disorders chondrocyte columnar organization and blocks terminal differentiation, producing the metaphyseal dysplasia that names the disease. Growth failure is largely prenatal in origin and then progressive through infancy and puberty. The zebrafish knockout adds a candidate effector, upregulated canonical Wnt/beta-catenin signalling, which is pharmacologically reversible in that model; it is recorded here as a model-organism lead rather than an established human mechanism.

chondrocyte CL:0000138

chondrocyte differentiation GO:0002062 ↓ DECREASED chondrocyte hypertrophy GO:0003415 ↓ DECREASED endochondral ossification GO:0001958 ↓ DECREASED

Experimental models

Rmrp-deficient ATDC5 chondrogenic cell model CELL LINE Measures chondrogenic differentiation and hypertrophy after Rmrp interference.

Animal models

rmrp knockout zebrafish Zebrafish partially recapitulates Reproduces dysregulated chondrogenesis and abnormal ossification, and implicates Wnt/beta-catenin as a reversible effector.

Downstream

Metaphyseal chondrodysplasia Growth-plate disorganization produces the metaphyseal dysplasia that names the disease.

Disproportionate short-limb short stature Failure of endochondral elongation in the limbs produces disproportionate short stature.

Genu varum Asymmetric metaphyseal growth about the knee produces varus deformity of the lower limbs.

Limited elbow extension Dysplastic elbow joint surfaces limit extension despite generalized ligamentous laxity elsewhere.

Joint hypermobility Abnormal cartilage and periarticular connective tissue produce generalized ligamentous laxity.

Lumbar hyperlordosis Altered spinal and pelvic proportions produce a compensatory lumbar lordosis.

Short metacarpal The same failure of endochondral growth shortens the short tubular bones of the hands and feet.

Coxa vara Growth failure at the proximal femoral physis, outpaced by trochanteric growth, reduces the femoral neck-shaft angle.

Scoliosis Vertebral growth-plate involvement contributes to lateral spinal curvature in a minority of patients.

Show evidence (5 references)

PMID:28743979 SUPPORT In Vitro

"Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."

Direct chondrocyte evidence coupling impaired pre-rRNA processing to deranged differentiation in the same experiment.

PMID:28743979 SUPPORT Model Organism

"Expression of Rmrp RNA and RNase MRP protein subunits was detected in the murine growth plate and during the course of chondrogenic differentiation of ATDC5 cultures, where Rmrp RNA expression was found to be correlated with chondrocyte hypertrophy."

Localizes RNase MRP expression to the growth plate and ties it to the hypertrophic step, supporting tissue specificity.

PMID:42170584 SUPPORT Human Clinical

"Histological examination of the patient's bone back in 1960s demonstrated the paucity of cartilage cells and disturbed columnar tissue organization"

Human histological correlate: the growth plate is hypocellular and loses its columnar architecture.

+ 2 more references

Defective Lymphocyte Proliferation and Combined Immunodeficiency

The proliferation block falls hardest on the lymphoid compartment, where clonal expansion is the mechanism of immunity itself. The characteristic pattern is depletion of exactly the rapidly proliferating populations: recent thymic emigrants and naive CD4 and CD8 cells are reduced while activated and memory subsets are relatively increased, and naive, transitional and memory B cells are reduced with an increase in activated CD21-low cells. Clinically this spans a wide range, from no signs at all through isolated humoral defects to frank combined immunodeficiency, and laboratory indices correlate only weakly with symptoms. Two features make this arm unusually treacherous: immune involvement is progressive, with adult-onset immunodeficiency documented, and specific antibody deficiency after polysaccharide vaccination is common and may mark more severe disease. A patient who looks immunologically well at one assessment cannot be assumed to remain so.

T cell CL:0000084 B cell CL:0000236

T cell proliferation GO:0042098 ↓ DECREASED T cell activation GO:0042110 ↓ DECREASED

Downstream

Combined immunodeficiency The lymphoid proliferation defect manifests clinically as combined immunodeficiency in a substantial minority.

Decreased total T cell count Reduced production of naive T cells and recent thymic emigrants lowers circulating T cell counts.

Recurrent respiratory infections Impaired cellular and humoral immunity permits recurrent sinopulmonary infection.

Severe varicella zoster infection Defective cellular immunity underlies the historically feared severe primary varicella.

Decreased specific antibody response to vaccination The B cell production and germinal-centre defect manifests as failure to mount specific antibody after polysaccharide challenge, even where total immunoglobulin is preserved.

Impaired Immune Surveillance and Lymphomagenesis The same lymphoid defect removes the surveillance that would otherwise contain emerging lymphoid clones.

Chronic Airway Infection and Bronchiectasis Repeated and incompletely cleared airway infection drives structural lung damage.

Immune Dysregulation and Autoimmunity The same disturbed lymphocyte compartment produces failures of tolerance as well as failures of defence.

Show evidence (5 references)

PMID:28284971 SUPPORT Human Clinical

"The reduced counts of rapidly proliferating cells (naive T, RTE, and B) support a disturbed cell cycle as an important pathogenic mechanism"

The authors' own reading of the immunophenotype as a proliferation defect, which is the link this node asserts between molecular and cellular levels.

PMID:28284971 SUPPORT Human Clinical

"decreased CD3+CD4+CD45RA+CD31+ recent thymic emigrants (RTE), naive CD4+ and CD8+ cells; 2) increased activated CD4+, central memory CD4+ and effector memory CD8+ cells"

Specifies the naive-depleted, memory-shifted pattern described here.

PMID:35115551 SUPPORT Model Organism

"Here, we analyzed disease-relevant primary cells, showing that mutations in RMRP impair mouse T cell activation and delay pre-rRNA processing."

Experimental demonstration that disrupting RMRP impairs T cell activation specifically; tagged MODEL_ORGANISM because the activation experiment was performed in mouse T cells.

+ 2 more references

Multilineage Bone Marrow Progenitor Failure

Marrow progenitors are the other highly proliferative compartment, and they fail in the same way. Colony formation is defective across erythroid, megakaryocyte and granulocyte-macrophage lineages even in patients whose peripheral counts are normal, and the defect is not explained by a shortage of progenitors: the progenitors are present but cannot form colonies under conditions sufficient for normal cells. Clinically the erythroid lineage is the one that decompensates, giving a macrocytic, often transfusion-dependent anemia most severe in early childhood and typically remitting with age. Bone marrow erythroid hypoplasia is found in all severely anemic patients who are examined.

erythroid progenitor cell CL:0000038

erythrocyte differentiation GO:0030218 ↓ DECREASED

Experimental models

Patient bone marrow progenitor colony-forming assay PRIMARY CELL CULTURE Measures colony formation across erythroid, megakaryocyte and granulocyte-macrophage lineages in patient-derived progenitors.

Downstream

Macrocytic anemia Failure of erythroid colony formation produces a macrocytic anemia.

Anemia Connects the progenitor defect to the general clinical phenotype.

Decreased total neutrophil count The granulocyte-macrophage arm of the colony-formation defect can decompensate into clinical neutropenia, though it usually does not.

Show evidence (4 references)

PMID:7895753 SUPPORT In Vitro

"The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH."

Establishes that the marrow defect spans lineages and is read by the authors as the same proliferation defect seen elsewhere.

PMID:7895753 SUPPORT In Vitro

"The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors."

Distinguishes a functional proliferation defect from progenitor depletion, which is the specific claim this node makes.

PMID:42170584 SUPPORT Human Clinical

"Bone marrow erythroid hypoplasia and poor growth of erythroid precursors have been demonstrated in all CHH patients with severe anemia who underwent bone marrow examinations"

In-patient marrow correlate of the culture findings for the severely anemic subgroup.

+ 1 more reference

Immune Dysregulation and Autoimmunity

The disturbed lymphocyte compartment fails at tolerance as well as at defence. Clinical autoimmunity affects about a tenth of patients and spans an unusually broad range, from autoimmune haemolytic anemia and thrombocytopenia to narcolepsy, psoriasis and neuropathy. Serum autoantibody positivity is considerably more common than clinical autoimmune disease, so antibodies alone should not be over-read. What makes this arm clinically important rather than a curiosity is that autoimmunity is associated with higher mortality and clusters with recurrent pneumonia and sepsis, and that autoimmunity in adulthood is one of the strongest reported risk factors for early death. Atopic disease is also strikingly prevalent.

Downstream

Autoimmunity Loss of tolerance manifests as clinical autoimmune disease.

Autoimmune hemolytic anemia The most common single autoimmune manifestation of CHH.

Asthma Immune dysregulation in CHH includes a markedly increased prevalence of atopic airway disease.

Allergic rhinitis Allergic rhinoconjunctivitis is excessively prevalent in the CHH population.

Show evidence (4 references)

PMID:30410491 SUPPORT Human Clinical

"Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy)."

Quantifies clinical autoimmunity and establishes the breadth of the spectrum.

PMID:30410491 SUPPORT Human Clinical

"AI diseases are common in Finnish patients with CHH and are associated with higher mortality, recurrent pneumonia, sepsis, high IgE and/or undetectable IgA levels."

Establishes the mortality association that makes this arm clinically consequential.

PMID:30410491 SUPPORT Human Clinical

"Several patients demonstrated serum autoantibody positivity without compatible symptoms."

Retained caveat: seropositivity substantially exceeds clinical disease, so autoantibodies alone do not establish autoimmunity in this population.

+ 1 more reference

Impaired Immune Surveillance and Lymphomagenesis

Malignancy is the most consequential downstream event in CHH and the clearest instance of the disease's central asymmetry: risk does not track clinical immune severity. The excess is overwhelmingly lymphoid, with non-Hodgkin lymphoma dominating and diffuse large B-cell lymphoma the most common subtype, presenting in young adulthood and usually at advanced stage. Basal cell carcinoma is the other strongly elevated cancer and occurs only on sun-exposed skin. Two mechanistic strands plausibly converge here, loss of lymphoid immune surveillance and the cell-cycle and telomere lesions acting cell-autonomously within the transforming clone, and the evidence does not separate them. What is established is that first-degree relatives carry no excess risk, so this is a consequence of the biallelic state rather than of shared environment.

Downstream

Non-Hodgkin lymphoma Loss of lymphoid surveillance and the intrinsic cell-cycle lesion converge on B-cell lymphoma.

Basal cell carcinoma Impaired cutaneous immune surveillance permits basal cell carcinoma on sun-exposed skin.

Neoplasm Connects the surveillance failure to the general malignancy phenotype.

Show evidence (6 references)

PMID:18698627 SUPPORT Human Clinical

"During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180)"

Registry-based quantification of the overall and lymphoma-specific excess risk against population expectation.

PMID:18698627 SUPPORT Human Clinical

"In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61)."

Quantifies the second component of the cancer excess.

PMID:10064668 SUPPORT Human Clinical

"The cancer incidence among the siblings or the parents did not differ from the average cancer incidence in the Finnish population."

Internal control establishing that the excess belongs to the biallelic disease state and not to family background or shared environment.

+ 3 more references

Chronic Airway Infection and Bronchiectasis

Recurrent and incompletely cleared sinopulmonary infection produces structural airway damage, and progressive lung disease is a leading cause of death in adults with CHH; in the 30-year prospective cohort, lung disease carried the highest cause-specific standardized mortality ratio of any category. The relationship to measured immunity is loose: bronchiectasis occurs in patients without hypogammaglobulinemia, and immunoglobulin replacement is often insufficient to halt it. Reported prevalence spans roughly a third to a half depending on cohort selection. Longitudinal imaging suggests that once established the changes are largely stable rather than relentlessly progressive in unselected patients, which argues for monitoring rather than assuming inevitable decline.

Downstream

Bronchiectasis Repeated airway infection and inflammation produce irreversible bronchial dilatation.

Recurrent pneumonia Impaired clearance and damaged airways predispose to repeated pneumonia.

Show evidence (4 references)

PMID:33675005 SUPPORT Human Clinical

"Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."

Establishes the infection-to-bronchiectasis link and the prevalence range quoted here.

PMID:31379817 SUPPORT Human Clinical

"Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3-11); most commonly from malignancy (n = 7, SMR = 10, 95%CI = 4.1-21) and lung disease (n = 4, SMR = 46, 95%CI = 9.5-130)."

Quantifies overall and cause-specific mortality, showing lung disease with the highest cause-specific ratio despite fewer deaths than malignancy.

PMID:33675005 SUPPORT Human Clinical

"In conclusion, our results suggest slow if any development of bronchiectasis in selected subjects with cartilage-hair hypoplasia."

Counterweight retained deliberately: in a prospectively followed selected cohort the structural changes did not progress, so this node should not be read as asserting inevitable decline. PARTIAL because the cohort was small and selected.

+ 1 more reference

Hair Follicle Hypoplasia

Hair hypoplasia gives the disease the second half of its name and is one of the phenotypes that tracks the messenger-RNA cleavage arm rather than the ribosomal one. The hair is fine, sparse and silky, ranging from mildly sparse scalp hair to complete alopecia in the most affected. The hair follicle is another compartment defined by continuous rapid proliferation, so its involvement fits the proliferative-demand logic; the more specific explanation is that RMRP-derived small RNAs regulate hair development programmes directly, which the ribosome arm alone does not account for.

Downstream

Fine hair Follicular hypoplasia produces abnormally fine, silky hair.

Sparse hair Reduced follicular output produces sparse scalp and body hair.

Show evidence (3 references)

PMID:22420014 SUPPORT Human Clinical

"Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."

Establishes fine silky hair as a characteristic feature of the spectrum.

PMID:17701897 SUPPORT In Vitro

"reduced mRNA cleavage, and thus cell-cycle impairment, predicts the presence of hair hypoplasia, immunodeficiency, and hematological abnormalities and thus increased cancer risk"

Assigns hair hypoplasia specifically to the messenger-RNA cleavage arm.

PMID:24009312 SUPPORT In Vitro

"Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes."

Provides the specific regulatory route to hair development that the ribosome arm does not supply.

Gastrointestinal and Enteric Nervous System Involvement

Hirschsprung disease is a well-established comorbidity, reported in roughly a tenth to a quarter of Finnish patients depending on era, and prolonged or recurrent diarrhoea with malabsorption is common independently of it. The mechanistic link between RNase MRP deficiency and failure of enteric neural crest colonization is genuinely unknown, which is unusual in this entry: every other arm has at least a candidate substrate. The zebrafish knockout shows a hypoplastic gut with reduced intestinal epithelial cell numbers and absent villi, consistent with a general proliferative defect in gut epithelium, but that is a different claim from aganglionosis. Hirschsprung disease is also one of the reported risk factors for early death, so this is not a cosmetic gap.

Downstream

Aganglionic megacolon Failure of enteric ganglion cell colonization produces Hirschsprung disease, by a route that remains unidentified.

Chronic diarrhea Enteropathy and malabsorption produce persistent or recurrent diarrhoea.

Show evidence (4 references)

PMID:32506568 SUPPORT Human Clinical

"Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."

Establishes Hirschsprung disease as part of the characteristic CHH phenotype.

PMID:42170584 SUPPORT Human Clinical

"Hirschsprung's disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown."

Explicit statement that the mechanism is unknown, which is why this node does not assert one.

PMID:30410491 SUPPORT Human Clinical

"Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."

Quantifies the non-Hirschsprung gastrointestinal burden in a defined cohort.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

32

Blood 4

Decreased total neutrophil count HP:0001875

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"Single patients also have neutropenia, either intrinsic or autoimmune"

Establishes neutropenia as an occasional feature and names both candidate mechanisms; the single-patient framing is why no frequency is assigned.

PMID:25764362 SUPPORT Human Clinical

"CHH is associated with a broad spectrum of mild-to-moderate, cell-mediated immunodysfunction, including occasionally severe combined immune deficiency, neutropenia, lymphopenia, disordered erythrogenesis, and a predisposition to lymphoma"

Independent listing of neutropenia among the recognized haematologic features of CHH.

Anemia FREQUENT HP:0001903

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"In a cohort of 88 Finnish patients, low hemoglobin levels were common in childhood (54/74, 73%), in addition to macrocytosis (in 47%), but were not seen in adult subjects"

Reports low haemoglobin in 73% (54/74) of children, which maps to the FREQUENT band (30-79%); the same source notes its absence in adults, which is why the description is age-qualified.

PMID:10690856 SUPPORT Human Clinical

"Retrospective analysis of hematological data of 114 patients showed that the severity of the anemia and macrocytosis in CHH varies with age. The anemia was most severe in early childhood."

Independent confirmation of the age dependence of the anemia.

Macrocytic anemia HP:0001972

Show evidence (2 references)

PMID:39321258 SUPPORT Human Clinical

"Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group."

Establishes the macrocytic character of the anemia across the published literature.

PMID:42170584 SUPPORT Human Clinical

"Reticulocyte index and haptoglobin, iron and transferrin concentrations, as well as vitamin B12 and folate levels were normal."

Excludes nutritional and haemolytic causes for the macrocytosis, which is what makes it a marker of the intrinsic marrow defect.

Autoimmune hemolytic anemia HP:0001890

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"Apart from hypoplastic anemia, autoimmune hemolytic anemia (AIHA) has also been described in multiple patients and is the most common autoimmune phenomenon in CHH."

Establishes AIHA as the leading autoimmune feature and distinguishes it from the hypoplastic anemia.

Digestive 1

Chronic diarrhea FREQUENT HP:0002028

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

"Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."

Reports persistent diarrhoea in 31% (32/104), which maps to the FREQUENT band (30-79%).

Immune 4

Combined immunodeficiency OCCASIONAL HP:0005387

Show evidence (3 references)

PMID:31379817 SUPPORT Human Clinical

"Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency."

Reports symptomatic combined immunodeficiency in 24% of an 80-patient prospective cohort, which maps to the OCCASIONAL band (5-29%).

PMID:28284971 SUPPORT Human Clinical

"We grouped patients as having: 1) no symptoms/signs of immunodeficiency (n=15, 27%), 2) features of humoral immunodeficiency only (n=26, 46%) and 3) features of combined immunodeficiency (CID, n=15, 27%)"

Independent cohort reporting 27%, consistent with the same band.

PMID:28284971 SUPPORT Human Clinical

"As mortality due to infections and malignancies is increased in CHH4, patients surviving into adulthood represent individuals with milder disease."

Ascertainment caveat retained: cohorts of living patients probably understate severity in the disease as a whole.

Recurrent respiratory infections HP:0002205

Show evidence (2 references)

PMID:33675005 SUPPORT Human Clinical

"Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."

Establishes the recurrent respiratory infection phenotype.

PMID:42170584 SUPPORT Human Clinical

"In the clinical cohorts, 33-78% of the patients have normal infection history"

Retained counterweight: a large fraction of patients are not clinically infection-prone, so no frequency band is assigned.

Recurrent pneumonia HP:0006532

Show evidence (2 references)

PMID:31379817 SUPPORT Human Clinical

"pneumonia in the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3-43/2.6-140)"

Establishes recurrent pneumonia as a prognostic risk factor rather than merely a manifestation.

PMID:33675005 SUPPORT Human Clinical

"Patients with subtle signs of bronchiectasis on imaging tended to have low immunoglobulin M levels, as well as suffered from pneumonia during the follow-up."

Links pneumonia during follow-up to the imaging changes in the same cohort.

Autoimmunity OCCASIONAL HP:0002960

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

"Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy)."

Reports clinical autoimmunity in 10.6% (11/104), which maps to the OCCASIONAL band (5-29%).

Integument 2

Sparse hair HP:0008070

Show evidence (2 references)

PMID:32506568 SUPPORT Human Clinical

"Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."

Names hypotrichosis as a defining feature of the syndrome.

PMID:42170584 SUPPORT Human Clinical

"Historically, CHH-HD has been associated with more severe growth failure, complete alopecia, and severe anemia"

Supports the severe end of the hair phenotype; PARTIAL because complete alopecia is described in the Hirschsprung subgroup rather than of CHH generally.

Basal cell carcinoma HP:0002671

Show evidence (2 references)

PMID:18698627 SUPPORT Human Clinical

"In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61)."

Quantifies the basal cell carcinoma excess against population expectation.

PMID:42170584 SUPPORT Human Clinical

"Skin cancer in CHH develops only on sun-exposed areas (95); therefore, enhanced sun protection should be emphasized."

Supports the anatomical restriction to sun-exposed skin and the resulting management advice.

Limbs 4

Limited elbow extension VERY_FREQUENT HP:0001377

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)"

Reports incomplete elbow extension in 92% (79/86), which maps to the VERY_FREQUENT band (80-100%).

Genu varum FREQUENT HP:0002970

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"

Reports lower-limb varus deformity in 63% (54/86), which maps to the FREQUENT band (30-79%).

PMID:42170584 SUPPORT Human Clinical

"The review of orthopedic data from 135 North American patients with CHH revealed that ~43% had required surgical realignment for the bowing of lower extremities"

Quantifies the surgical burden arising from the deformity.

Short metacarpal HP:0010049

Show evidence (2 references)

PMID:25764362 SUPPORT Human Clinical

"There is marked shortening of the metacarpals, metatarsals, and phalanges, with metaphyseal cupping"

Directly describes the shortened metacarpals this phenotype records, in the largest reported orthopaedic series of CHH patients.

PMID:42170584 SUPPORT Human Clinical

"Typical features in addition to short limbs include short hands"

Independent confirmation that short hands are a typical feature, though stated clinically rather than at the level of the individual bone.

Coxa vara OCCASIONAL HP:0002812

Show evidence (1 reference)

PMID:25764362 SUPPORT Human Clinical

"In our series, 27 % of the cases where radiographs were reviewed (19/71) showed coxa vara radiographically."

Reports coxa vara in 27% (19/71), which maps to the OCCASIONAL band (5-29%).

Musculoskeletal 3

Joint hypermobility VERY_FREQUENT HP:0001382

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)"

Reports ligamentous laxity in 95% (81/85), which maps to the VERY_FREQUENT band (80-100%).

Lumbar hyperlordosis VERY_FREQUENT HP:0002938

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"

Reports lumbar lordosis in 85% (72/85), which maps to the VERY_FREQUENT band (80-100%).

Scoliosis OCCASIONAL HP:0002650

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"

Reports scoliosis in 21% (18/86), which maps to the OCCASIONAL band (5-29%).

Respiratory 1

Bronchiectasis FREQUENT HP:0002110

Show evidence (2 references)

PMID:33675005 SUPPORT Human Clinical

"Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."

Reports a prevalence range of 29-52%, which sits in the FREQUENT band (30-79%) apart from its lowest reported value at the band boundary.

PMID:42170584 SUPPORT Human Clinical

"In an unselected cohort of 34 Finnish patients, aged 13-68 years, 10 (29%) had bronchiectasis on chest HRCT imaging"

Gives the unselected-cohort figure anchoring the lower end of the range.

Growth 1

Disproportionate short-limb short stature VERY_FREQUENT HP:0008873

Show evidence (3 references)

PMID:22420014 SUPPORT Human Clinical

"CHH-AD spectrum disorders are characterized by severe disproportionate (short-limb) short stature that is usually recognized in the newborn, and occasionally prenatally because of the short extremities."

Establishes short-limb disproportionate short stature as a defining and near-universal feature of the spectrum, supporting the VERY_FREQUENT band.

PMID:42170584 SUPPORT Human Clinical

"The growth failure is progressive, particularly during the first year of life and during puberty, resulting in the median adult height of 131 cm for males and 123 cm for females"

Quantifies the adult height outcome described here.

PMID:42170584 SUPPORT Human Clinical

"While short stature was first thought to be invariably present in CHH patients, individuals with normal height have since been reported"

Retained qualification: short stature is characteristic but not obligatory, which is why the band is VERY_FREQUENT rather than obligate.

Neoplasm 1

Neoplasm HP:0002664

Show evidence (2 references)

PMID:18698627 SUPPORT Human Clinical

"During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12)."

Quantifies the overall cancer excess.

PMID:18698627 SUPPORT Human Clinical

"Nine of the 14 cancers were diagnosed in patients less than 45 years of age."

Supports the concentration of malignancy in younger patients.

Other 11

Metaphyseal chondrodysplasia HP:0005871

Show evidence (2 references)

PMID:42170584 SUPPORT Human Clinical

"Radiologically, metaphyseal abnormalities included flaring, cupping, widening, cysts, fragmentation, and scalloping of metaphyses in the tubular bones, particularly at the knee."

Describes the specific radiographic metaphyseal changes of CHH.

PMID:42170584 SUPPORT Human Clinical

"Importantly, metaphyseal changes may not be apparent in the first 2 years of life"

Supports the diagnostic caveat that early radiographs may be uninformative.

Decreased specific antibody response to vaccination HP:0032140

Show evidence (2 references)

PMID:28284971 SUPPORT Human Clinical

"patients who agreed to receive Pneumovax"

Marks the vaccine-challenge experiment in which seven of eight participants demonstrated specific antibody deficiency. No frequency band is assigned because only eight patients consented, so the proportion is not a population estimate.

PMID:42170584 SUPPORT Human Clinical

"While B cell counts are often decreased, hypogammaglobulinemia is rare in patients with CHH; moreover, some individuals have hypergammaglobulinemia"

Establishes that total immunoglobulin concentration is usually preserved in CHH, which is why the humoral defect is curated here as an impaired specific antibody response rather than as decreased circulating immunoglobulin.

Fine hair HP:0002213

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."

Establishes fine silky hair as a characteristic feature.

Decreased total T cell count HP:0005403

Show evidence (1 reference)

PMID:28284971 SUPPORT Human Clinical

"Patients with clinically suggested CID showed decreased median CD3+, CD8+ and RTE counts"

Directly reports reduced T cell counts in the clinically affected subgroup.

Asthma OCCASIONAL HP:0002099

Show evidence (1 reference)

PMID:30410491 SUPPORT Human Clinical

"We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%)."

Reports asthma in 23%, which maps to the OCCASIONAL band (5-29%).

Allergic rhinitis FREQUENT HP:0003193

Show evidence (2 references)

PMID:30410491 SUPPORT Human Clinical

"We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%)."

Reports allergic rhinoconjunctivitis in 39%, which maps to the FREQUENT band (30-79%).

PMID:30410491 SUPPORT Human Clinical

"Despite the history of allergic rhinitis, no eosinophils were observed in nasal cytology in five tested patients."

Retained negative finding qualifying the atopic interpretation; PARTIAL because only five patients were tested.

Aganglionic megacolon OCCASIONAL HP:0002251

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The prevalence of HD in the Finnish CHH cohort has increased from 9% (13/142) in the 20th century to 25% (8/32) in the 2000s"

Both reported figures, 9% and 25%, fall within the OCCASIONAL band (5-29%).

Non-Hodgkin lymphoma HP:0012539

Show evidence (3 references)

PMID:18698627 SUPPORT Human Clinical

"Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1)."

Quantifies the non-Hodgkin lymphoma excess against population expectation.

PMID:36211439 SUPPORT Human Clinical

"Lymphoma was diagnosed in young adulthood (median age 26.4 years, range from 6.4 to 69.5 years), mostly in advanced stage."

Establishes the age at presentation and the advanced stage driving the poor outcome.

PMID:36211439 SUPPORT Human Clinical

"Altogether, eleven CHH patients died due to lymphomas (11/16, 69%)."

Quantifies lymphoma mortality within the case series.

Severe varicella zoster infection HP:0032170

Show evidence (3 references)

PMID:22420014 SUPPORT Human Clinical

"immediate high-dose intravenous acyclovir for varicella infection"

The management recommendation presupposes varicella as a recognized severe risk in this population.

PMID:42170584 SUPPORT Human Clinical

"This has not been reported in later case series; vice versa, the majority of patients with CHH clear varicella without antiviral medications or any complications"

Retained counterweight: severe varicella is a real but uncommon outcome, so no frequency band is assigned and the historical framing is qualified.

PMID:28284971 SUPPORT Human Clinical

"Lower median IgG2 concentrations (1.08 vs 1.96 g/l, p=0.016) were observed in patients who required hospitalization for VZV infection."

Supports the IgG2 association described here.

Short telomere length HP:0031413

Show evidence (2 references)

PMID:27986801 SUPPORT Human Clinical

"In particular children (<18 years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008)."

Directly measures the shortened telomere phenotype in children.

PMID:28126377 SUPPORT Human Clinical

"Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH."

Independent measurement in lymphocyte subsets, adding the telomerase activity deficit.

Abnormal spermatogenesis HP:0008669

Show evidence (2 references)

PMID:22420014 SUPPORT Human Clinical

"Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."

Names impaired spermatogenesis as a feature of the spectrum.

PMID:31551465 SUPPORT Human Clinical

"A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis"

Supports routing this phenotype to the cell-cycle arm; PARTIAL because the authors present the proliferation explanation as speculation rather than as an established mechanism for spermatogenesis specifically.

🧬

Genetic Associations

1

RMRP (Pathogenic Variants)

Gene: RMRP hgnc:10031 relationship_type: CAUSATIVE

Show evidence (8 references)

PMID:11207361 SUPPORT Human Clinical

"We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype."

The original cosegregation evidence establishing RMRP as the CHH gene.

PMID:31551465 SUPPORT Human Clinical

"RMRP was the first non-coding nuclear RNA gene implicated in a disease."

Supports the historical significance noted here.

PMID:31551465 SUPPORT Human Clinical

"The founder mutation n.71 A > G (NCBI reference sequence: NR_003051.3) has been detected in almost all previously reported Finnish patients with CHH either in homozygous or heterozygous state3."

Specifies the founder allele and its reference sequence, and its dominance in the Finnish population.

+ 5 more references

💊

Medical Actions

9

Hematopoietic stem cell transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Allogeneic HSCT is the only curative option for the immune and severe haematological manifestations of CHH. It corrects the marrow-derived arm while leaving growth failure untouched, which is the cleanest available demonstration that the skeletal phenotype is chondrocyte-autonomous rather than secondary to immune or haematological disease. In a European collaborative survey of 16 transplanted patients, 10 were long-term survivors, with normalization of T-lymphocyte numbers and function and resolution of autoimmunity in all survivors. Its role in mildly symptomatic patients remains debated; the argument for transplanting earlier is that outcomes worsen once severe infection, organ damage or malignancy has supervened.

Mechanism Target:

RESTORES Defective Lymphocyte Proliferation and Combined Immunodeficiency — Replacing the haematopoietic compartment with donor cells carrying functional RMRP restores lymphocyte numbers and function.

Show evidence (1 reference)

PMID:20375313 SUPPORT Human Clinical

"T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors."

Direct evidence that transplantation corrects the lymphoid arm modeled by this node.

RESTORES Multilineage Bone Marrow Progenitor Failure — Donor progenitors restore erythropoiesis, curing transfusion-dependent anemia.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The only curative option for severe anemia in CHH remains HSCT, with multiple case reports of successful resolution"

Direct evidence that transplantation corrects the marrow arm modeled by this node.

RESTORES Immune Dysregulation and Autoimmunity — Autoimmunity resolved in all long-term survivors of transplantation, consistent with the dysregulation being intrinsic to the haematopoietic compartment.

Show evidence (1 reference)

PMID:20375313 SUPPORT Human Clinical

"T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors."

Direct evidence of resolution of the autoimmune arm after transplantation.

Show evidence (4 references)

PMID:20375313 SUPPORT Human Clinical

"Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected."

Establishes both the efficacy for immunodeficiency and the failure to affect growth, the dissociation this entry rests on.

PMID:20375313 SUPPORT Human Clinical

"Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years."

Quantifies long-term survival in the largest reported transplanted cohort.

PMID:20375313 SUPPORT Human Clinical

"HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients."

Supports the timing argument for earlier transplantation.

+ 1 more reference

Immunoglobulin replacement therapy

Action: immunoglobulin therapy Ontology label: Immunoglobulin Therapy NCIT:C62710

Immunoglobulin replacement is used for patients with humoral immunodeficiency and recurrent infection. Its limits should be stated plainly: progressive lung disease occurs in patients with and without hypogammaglobulinemia, and replacement is often insufficient to prevent deterioration, so it should not be treated as protective against bronchiectasis.

Mechanism Target:

BYPASSES Defective Lymphocyte Proliferation and Combined Immunodeficiency — Passive antibody substitutes for what the patient's defective B cell compartment cannot reliably make, without correcting the underlying proliferation defect.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy"

Establishes immunoglobulin replacement as recommended management for the immune defect.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"Hypogammaglobulinemia is present in some, but not all, of these patients, and immunoglobulin replacement therapy (IGRT) is often insufficient to prevent deterioration."

PARTIAL because it establishes the therapy's use while limiting the claim of benefit against progressive lung disease.

Antimicrobial prophylaxis and treatment of infection

Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620

Infections are treated according to type, location and severity, with prophylactic antibiotics considered in selected patients. Antimicrobial management is directed at the consequences of the immune defect rather than at the defect itself.

Mechanism Target:

INHIBITS Chronic Airway Infection and Bronchiectasis — Suppressing recurrent airway infection is the available lever on the infection-to-structural-damage sequence.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"treatment of underlying infections based on their type, location, and severity; immediate high-dose intravenous acyclovir for varicella infection; consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy"

Establishes both treatment of infection and prophylaxis as recommended management.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"physiotherapy and other acute and long-term medical management for bronchiectasis per pulmonologist"

Supports the specialist respiratory management arm alongside antimicrobials.

High-dose intravenous acyclovir for varicella

Action: antiviral therapy Ontology label: Antiviral Therapy NCIT:C16119

Agent: acyclovir CHEBI:2453

Varicella infection in CHH warrants immediate high-dose intravenous acyclovir, a recommendation inherited from the historically fatal varicella of the original Amish series. Most patients now clear varicella uneventfully, so this is a precaution proportionate to a severe but uncommon outcome rather than an expectation of severe disease.

Mechanism Target:

BYPASSES Defective Lymphocyte Proliferation and Combined Immunodeficiency — Pharmacological suppression of viral replication substitutes for the cellular immunity the patient cannot mount.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"immediate high-dose intravenous acyclovir for varicella infection"

States the specific antiviral recommendation for this population.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"immediate high-dose intravenous acyclovir for varicella infection"

The GeneReviews management recommendation this treatment records.

Live viral vaccination, contraindicated when immune function is abnormal

Action: vaccination Ontology label: Vaccination NCIT:C15346

This is the principal drug-safety consideration in CHH, and the evidence points two ways, so it is recorded with both directions intact. GeneReviews lists administration of live vaccines as an agent to avoid when there are signs of abnormal immunologic function or severe combined immunodeficiency, and vaccine-strain rubella has caused skin granulomas in a CHH patient. Set against that, a Finnish cohort of 104 patients in which 38% received MMR and 10% received varicella vaccine recorded no serious adverse events, with durable seropositivity and both humoral and cellular responses in a small prospective trial. The defensible position is the one the vaccine study itself takes: live vaccines may be considered in selected patients with no or clinically mild immunodeficiency, which makes immunological assessment before immunization the decisive step rather than a blanket rule either way.

Show evidence (5 references)

PMID:22420014 SUPPORT Human Clinical

"Agents/circumstances to avoid: Administration of live vaccines when signs of abnormal immunologic function or SCID are present."

The explicit GeneReviews agents-to-avoid warning, recorded verbatim.

PMID:42170584 SUPPORT Human Clinical

"as well as vaccine-strain rubella virus-induced skin granulomas"

Documents a realized live-vaccine complication in CHH, the concrete basis for the warning.

PMID:32849667 SUPPORT Human Clinical

"No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines."

Direct counterweight to a blanket contraindication; PARTIAL because it is a single-population retrospective series plus a five-subject trial, and does not license live vaccination in patients with abnormal immune function.

+ 2 more references

Red blood cell transfusion with iron chelation

Action: blood transfusion Ontology label: Blood Transfusion NCIT:C15192

Severe anemia is managed with red cell transfusion, and iron chelation is recommended for those requiring repeated transfusion. Transfusion dependency typically presents in the first months of life and may remit spontaneously or recur after prolonged remission, so the requirement should be reassessed rather than assumed permanent.

Mechanism Target:

BYPASSES Multilineage Bone Marrow Progenitor Failure — Transfused red cells substitute for the erythropoiesis the marrow cannot sustain, without correcting the progenitor defect.

Show evidence (1 reference)

PMID:39321258 SUPPORT Human Clinical

"Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group."

Establishes transfusion as the standard supportive approach to the anemia.

Show evidence (2 references)

PMID:39321258 SUPPORT Human Clinical

"Recommended guidelines for managing anemia in CHH patients include iron chelation therapy for those requiring multiple blood transfusions, regular assessment of anemia symptoms, red blood cell parameters, and immune system function."

States the chelation and monitoring recommendations recorded here.

PMID:22420014 SUPPORT Human Clinical

"red blood cell transfusions for severe anemia with iron chelation as needed"

Independent statement of the same management pairing.

Orthopedic surgical management

Action: orthopedic surgical procedure Ontology label: Orthopedic Surgical Procedure NCIT:C16186

Corrective osteotomy may be required for progressive varus deformity of the lower extremities, and roughly 43% of North American patients in one orthopedic review had required surgical realignment. Surgery addresses the consequences of the growth-plate lesion; it does not modify it.

Mechanism Target:

INHIBITS Genu varum — Realignment osteotomy corrects the varus deformity produced by asymmetric metaphyseal growth.

Show evidence (1 reference)

PMID:22420014 SUPPORT Human Clinical

"corrective osteotomies may be required for progressive varus deformity of the lower extremities"

States the surgical indication for the deformity targeted here.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The review of orthopedic data from 135 North American patients with CHH revealed that ~43% had required surgical realignment for the bowing of lower extremities"

Quantifies the proportion of patients requiring realignment surgery.

Growth hormone therapy, generally not recommended

Action: Pharmacotherapy NCIT:C15986

This is a negative recommendation, and it is load-bearing for a disorder defined by short stature: growth hormone is the intervention families most often ask about, and it is mostly considered futile in CHH. Eight patients across several case reports had therapy that was ineffective or at best temporarily beneficial. The mechanism fits the failure, since the lesion is a chondrocyte-autonomous block in growth-plate differentiation rather than a deficiency of growth-promoting hormone, and the same futility is documented for the hypoplastic anemia. The one carve-out is real and should not be lost: where genuine growth hormone deficiency coexists, treatment may help, so the recommendation is against reflexive use rather than against ever testing for a treatable pituitary cause.

Mechanism Target:

MODULATES Growth Plate Chondrocyte Differentiation Failure — Growth hormone acts on a growth plate whose defect is intrinsic to the chondrocyte, which is the mechanistic reason the intervention mostly fails; MODULATES rather than RESTORES because no durable correction of this node is demonstrated.

Show evidence (1 reference)

PMID:42170584 REFUTE Human Clinical

"Several case reports (altogether, of eight patients) have described GH therapy as ineffective or, at most, with temporary benefit"

Direct negative evidence that growth hormone does not durably correct the growth-plate defect.

Show evidence (3 references)

PMID:42170584 REFUTE Human Clinical

"Growth hormone (GH) treatment in CHH is mostly considered futile."

States the negative recommendation this treatment entry records.

PMID:42170584 SUPPORT Human Clinical

"However, GH deficiency has also been reported in CHH patients, and for them, GH treatment might be beneficial"

The exception that keeps this from being an absolute contraindication: coexisting growth hormone deficiency remains a treatable indication.

PMID:10690856 REFUTE Human Clinical

"Bone marrow cultures obtained from six patients with CHH showed reduced or totally absent erythroid colony formation, which was not influenced by GH or IGF-I in vitro or by GH treatment in vivo."

Independent negative result for the haematologic arm, showing growth hormone does not rescue the erythroid defect either in vitro or in vivo.

Malignancy surveillance

Action: cancer screening Ontology label: Cancer Screening NCIT:C15406

Lifelong malignancy surveillance is recommended, with clinical and laboratory examination annually in childhood and abdominal ultrasound every one to two years, continuing beyond paediatric age. The rationale is unusually strong: over half of non-skin cancers in prospective follow-up arose in patients with no preceding clinical symptoms of immune defect, and nearly all surviving lymphoma patients were diagnosed through routine screening or evaluation of mild non-specific symptoms rather than overt presentation.

Show evidence (4 references)

PMID:22420014 SUPPORT Human Clinical

"Clinical and laboratory examination for manifestations of malignancy annually in children and as needed in adults; abdominal ultrasound every one to two years in children and as needed in adults."

States the surveillance schedule recorded here.

PMID:36211439 SUPPORT Human Clinical

"In almost all surviving lymphoma patients, the diagnosis was made either during routine follow-up or after evaluation for non-specific mild symptoms."

The strongest available argument for surveillance: survival was associated with detection during routine follow-up rather than clinical presentation.

PMID:36211439 SUPPORT Human Clinical

"Other CHH-related manifestations poorly predicted lymphoma development, implying that all CHH patients should be regularly screened for malignancy."

Supports universal rather than risk-stratified screening.

+ 1 more reference

🔬

Diagnosis

3

Clinical and radiographic diagnosis

Diagnosis is established in a proband with characteristic clinical and radiographic findings. Metaphyseal changes may be absent in the first two years of life and some patients never show them, so normal radiographs do not exclude CHH.

skeletal radiography NCIT:C38101

Show evidence (2 references)

PMID:22420014 SUPPORT Human Clinical

"Diagnosis of a CHH-AD spectrum disorder is established in a proband with characteristic clinical and radiographic findings."

States the clinical and radiographic basis of diagnosis.

PMID:42170584 SUPPORT Human Clinical

"Some patients' radiographs show no signs of metaphyseal dysplasia despite evident short stature (19) or severe immunodeficiency"

Supports the caveat that radiographic normality does not exclude the diagnosis.

Molecular genetic testing

Identification of biallelic RMRP variants confirms the diagnosis and enables family studies, carrier testing and prenatal or preimplantation testing. Testing must specifically cover the non-coding gene including its promoter region, since standard exome capture may miss it; whole-genome sequencing, targeted panels fully covering RMRP, or copy-number assessment are the reliable options.

molecular genetic testing NCIT:C19770

Show evidence (2 references)

PMID:22420014 SUPPORT Human Clinical

"identification of biallelic pathogenic variants in RMRP by molecular genetic testing can confirm the diagnosis and allow for family studies"

Specifies the role of molecular testing relative to clinical diagnosis.

PMID:42170584 SUPPORT Human Clinical

"diagnostic approach can include whole-genome sequencing or targeted panels that fully capture the RMRP gene, including the promoter region, as well as copy number variation assessment"

Specifies the testing strategies that reliably cover a non-coding gene and its promoter.

Immunological assessment and surveillance

Baseline and serial immunological assessment is recommended in all patients including asymptomatic ones, because laboratory abnormalities are common, correlate poorly with symptoms, and progress over time, with adult-onset immunodeficiency documented. Vaccine responses should be studied after infancy, since specific antibody deficiency is common and may mark more severe disease.

laboratory assessment of immune function NCIT:C19770

Show evidence (3 references)

PMID:32506568 SUPPORT Human Clinical

"Regular follow-up by a multidisciplinary team should be implemented to address immune dysfunction in all patients with CHH, also in asymptomatic cases."

Directly supports assessing asymptomatic patients rather than testing on symptoms alone.

PMID:31379817 SUPPORT Human Clinical

"In conclusion, patients with CHH may develop adult-onset immunodeficiency or malignancy without preceding clinical symptoms of immune defect, warranting careful follow-up."

The prospective-cohort conclusion that makes lifelong surveillance the recommended model rather than symptom-triggered testing.

PMID:28284971 SUPPORT Human Clinical

"SAD may therefore be a marker of more severe disease and vaccine responses should be routinely studied after infancy."

Supports routine vaccine-response testing as part of immunological assessment.

📊

Prevalence

3

Old Order Amish

Birth Prevalence 74.6 per 100,000 >1 in 1,000

Estimated incidence of 1 in 1,340 births, the highest reported for any population; CHH is one of the classic Amish founder disorders, described by McKusick in the Old Order Amish of Lancaster County.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"

Direct source for the Amish birth incidence converted to the rate here.

Finland

Birth Prevalence 4.35 per 100,000 1–9 per 10,000

Estimated incidence of 1 in 23,000 births. CHH belongs to the Finnish disease heritage, and almost all Finnish patients carry the founder variant, which is why the Finnish cohort dominates the literature and why its figures should be read as founder-population figures rather than universal ones.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"

Direct source for the Finnish birth incidence converted to the rate here.

Old Order Amish

Carrier Frequency 5263.0 per 100,000 >1 in 1,000

Founder variant carrier rate of 1 in 19, reported alongside a Finnish carrier rate of 1 in 76.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"The carrier rates of the founder variant are 1:19 and 1:76 among Amish and Finnish individuals, respectively"

Direct source for the Amish founder-variant carrier frequency.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Cartilage-hair hypoplasia:

Anauxetic dysplasia MONDO:0011773

Overlapping Features The severe end of the same RMRP spectrum, reached by allele combinations producing the greatest loss of rRNA cleavage activity. It shares the molecular lesion but is skeletally far more severe and may include atlantoaxial subluxation and cognitive deficiency, while the hair, immune and haematologic features characteristic of CHH are not assumed to be present.

Distinguishing Features

Markedly more severe skeletal dysplasia, with the most pronounced short stature of the spectrum.
Atlantoaxial subluxation may be present in the newborn, which is not characteristic of CHH.
Cognitive deficiency may occur, which is not a feature of CHH.
Hair, immune and haematologic involvement is conditional rather than characteristic.

Show evidence (2 references)

PMID:17701897 SUPPORT Human Clinical

"Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD)."

Places CHH and anauxetic dysplasia at different points of one allelic spectrum.

PMID:22420014 SUPPORT Human Clinical

"The most severe phenotype, AD, has the most pronounced skeletal phenotype, may be associated with atlantoaxial subluxation in the newborn, and may include cognitive deficiency."

Names the features that separate anauxetic dysplasia from CHH clinically.

Metaphyseal dysplasia without hypotrichosis Not Yet Curated MONDO:0009601

Overlapping Features The mild end of the same RMRP spectrum, distinguished from CHH by absence of hair involvement. Its status as a separate entity is doubtful: longitudinal follow-up of such individuals has revealed late-onset immune abnormalities typical of CHH, so the distinction may reflect age at assessment rather than a different disease.

Distinguishing Features

Absence of hypotrichosis, as reflected in the disease name.
Milder skeletal phenotype than CHH.
May be reclassified as CHH on longer follow-up once immune features emerge.

Show evidence (2 references)

PMID:17701897 SUPPORT Human Clinical

"Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD)."

Places metaphyseal dysplasia without hypotrichosis at the mild end of the same spectrum as CHH.

PMID:42170584 SUPPORT Human Clinical

"However, the longitudinal follow-up of such individuals has revealed late-onset development of immune abnormalities typical for CHH."

Supports treating the distinction as provisional rather than a firm diagnostic boundary.

Schmid metaphyseal chondrodysplasia MONDO:0007983

Overlapping Features An autosomal dominant COL10A1-related metaphyseal dysplasia sharing short stature, metaphyseal changes and genu varum with CHH but with no hair, immune, haematologic or malignancy involvement, and dominant rather than recessive inheritance. It is the differential that matters when radiographs are the presenting finding.

Distinguishing Features

Autosomal dominant inheritance rather than autosomal recessive.
Caused by COL10A1 rather than RMRP.
No hair hypoplasia, immunodeficiency, anemia or cancer predisposition.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"Typical clinical manifestations of CHH include chondrodysplasia with short stature, hair hypoplasia, combined immunodeficiency, and anemia."

PARTIAL because this establishes the extraskeletal features that separate CHH from an isolated metaphyseal dysplasia, but does not itself discuss the Schmid type.

Shwachman-Diamond syndrome MONDO:0009833

Overlapping Features The other classic metaphyseal dysplasia with marrow failure, and the closest mechanistic analogue: also a ribosome-related disorder combining skeletal dysplasia with cytopenias and malignancy risk. It is distinguished by exocrine pancreatic insufficiency, by neutropenia rather than anemia as the dominant cytopenia, and by myeloid rather than lymphoid malignancy.

Distinguishing Features

Exocrine pancreatic insufficiency, absent in CHH.
Neutropenia is the characteristic cytopenia rather than macrocytic anemia.
Malignant risk is predominantly myelodysplasia and acute myeloid leukemia rather than non-Hodgkin lymphoma.
No hair hypoplasia.

Show evidence (1 reference)

PMID:42170584 SUPPORT Human Clinical

"These findings, together with other known ribosomopathies affecting the skeleton (RPL13, SBDS, and NEPRO gene defects), emphasize the pivotal role of ribosomes in skeletal development"

PARTIAL because it establishes SBDS-related disease as a fellow skeleton-affecting ribosomopathy, the basis for including it here, without itself enumerating the distinguishing clinical features.

Dyskeratosis congenita MONDO:0015780

Overlapping Features The prototypical telomere biology disorder, and a differential CHH earns by mechanism rather than by appearance: both combine bone marrow failure, immunodeficiency and cancer predisposition with measurably short telomeres. The skeletal dysplasia and hair hypoplasia of CHH, and the mucocutaneous triad of dyskeratosis congenita, separate them clinically.

Distinguishing Features

Mucocutaneous triad of nail dystrophy, oral leukoplakia and reticular skin pigmentation.
No metaphyseal chondrodysplasia or disproportionate short-limb short stature.
Caused by telomere maintenance genes rather than by RMRP.

Show evidence (1 reference)

PMID:28126377 SUPPORT Human Clinical

"The CHH disease phenotype has some overlap with dyskeratosis congenita, a well-known "telomere disorder.""

Explicitly names the phenotypic overlap that makes this a mechanistically motivated differential.

🔬

Clinical Trials

1

NCT02383797 COMPLETED

Prospective immunization of carefully selected CHH patients who lacked a varicella history and were seronegative for varicella zoster virus, with live attenuated VZV vaccine, assessing both humoral and cell-mediated responses. The design is the interesting part: participants were chosen by disease severity and degree of immunodeficiency including CD4 counts, and acyclovir was held ready for any vaccine-related symptoms, so it is a controlled test of exactly the contraindication that GeneReviews states. Trial participants developed humoral and cellular responses; one developed a post-immunization rash and knee swelling, both of which resolved without treatment.

Target Phenotypes: Severe varicella zoster infection HP:0032170 Decreased specific antibody response to vaccination HP:0032140

Show evidence (3 references)

clinicaltrials:NCT02383797 SUPPORT Human Clinical

"The investigators will verify the development of immune response to vaccination by testing for VZV antibodies and cell-mediated immunity."

The registered protocol's stated objective, matching the immunization question this entry curates under live viral vaccination.

PMID:32849667 SUPPORT Human Clinical

"We conducted a clinical trial (ClinicalTrials.gov identifier: NCT02383797) of live VZV vaccine on five subjects with CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and were seronegative for VZV"

Ties the registered trial to its publication and states the enrolment criteria that scope its conclusion to mildly affected patients.

PMID:32849667 SUPPORT Human Clinical

"Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment."

Reports the trial outcome including its single adverse event; PARTIAL because five participants cannot establish safety in patients with abnormal immune function.

🧫

Experimental Models

3

Rmrp-deficient ATDC5 chondrogenic cell model CELL_LINE

Rmrp interference in ATDC5 cells couples impaired pre-rRNA processing to a particularly strong defect in chondrocyte hypertrophy, the step this entry identifies as the skeletal bottleneck. It is a two-dimensional mouse-derived line and reproduces neither growth-plate architecture nor any extraskeletal feature.

Organism

mouse NCBITaxon:10090

Cell source

Mouse ATDC5 chondrogenic cell line

Culture

Monolayer chondrogenic differentiation culture with Rmrp RNA interference

Publication

PMID:28743979

Pathograph links

Growth Plate Chondrocyte Differentiation Failure recapitulates fidelity: moderate Measures chondrogenic differentiation and hypertrophy after Rmrp interference.

Limitations: A murine immortalized chondrogenic line in monolayer culture; it models the differentiation step but not growth-plate architecture, limb proportion, or any extraskeletal disease.

Readouts

Chondrogenic differentiation and hypertrophy

Direction: DECREASED

Interpretation: Cellular correlate of the growth-plate differentiation node.

Show evidence (1 reference)

PMID:28743979 SUPPORT In Vitro

"Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."

Directly demonstrates the differentiation and hypertrophy defect.

Show evidence (1 reference)

PMID:28743979 SUPPORT In Vitro

"Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."

Supports treating this model as informative for the growth-plate node.

Show evidence (1 reference)

PMID:28743979 SUPPORT In Vitro

"Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."

Establishes the model, perturbation, molecular readout and cellular phenotype.

CHH patient-derived fibroblast cell-cycle and transcriptome model PRIMARY_CELL_CULTURE

The most direct human evidence for the cell-cycle arm. Combining transcriptomics with single-cell tracking in patient fibroblasts localizes the defect to the G2-to-mitosis passage specifically, rather than inferring a generic proliferation problem, and shows the affected gene programmes reach bone, cartilage and lymphocyte function. Fibroblasts are an accessible surrogate rather than a disease-target tissue, which is the main caveat.

Organism

human NCBITaxon:9606

Cell source

Primary dermal fibroblasts from patients with cartilage-hair hypoplasia and healthy controls

Culture

Monolayer culture with pulse-labeling, time-lapse microscopy and RNA sequencing

Publication

PMID:31551465

Pathograph links

Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay recapitulates fidelity: high Directly measures cell-cycle progression and transcriptome changes in patient-derived cells carrying the disease genotype.

Limitations: Dermal fibroblasts are not one of the tissues that fails clinically, so the model demonstrates the lesion is cell-intrinsic and general without showing why chondrocytes, lymphocytes and erythroid progenitors are the ones that decompensate.

Readouts

G2-to-mitosis transit time

Direction: DECREASED

Interpretation: Delayed passage from G2 into mitosis is the specific cell-cycle lesion this node asserts.

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."

The direct measurement of the readout in patient cells.

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"We combined transcriptome analysis with single-cell analysis using fibroblasts from CHH patients and healthy controls."

Establishes the model system and the two orthogonal measurement approaches.

Findings

Downregulated genes in CHH fibroblasts are significantly connected to the cell cycle, with additional effects on apoptosis, bone and cartilage formation and lymphocyte function.

"The downregulated genes were significantly connected to the cell cycle."

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle."

The experimental result is quoted directly from the publication abstract.

Show evidence (1 reference)

PMID:31551465 SUPPORT In Vitro

"To directly assess cell cycle progression, we followed CHH fibroblasts by pulse-labeling and time-lapse microscopy."

Establishes the direct cell-cycle measurement rather than inference from static assays.

Patient bone marrow progenitor colony-forming assay PRIMARY_CELL_CULTURE

The closest thing CHH has to a functional test of the marrow arm, and its value lies in a specific control: showing progenitor numbers are normal or increased while colony formation fails separates a proliferation defect from progenitor depletion. The limitation is that colony formation did not correlate with haemoglobin, platelet or neutrophil counts, so the assay reports the cellular lesion rather than predicting the clinical blood count.

Organism

human NCBITaxon:9606

Cell source

Bone marrow and peripheral blood from patients with cartilage-hair hypoplasia

Culture

Semi-solid colony-forming assay for erythroid, megakaryocyte and granulocyte-macrophage progenitors

Publication

PMID:7895753

Pathograph links

Multilineage Bone Marrow Progenitor Failure recapitulates fidelity: high Measures colony formation across erythroid, megakaryocyte and granulocyte-macrophage lineages in patient-derived progenitors.

Limitations: Ex vivo culture in eight patients; the defect did not track peripheral blood counts, so it cannot serve as a severity readout for an individual patient.

Readouts

Erythroid, megakaryocyte and granulocyte-macrophage colony formation

Direction: DECREASED

Interpretation: Functional demonstration of the multilineage progenitor defect in patient cells.

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"All patients showed decreased erythroid and megakaryocyte colony formation. Only one patient had a normal granulocyte-macrophage growth, while the others showed decreased numbers of colonies."

Reports the measured colony deficit across all three lineages.

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH."

Supports treating this assay as informative for the marrow-failure node.

Findings

Colony formation fails despite normal or increased progenitor numbers, identifying a functional proliferation defect rather than progenitor depletion.

"The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures."

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors."

The experimental result is quoted directly from the publication abstract.

Show evidence (1 reference)

PMID:7895753 SUPPORT In Vitro

"In the present study erythroid, megakaryocyte, and granulocyte-macrophage colony formation in vitro by progenitors from bone marrow and blood was investigated in eight patients with CHH."

Establishes the model system, cell source and readout.

🐁

Animal Models

1

rmrp knockout zebrafish

The only viable whole-organism model of RMRP deficiency, because mouse knockouts die before embryonic day 6.5. It reproduces disrupted chondrogenesis with altered ossification, links it to inhibited proliferation and increased apoptosis, and identifies upregulated canonical Wnt/beta-catenin signalling as a candidate effector that can be pharmacologically inhibited with partial rescue. That rescue is the only mechanistic handle on the skeletal phenotype anywhere in this entry, which makes the model disproportionately important and also disproportionately in need of mammalian confirmation.

Species

Zebrafish

Genotype

rmrp knockout

Publication

PMID:31237961

Pathograph links

Growth Plate Chondrocyte Differentiation Failure partially recapitulates fidelity: moderate Reproduces dysregulated chondrogenesis and abnormal ossification, and implicates Wnt/beta-catenin as a reversible effector.

Limitations: Zebrafish cartilage development differs architecturally from the mammalian endochondral growth plate, and the primary readouts are pharyngeal arch patterning and skull and vertebral ossification rather than long-bone metaphyseal growth; ossification effects are directionally mixed, being inhibited in skull and promoted in vertebrae, which has no clean human counterpart.

Readouts

Chondrogenesis and bone ossification

Direction: ALTERED

Interpretation: Whole-organism correlate of the cartilage differentiation node; ALTERED rather than DECREASED because ossification changed in opposite directions in different skeletal elements.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis."

Reports the cartilage and ossification phenotype, including its direction-dependence by skeletal element.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants."

Pharmacological rescue supports the model being mechanistically informative rather than merely phenotypically similar.

Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay recapitulates fidelity: moderate Reproduces inhibited proliferation and increased apoptosis with dysregulation of cell-cycle and apoptosis genes.

Limitations: Gene-expression-level evidence in a whole zebrafish embryo; it does not resolve the specific G2-to-M step identified in human patient cells.

Readouts

Cell proliferation and apoptosis

Direction: DECREASED

Interpretation: Whole-organism correlate of the proliferation defect.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."

Reports the proliferation and apoptosis readouts in the model.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."

Supports treating the model as informative for the proliferation arm.

Show evidence (1 reference)

PMID:31237961 SUPPORT Model Organism

"Currently, the pathogenesis of osteochondrodysplasia and extraskeletal manifestations in CHH patients remains incompletely understood; in addition, there are no viable animal models for CHH. We generated an rmrp KO zebrafish model to study the developmental mechanisms of CHH."

Establishes both the model and the absence of any prior viable animal model, which is why it carries so much weight here.

{ }

Source YAML

click to show

name: Cartilage-hair hypoplasia
creation_date: "2026-08-14T00:00:00Z"
description: >-
  Cartilage-hair hypoplasia (CHH) is an autosomal recessive immuno-osseous
  dysplasia caused by biallelic variants in RMRP, the untranslated RNA component
  of the RNase MRP endoribonuclease. It occupies the middle of the cartilage-hair
  hypoplasia to anauxetic dysplasia (CHH-AD) spectrum, milder skeletally than
  anauxetic dysplasia but far richer extraskeletally, and it is the form in which
  hair hypoplasia, combined immunodeficiency, anemia, Hirschsprung disease and a
  striking excess of lymphoma are characteristic rather than conditional. Its
  mechanistic interest lies in how one small non-coding RNA reaches four organ
  systems at once: RNase MRP cleaves pre-ribosomal RNA, cleaves Cyclin B2
  messenger RNA to license mitotic exit, partners with TERT, and is itself
  processed into gene-silencing small RNAs. A single RNA-folding lesion therefore
  starves the most biosynthetically demanding cells in the growth plate while
  stalling the most rapidly dividing cells in the marrow, thymus and hair
  follicle. The clinical consequence is that the phenotype tracks proliferative
  demand rather than any one tissue lineage, and that the immune arm, not the
  skeletal one, drives mortality. The hardest fact for management is that
  malignancy and adult-onset immunodeficiency both occur in patients who never
  showed a clinical immune symptom.
category: Mendelian
parents:
- osteochondrodysplasia
- immuno-osseous dysplasia
- autosomal recessive disease
synonyms:
- CHH
- metaphyseal chondrodysplasia, McKusick type
- McKusick Type Metaphyseal Chondrodysplasia
- autosomal recessive metaphyseal chondrodysplasia
disease_term:
  preferred_term: cartilage-hair hypoplasia
  term:
    id: MONDO:0009595
    label: cartilage-hair hypoplasia
classifications:
  iuis_category:
    classification_value: combined immunodeficiency with syndromic features
    notes: >-
      IUIS phenotypic classification of inborn errors of immunity; CHH is a
      syndromic combined immunodeficiency, grouped with the immuno-osseous
      dysplasias rather than with the isolated combined immunodeficiencies.
    evidence:
    - reference: PMID:42170584
      reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cartilage-hair hypoplasia (CHH) is a rare syndromic inborn error of immunity, caused by variants in the noncoding RNA gene RMRP."
      explanation: >-
        Names CHH as a syndromic inborn error of immunity, the basis for the
        syndromic-features assignment.
  isds_skeletal_category:
  - classification_value: metaphyseal_dysplasias
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, 2019
      revision (Mortier et al., PMID:31633310), Table 1 group 11 "Metaphyseal
      dysplasias"; listed as cartilage-hair hypoplasia, the McKusick type
      metaphyseal chondrodysplasia.
inheritance:
- name: Autosomal recessive inheritance
  description: >-
    CHH is autosomal recessive, arising from biallelic variants in RMRP.
    Heterozygous carriers are asymptomatic and do not show the cellular
    proliferation defect, although telomerase activity is reduced in carriers in
    a gene-dose-dependent manner, so the carrier state is not entirely silent at
    every molecular level. Each sib of an affected individual has a 25%
    recurrence risk.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:32506568
    reference_title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."
    explanation: >-
      States the autosomal recessive mode of inheritance alongside the defining
      multisystem phenotype.
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If both parents are known to be heterozygous for an RMRP pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: >-
      GeneReviews recurrence risks used in counselling families.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "humans carrying pathogenic variants in a single allele remain asymptomatic (8, 64) and do not demonstrate cell proliferation defects (42)"
    explanation: >-
      Establishes that heterozygous carriers are unaffected at both the clinical
      and the cellular proliferation level.
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH."
    explanation: >-
      PARTIAL, and retained deliberately: it qualifies the clean recessive
      picture by showing a measurable intermediate molecular phenotype in
      carriers who remain clinically well.
prevalence:
- population: Old Order Amish
  measure_type: BIRTH_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 74.6
  notes: >-
    Estimated incidence of 1 in 1,340 births, the highest reported for any
    population; CHH is one of the classic Amish founder disorders, described by
    McKusick in the Old Order Amish of Lancaster County.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"
    explanation: >-
      Direct source for the Amish birth incidence converted to the rate here.
- population: Finland
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 4.35
  notes: >-
    Estimated incidence of 1 in 23,000 births. CHH belongs to the Finnish
    disease heritage, and almost all Finnish patients carry the founder variant,
    which is why the Finnish cohort dominates the literature and why its figures
    should be read as founder-population figures rather than universal ones.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an estimated incidence of 1 in 1,340 in Amish and 1 in 23,000 births in Finnish"
    explanation: >-
      Direct source for the Finnish birth incidence converted to the rate here.
- population: Old Order Amish
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 5263.0
  notes: >-
    Founder variant carrier rate of 1 in 19, reported alongside a Finnish
    carrier rate of 1 in 76.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The carrier rates of the founder variant are 1:19 and 1:76 among Amish and Finnish individuals, respectively"
    explanation: >-
      Direct source for the Amish founder-variant carrier frequency.
pathophysiology:
- name: RMRP Non-Coding RNA Loss of Function
  biological_scale: MOLECULAR
  description: >-
    RMRP is a 269-nucleotide gene encoding the untranslated RNA subunit of RNase
    MRP, a nucleolar ribonucleoprotein endoribonuclease. The lesion is one of RNA
    dosage and RNA folding rather than of a protein coding sequence, and the two
    classes of pathogenic variant act by different routes: insertions and
    duplications between the TATA box and the transcription start site silence or
    reduce transcription, while variants inside the transcribed region leave
    transcription intact and instead perturb conserved nucleotides and stem
    pairings. Notably the variants do not prevent the protein subunits binding
    the RNA; what the common founder allele does is reduce the amount of intact
    complex assembled. Complete absence of the RNA appears incompatible with
    life, so every recognized patient is a partial loss of function and the
    disease is graded rather than all-or-none.
  genes:
  - preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  evidence:
  - reference: PMID:11207361
    reference_title: "Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype."
    explanation: >-
      The original identification of RMRP as the CHH gene and of the gene
      product as an untranslated RNA.
  - reference: PMID:11207361
    reference_title: "Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not."
    explanation: >-
      Establishes the two mechanistically distinct classes of pathogenic
      variant, promoter-silencing versus structure-perturbing.
  - reference: PMID:11207361
    reference_title: "Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The association of protein subunits with RNA appears unaltered."
    explanation: >-
      Rules out failure of protein binding as the mechanism, which is what makes
      the later finding of reduced intact complex abundance informative rather
      than redundant.
  - reference: PMID:35115551
    reference_title: "A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes."
    explanation: >-
      Identifies reduced holoenzyme abundance, rather than mis-assembly or
      failed subunit binding, as the proximal consequence of the common founder
      allele.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants in the promoter region imply insertions, duplications, or triplications localized between the TATA box and the transcription initiation site."
    explanation: >-
      Locates the promoter class of variant precisely, supporting the
      transcriptional-silencing route described in this node.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This, together with failure to produce RMRP knockout yeast or mice, suggests that RMRP expression might exhibit a dose-dependent phenotype correlation and that complete RMRP deficiency is lethal."
    explanation: >-
      Supports the claim that complete loss is lethal and surviving disease is
      partial loss of function; PARTIAL because lethality of the null is
      inferred from model organisms rather than demonstrated in humans.
  downstream:
  - target: Impaired Pre-rRNA Processing and Ribosome Biogenesis
    description: >-
      Loss of RNase MRP activity on its pre-ribosomal RNA substrate compromises
      ribosome synthesis.
  - target: Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
    description: >-
      Loss of activity on the messenger-RNA substrate that licenses mitotic exit
      dysregulates cell-cycle progression.
  - target: Impaired Telomere Maintenance
    description: >-
      RMRP partners with TERT, so loss of the RNA also perturbs telomerase
      activity and telomere length.
  - target: Loss of RMRP-Derived Small RNA Gene Silencing
    description: >-
      The RNA is itself processed into gene-silencing small RNAs, and several
      disease-causing variants fall within them.
  - target: Gastrointestinal and Enteric Nervous System Involvement
    description: >-
      Hirschsprung disease and enteropathy occur at increased frequency in
      RMRP-deficient patients. The edge is drawn from the genetic lesion
      directly because no intermediate mechanism has been identified; it records
      an established association of the biallelic state, not a known route.
- name: Impaired Pre-rRNA Processing and Ribosome Biogenesis
  biological_scale: MOLECULAR
  description: >-
    The first substrate arm, and the one that earns CHH the ribosomopathy label.
    RNase MRP cleaves pre-ribosomal RNA in the internal transcribed spacer 1
    region during ribosome synthesis. Engineering the common founder allele into
    human cells specifically impairs that step, reducing mature rRNA and, more
    tellingly, lowering the ratio of cytosolic to mitochondrial ribosomes; the
    same processing delay is seen in patient-derived fibroblasts, so this is not
    an artefact of engineered or immortalized cells. Because activating a naive T
    cell requires roughly a tenfold increase in per-cell ribosome abundance, a
    ceiling on ribosome synthesis is felt first by exactly the cells that must
    build ribosomes fastest, which is the unifying logic of the whole disease.
    The magnitude of residual rRNA cleavage tracks skeletal severity across the
    CHH-AD spectrum, and CHH sits where enough activity is retained to avoid the
    anauxetic skeleton but not enough to build a normal growth plate.
  biological_processes:
  - preferred_term: rRNA processing
    term:
      id: GO:0006364
      label: rRNA processing
    modifier: DECREASED
  - preferred_term: ribosome biogenesis
    term:
      id: GO:0042254
      label: ribosome biogenesis
    modifier: DECREASED
  evidence:
  - reference: PMID:35115551
    reference_title: "A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes."
    explanation: >-
      The most specific available molecular statement of this node: the founder
      allele impairs pre-rRNA processing and shifts ribosome composition.
  - reference: PMID:35115551
    reference_title: "A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay."
    explanation: >-
      Confirms the processing delay in primary patient cells rather than only in
      engineered or cancer-derived lines.
  - reference: PMID:35115551
    reference_title: "A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Together, these results indicate that CHH is a ribosomopathy."
    explanation: >-
      The authors' explicit conclusion, which is the strongest direct support
      for the ribosomopathy framing this node adopts.
  - reference: PMID:17701897
    reference_title: "Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In vitro testing of RNase MRP multiprotein-specific mRNA and rRNA cleavage of different mutations revealed a strong correlation between the decrease in rRNA cleavage in ribosomal assembly and the degree of bone dysplasia"
    explanation: >-
      Establishes the quantitative link between loss of rRNA cleavage and
      skeletal severity that positions CHH within the spectrum.
  - reference: PMID:21396580
    reference_title: "The molecular basis of the cartilage-hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The degree of skeletal dysplasia correlates mainly with the rRNA cleavage activity, whereas significantly diminished mRNA cleavage activity is a prerequisite for immunodeficiency."
    explanation: >-
      Independent statement of the two-substrate dissociation that organizes
      this pathograph into a skeletal and an extraskeletal arm.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The increase of ITS1 pre-rRNA processing intermediate has been demonstrated also in dermal fibroblasts from patients with CHH"
    explanation: >-
      Independent in-patient confirmation that the ITS1 processing step is
      blocked.
  downstream:
  - target: Growth Plate Chondrocyte Differentiation Failure
    description: >-
      Reduced ribosome synthesis strikes hardest at the most biosynthetically
      demanding cells of the growth plate.
  - target: Defective Lymphocyte Proliferation and Combined Immunodeficiency
    description: >-
      T cell activation demands a large increase in ribosome abundance, so a
      ceiling on ribosome synthesis limits the activation programme directly.
- name: Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
  biological_scale: CELLULAR
  description: >-
    The second substrate arm, and the one that carries the extraskeletal disease.
    RNase MRP cleaves Cyclin B2 messenger RNA at the end of mitosis, so losing
    that activity leaves mitotic cyclin turnover dysregulated. Patient
    fibroblasts followed by pulse-labelling and time-lapse microscopy are delayed
    specifically at the G2-to-mitosis transition, and their transcriptomes show
    coordinated downregulation of cell-cycle genes together with effects on
    apoptosis, bone and cartilage formation and lymphocyte function. Residual
    mRNA cleavage activity, not rRNA activity, predicts hair hypoplasia,
    immunodeficiency and haematological abnormality across the spectrum, which is
    why CHH is the end where those features are expected rather than conditional.
  biological_processes:
  - preferred_term: regulation of cell cycle
    term:
      id: GO:0051726
      label: regulation of cell cycle
    modifier: DECREASED
  - preferred_term: G2/M transition of mitotic cell cycle
    term:
      id: GO:0000086
      label: G2/M transition of mitotic cell cycle
    modifier: DECREASED
  evidence:
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."
    explanation: >-
      Direct measurement in patient-derived cells localizing the block to the
      G2-to-M transition, which is what this node asserts.
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle."
    explanation: >-
      Transcriptomic support that the cell cycle is the dominant affected
      programme in patient cells.
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Multiple other pathways, involving regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as well as PI3K-Akt signaling."
    explanation: >-
      Shows the same lesion touching the bone and lymphocyte programmes, which
      is the transcriptomic counterpart of the clinical pleiotropy.
  - reference: PMID:17701897
    reference_title: "Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "reduced mRNA cleavage, and thus cell-cycle impairment, predicts the presence of hair hypoplasia, immunodeficiency, and hematological abnormalities and thus increased cancer risk"
    explanation: >-
      Establishes that the messenger-RNA arm determines the extraskeletal
      phenotype that defines CHH.
  - reference: PMID:21396580
    reference_title: "The molecular basis of the cartilage-hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This complex is involved in the ribosome assembly by cleavage of 5.8S rRNA, cell cycle control by Cyclin B2 mRNA cleavage at the end of mitosis, processing the mitochondrial RNA, and forming a complex with hTERT suggesting a possible involvement in expression regulation by siRNA synthesis."
    explanation: >-
      Names the concrete substrate for this node, Cyclin B2 messenger RNA
      cleaved at the end of mitosis.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Defective lymphocyte proliferation is the most clear disease mechanism in CHH, connecting multiple molecular abnormalities with clinical features, including increased susceptibility to infections, autoimmunity, and malignancies."
    explanation: >-
      Identifies the proliferation defect as the best-established mechanistic
      bridge from molecule to clinical phenotype in CHH.
  downstream:
  - target: Defective Lymphocyte Proliferation and Combined Immunodeficiency
    description: >-
      Rapidly dividing lymphoid populations are least able to tolerate a
      cell-cycle block.
  - target: Multilineage Bone Marrow Progenitor Failure
    description: >-
      Marrow progenitors, likewise proliferation-dependent, fail to form
      colonies.
  - target: Hair Follicle Hypoplasia
    description: >-
      Hair hypoplasia tracks the messenger-RNA cleavage arm specifically.
  - target: Growth Plate Chondrocyte Differentiation Failure
    description: >-
      Chondrocyte proliferation in the growth plate is subject to the same
      cell-cycle constraint, and bone and cartilage formation genes are among
      those dysregulated in patient cells.
  - target: Abnormal spermatogenesis
    description: >-
      Spermatogenesis is among the proliferation-dependent processes the
      generalized cell-cycle defect has been invoked to explain.
- name: Impaired Telomere Maintenance
  biological_scale: MOLECULAR
  description: >-
    A third arm, and the one that aligns CHH with the telomere biology disorders
    it clinically resembles. RMRP binds telomerase reverse transcriptase, and
    patient lymphocytes show both shortened telomeres and reduced telomerase
    activity, the latter scaling with gene dose between carriers and patients.
    The mechanism is not simply reduced telomerase gene expression: transcript
    levels are normal, so the defect is post-transcriptional and remains
    unidentified. Population-level telomere shortening is real but does not
    correlate with genotype or with any clinical or laboratory feature within
    CHH, so this arm should not be read as explaining an individual patient's
    course.
  biological_processes:
  - preferred_term: telomere maintenance
    term:
      id: GO:0000723
      label: telomere maintenance
    modifier: DECREASED
  evidence:
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH."
    explanation: >-
      Direct measurement of both telomere length and telomerase activity in
      patient lymphocytes.
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."
    explanation: >-
      Negative result excluding the simplest explanation and establishing that
      the defect is post-transcriptional.
  - reference: PMID:27986801
    reference_title: "Decreased telomere length in children with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with age-matched and sex-matched healthy controls, median RTL was significantly shorter in patients with CHH (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10, p=0.224)."
    explanation: >-
      Independent quantification of telomere shortening in a larger patient
      cohort.
  - reference: PMID:27986801
    reference_title: "Decreased telomere length in children with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with CHH, RTL showed no correlation with genotype, clinical or laboratory characteristics."
    explanation: >-
      Retained negative result: the telomere arm is real at the population level
      but does not explain individual clinical variation.
  downstream:
  - target: Short telomere length
    description: >-
      Connects the molecular arm to its directly measured clinical correlate.
  - target: Defective Lymphocyte Proliferation and Combined Immunodeficiency
    description: >-
      Impaired telomere homeostasis limits the replicative capacity of the
      lymphocyte compartment.
- name: Loss of RMRP-Derived Small RNA Gene Silencing
  biological_scale: MOLECULAR
  description: >-
    A fourth arm that is easy to overlook and is the best available explanation
    for the hair phenotype specifically, which the ribosome arm accounts for
    poorly. The RMRP transcript is itself processed into at least two short RNAs,
    RMRP-S1 and RMRP-S2, that behave as microRNAs, and several disease-causing
    variants map inside them. Both are markedly reduced in cells from patients.
    Their regulatory targets are enriched for skeletal development, hair
    development and haematopoietic differentiation programmes, naming PTCH2 and
    SOX4 among others, so the disease may be as much a disorder of lost
    small-RNA regulation as of lost cleavage activity.
  biological_processes:
  - preferred_term: miRNA-mediated post-transcriptional gene silencing
    term:
      id: GO:0035195
      label: miRNA-mediated post-transcriptional gene silencing
    modifier: DECREASED
  evidence:
  - reference: PMID:24009312
    reference_title: "Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We show that the 268-nt non-coding RNA component of mitochondrial RNA processing endoribonuclease, (RNase MRP), is the source of at least two short (∼20 nt) RNAs designated RMRP-S1 and RMRP-S2, which function as miRNAs."
    explanation: >-
      Establishes the existence and microRNA function of the RMRP-derived small
      RNAs on which this node rests.
  - reference: PMID:24009312
    reference_title: "Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Point mutations in RNase MRP cause human cartilage-hair hypoplasia (CHH), and several disease-causing mutations map to RMRP-S1 and -S2."
    explanation: >-
      Links the disease alleles physically to the small RNAs, which is what
      makes this arm disease-relevant rather than incidental biology.
  - reference: PMID:24009312
    reference_title: "Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "RMRP-S1 and -S2 are significantly reduced in two fibroblast cell lines and a B-cell line derived from CHH patients."
    explanation: >-
      Demonstrates loss of the small RNAs in patient-derived cells.
  - reference: PMID:24009312
    reference_title: "Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes."
    explanation: >-
      Connects the lost silencing activity to the specific developmental
      programmes affected in CHH, including hair.
  downstream:
  - target: Hair Follicle Hypoplasia
    description: >-
      Loss of small-RNA regulation of hair development programmes is the most
      direct available route to the hair phenotype.
  - target: Growth Plate Chondrocyte Differentiation Failure
    description: >-
      Skeletal development genes are among the programmes these small RNAs
      regulate.
- name: Growth Plate Chondrocyte Differentiation Failure
  biological_scale: TISSUE
  description: >-
    Chondrocytes in the growth plate are among the most biosynthetically
    demanding cells in the developing skeleton, which is why a ceiling on
    ribosome synthesis strikes them first. RNase MRP is itself expressed in the
    growth plate, with the RNA and its protein subunits co-clustering to the
    hypertrophic zone, so this is tissue-specific expression rather than a purely
    quantitative demand argument. Loss of function disorders chondrocyte columnar
    organization and blocks terminal differentiation, producing the metaphyseal
    dysplasia that names the disease. Growth failure is largely prenatal in
    origin and then progressive through infancy and puberty. The zebrafish
    knockout adds a candidate effector, upregulated canonical Wnt/beta-catenin
    signalling, which is pharmacologically reversible in that model; it is
    recorded here as a model-organism lead rather than an established human
    mechanism.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: chondrocyte differentiation
    term:
      id: GO:0002062
      label: chondrocyte differentiation
    modifier: DECREASED
  - preferred_term: chondrocyte hypertrophy
    term:
      id: GO:0003415
      label: chondrocyte hypertrophy
    modifier: DECREASED
  - preferred_term: endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  evidence:
  - reference: PMID:28743979
    reference_title: "Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."
    explanation: >-
      Direct chondrocyte evidence coupling impaired pre-rRNA processing to
      deranged differentiation in the same experiment.
  - reference: PMID:28743979
    reference_title: "Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Expression of Rmrp RNA and RNase MRP protein subunits was detected in the murine growth plate and during the course of chondrogenic differentiation of ATDC5 cultures, where Rmrp RNA expression was found to be correlated with chondrocyte hypertrophy."
    explanation: >-
      Localizes RNase MRP expression to the growth plate and ties it to the
      hypertrophic step, supporting tissue specificity.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Histological examination of the patient's bone back in 1960s demonstrated the paucity of cartilage cells and disturbed columnar tissue organization"
    explanation: >-
      Human histological correlate: the growth plate is hypocellular and loses
      its columnar architecture.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Short stature in CHH is mostly prenatal, with birth length corrected for gestational age being -2.9 standard deviation score (SDS) for boys and -3.0 SDS for girls"
    explanation: >-
      Establishes that the growth deficit is largely established before birth,
      consistent with a developmental growth-plate lesion.
  - reference: PMID:31237961
    reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants."
    explanation: >-
      PARTIAL by design: the Wnt effector and its pharmacological reversal are
      demonstrated only in zebrafish and are not established in human
      chondrocytes, so they inform this node without being asserted of it.
  downstream:
  - target: Metaphyseal chondrodysplasia
    description: >-
      Growth-plate disorganization produces the metaphyseal dysplasia that names
      the disease.
  - target: Disproportionate short-limb short stature
    description: >-
      Failure of endochondral elongation in the limbs produces disproportionate
      short stature.
  - target: Genu varum
    description: >-
      Asymmetric metaphyseal growth about the knee produces varus deformity of
      the lower limbs.
  - target: Limited elbow extension
    description: >-
      Dysplastic elbow joint surfaces limit extension despite generalized
      ligamentous laxity elsewhere.
  - target: Joint hypermobility
    description: >-
      Abnormal cartilage and periarticular connective tissue produce generalized
      ligamentous laxity.
  - target: Lumbar hyperlordosis
    description: >-
      Altered spinal and pelvic proportions produce a compensatory lumbar
      lordosis.
  - target: Short metacarpal
    description: >-
      The same failure of endochondral growth shortens the short tubular bones
      of the hands and feet.
  - target: Coxa vara
    description: >-
      Growth failure at the proximal femoral physis, outpaced by trochanteric
      growth, reduces the femoral neck-shaft angle.
  - target: Scoliosis
    description: >-
      Vertebral growth-plate involvement contributes to lateral spinal
      curvature in a minority of patients.
- name: Defective Lymphocyte Proliferation and Combined Immunodeficiency
  biological_scale: CELLULAR
  description: >-
    The proliferation block falls hardest on the lymphoid compartment, where
    clonal expansion is the mechanism of immunity itself. The characteristic
    pattern is depletion of exactly the rapidly proliferating populations: recent
    thymic emigrants and naive CD4 and CD8 cells are reduced while activated and
    memory subsets are relatively increased, and naive, transitional and memory B
    cells are reduced with an increase in activated CD21-low cells. Clinically
    this spans a wide range, from no signs at all through isolated humoral
    defects to frank combined immunodeficiency, and laboratory indices correlate
    only weakly with symptoms. Two features make this arm unusually treacherous:
    immune involvement is progressive, with adult-onset immunodeficiency
    documented, and specific antibody deficiency after polysaccharide vaccination
    is common and may mark more severe disease. A patient who looks
    immunologically well at one assessment cannot be assumed to remain so.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: T cell proliferation
    term:
      id: GO:0042098
      label: T cell proliferation
    modifier: DECREASED
  - preferred_term: T cell activation
    term:
      id: GO:0042110
      label: T cell activation
    modifier: DECREASED
  evidence:
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The reduced counts of rapidly proliferating cells (naive T, RTE, and B) support a disturbed cell cycle as an important pathogenic mechanism"
    explanation: >-
      The authors' own reading of the immunophenotype as a proliferation defect,
      which is the link this node asserts between molecular and cellular levels.
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "decreased CD3+CD4+CD45RA+CD31+ recent thymic emigrants (RTE), naive CD4+ and CD8+ cells; 2) increased activated CD4+, central memory CD4+ and effector memory CD8+ cells"
    explanation: >-
      Specifies the naive-depleted, memory-shifted pattern described here.
  - reference: PMID:35115551
    reference_title: "A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we analyzed disease-relevant primary cells, showing that mutations in RMRP impair mouse T cell activation and delay pre-rRNA processing."
    explanation: >-
      Experimental demonstration that disrupting RMRP impairs T cell activation
      specifically; tagged MODEL_ORGANISM because the activation experiment was
      performed in mouse T cells.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a significant proportion of patients (17/79, 22%), clinical features of immunodeficiency progressed over time."
    explanation: >-
      Establishes progression of immune involvement over time, the basis for
      treating a single normal assessment as insufficient.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency."
    explanation: >-
      Quantifies the clinical spread in a 30-year prospective cohort and
      documents adult-onset presentation.
  downstream:
  - target: Combined immunodeficiency
    description: >-
      The lymphoid proliferation defect manifests clinically as combined
      immunodeficiency in a substantial minority.
  - target: Decreased total T cell count
    description: >-
      Reduced production of naive T cells and recent thymic emigrants lowers
      circulating T cell counts.
  - target: Recurrent respiratory infections
    description: >-
      Impaired cellular and humoral immunity permits recurrent sinopulmonary
      infection.
  - target: Severe varicella zoster infection
    description: >-
      Defective cellular immunity underlies the historically feared severe
      primary varicella.
  - target: Decreased specific antibody response to vaccination
    description: >-
      The B cell production and germinal-centre defect manifests as failure to
      mount specific antibody after polysaccharide challenge, even where total
      immunoglobulin is preserved.
  - target: Impaired Immune Surveillance and Lymphomagenesis
    description: >-
      The same lymphoid defect removes the surveillance that would otherwise
      contain emerging lymphoid clones.
  - target: Chronic Airway Infection and Bronchiectasis
    description: >-
      Repeated and incompletely cleared airway infection drives structural lung
      damage.
  - target: Immune Dysregulation and Autoimmunity
    description: >-
      The same disturbed lymphocyte compartment produces failures of tolerance
      as well as failures of defence.
- name: Multilineage Bone Marrow Progenitor Failure
  biological_scale: CELLULAR
  description: >-
    Marrow progenitors are the other highly proliferative compartment, and they
    fail in the same way. Colony formation is defective across erythroid,
    megakaryocyte and granulocyte-macrophage lineages even in patients whose
    peripheral counts are normal, and the defect is not explained by a shortage
    of progenitors: the progenitors are present but cannot form colonies under
    conditions sufficient for normal cells. Clinically the erythroid lineage is
    the one that decompensates, giving a macrocytic, often transfusion-dependent
    anemia most severe in early childhood and typically remitting with age. Bone
    marrow erythroid hypoplasia is found in all severely anemic patients who are
    examined.
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  biological_processes:
  - preferred_term: erythrocyte differentiation
    term:
      id: GO:0030218
      label: erythrocyte differentiation
    modifier: DECREASED
  evidence:
  - reference: PMID:7895753
    reference_title: "Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH."
    explanation: >-
      Establishes that the marrow defect spans lineages and is read by the
      authors as the same proliferation defect seen elsewhere.
  - reference: PMID:7895753
    reference_title: "Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors."
    explanation: >-
      Distinguishes a functional proliferation defect from progenitor depletion,
      which is the specific claim this node makes.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone marrow erythroid hypoplasia and poor growth of erythroid precursors have been demonstrated in all CHH patients with severe anemia who underwent bone marrow examinations"
    explanation: >-
      In-patient marrow correlate of the culture findings for the severely
      anemic subgroup.
  - reference: PMID:10690856
    reference_title: "Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Retrospective analysis of hematological data of 114 patients showed that the severity of the anemia and macrocytosis in CHH varies with age. The anemia was most severe in early childhood."
    explanation: >-
      Establishes the age dependence of the anemia, which makes it a childhood
      rather than lifelong management problem in most patients.
  downstream:
  - target: Macrocytic anemia
    description: >-
      Failure of erythroid colony formation produces a macrocytic anemia.
  - target: Anemia
    description: >-
      Connects the progenitor defect to the general clinical phenotype.
  - target: Decreased total neutrophil count
    description: >-
      The granulocyte-macrophage arm of the colony-formation defect can
      decompensate into clinical neutropenia, though it usually does not.
- name: Immune Dysregulation and Autoimmunity
  biological_scale: ORGANISM
  description: >-
    The disturbed lymphocyte compartment fails at tolerance as well as at
    defence. Clinical autoimmunity affects about a tenth of patients and spans an
    unusually broad range, from autoimmune haemolytic anemia and thrombocytopenia
    to narcolepsy, psoriasis and neuropathy. Serum autoantibody positivity is
    considerably more common than clinical autoimmune disease, so antibodies
    alone should not be over-read. What makes this arm clinically important
    rather than a curiosity is that autoimmunity is associated with higher
    mortality and clusters with recurrent pneumonia and sepsis, and that
    autoimmunity in adulthood is one of the strongest reported risk factors for
    early death. Atopic disease is also strikingly prevalent.
  evidence:
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy)."
    explanation: >-
      Quantifies clinical autoimmunity and establishes the breadth of the
      spectrum.
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AI diseases are common in Finnish patients with CHH and are associated with higher mortality, recurrent pneumonia, sepsis, high IgE and/or undetectable IgA levels."
    explanation: >-
      Establishes the mortality association that makes this arm clinically
      consequential.
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several patients demonstrated serum autoantibody positivity without compatible symptoms."
    explanation: >-
      Retained caveat: seropositivity substantially exceeds clinical disease, so
      autoantibodies alone do not establish autoimmunity in this population.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "autoimmunity in adulthood (OR = 39, 95%CI = 3.5-430)"
    explanation: >-
      Quantifies adult autoimmunity as a mortality risk factor; the very wide
      confidence interval is itself informative about the precision available in
      a cohort this size.
  downstream:
  - target: Autoimmunity
    description: >-
      Loss of tolerance manifests as clinical autoimmune disease.
  - target: Autoimmune hemolytic anemia
    description: >-
      The most common single autoimmune manifestation of CHH.
  - target: Asthma
    description: >-
      Immune dysregulation in CHH includes a markedly increased prevalence of
      atopic airway disease.
  - target: Allergic rhinitis
    description: >-
      Allergic rhinoconjunctivitis is excessively prevalent in the CHH
      population.
- name: Impaired Immune Surveillance and Lymphomagenesis
  biological_scale: ORGANISM
  description: >-
    Malignancy is the most consequential downstream event in CHH and the clearest
    instance of the disease's central asymmetry: risk does not track clinical
    immune severity. The excess is overwhelmingly lymphoid, with non-Hodgkin
    lymphoma dominating and diffuse large B-cell lymphoma the most common
    subtype, presenting in young adulthood and usually at advanced stage. Basal
    cell carcinoma is the other strongly elevated cancer and occurs only on
    sun-exposed skin. Two mechanistic strands plausibly converge here, loss of
    lymphoid immune surveillance and the cell-cycle and telomere lesions acting
    cell-autonomously within the transforming clone, and the evidence does not
    separate them. What is established is that first-degree relatives carry no
    excess risk, so this is a consequence of the biallelic state rather than of
    shared environment.
  evidence:
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180)"
    explanation: >-
      Registry-based quantification of the overall and lymphoma-specific excess
      risk against population expectation.
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61)."
    explanation: >-
      Quantifies the second component of the cancer excess.
  - reference: PMID:10064668
    reference_title: "Increased incidence of cancer in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cancer incidence among the siblings or the parents did not differ from the average cancer incidence in the Finnish population."
    explanation: >-
      Internal control establishing that the excess belongs to the biallelic
      disease state and not to family background or shared environment.
  - reference: PMID:10064668
    reference_title: "Increased incidence of cancer in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study confirms an increased risk of cancer, especially non-Hodgkin's lymphoma, probably attributable to defective immunity, among patients with CHH."
    explanation: >-
      PARTIAL because the attribution to defective immunity is offered as
      probable rather than demonstrated; the surveillance mechanism is not
      established against the cell-autonomous alternative.
  - reference: PMID:36211439
    reference_title: "Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common lymphoma type was diffuse large cell B-cell lymphoma (DLBCL) (6/16, 38%). Eight patients received chemotherapy (8/16, 50%), and two of them survived."
    explanation: >-
      Characterizes the dominant lymphoma subtype and the poor treatment
      outcome.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 15 patients with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency."
    explanation: >-
      The key surveillance-relevant observation: over half of cancers arose in
      patients with no clinical immune symptoms, which is why screening is
      universal rather than risk-stratified.
  downstream:
  - target: Non-Hodgkin lymphoma
    description: >-
      Loss of lymphoid surveillance and the intrinsic cell-cycle lesion converge
      on B-cell lymphoma.
  - target: Basal cell carcinoma
    description: >-
      Impaired cutaneous immune surveillance permits basal cell carcinoma on
      sun-exposed skin.
  - target: Neoplasm
    description: >-
      Connects the surveillance failure to the general malignancy phenotype.
- name: Chronic Airway Infection and Bronchiectasis
  biological_scale: TISSUE
  description: >-
    Recurrent and incompletely cleared sinopulmonary infection produces
    structural airway damage, and progressive lung disease is a leading cause of
    death in adults with CHH; in the 30-year prospective cohort, lung disease
    carried the highest cause-specific standardized mortality ratio of any
    category. The relationship to measured immunity is loose: bronchiectasis
    occurs in patients without hypogammaglobulinemia, and immunoglobulin
    replacement is often insufficient to halt it. Reported prevalence spans
    roughly a third to a half depending on cohort selection. Longitudinal imaging
    suggests that once established the changes are largely stable rather than
    relentlessly progressive in unselected patients, which argues for monitoring
    rather than assuming inevitable decline.
  evidence:
  - reference: PMID:33675005
    reference_title: "Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."
    explanation: >-
      Establishes the infection-to-bronchiectasis link and the prevalence range
      quoted here.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3-11); most commonly from malignancy (n = 7, SMR = 10, 95%CI = 4.1-21) and lung disease (n = 4, SMR = 46, 95%CI = 9.5-130)."
    explanation: >-
      Quantifies overall and cause-specific mortality, showing lung disease with
      the highest cause-specific ratio despite fewer deaths than malignancy.
  - reference: PMID:33675005
    reference_title: "Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In conclusion, our results suggest slow if any development of bronchiectasis in selected subjects with cartilage-hair hypoplasia."
    explanation: >-
      Counterweight retained deliberately: in a prospectively followed selected
      cohort the structural changes did not progress, so this node should not be
      read as asserting inevitable decline. PARTIAL because the cohort was small
      and selected.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypogammaglobulinemia is present in some, but not all, of these patients, and immunoglobulin replacement therapy (IGRT) is often insufficient to prevent deterioration."
    explanation: >-
      Establishes the dissociation between measurable antibody deficiency and
      lung disease, and the limits of replacement therapy.
  downstream:
  - target: Bronchiectasis
    description: >-
      Repeated airway infection and inflammation produce irreversible bronchial
      dilatation.
  - target: Recurrent pneumonia
    description: >-
      Impaired clearance and damaged airways predispose to repeated pneumonia.
- name: Hair Follicle Hypoplasia
  biological_scale: TISSUE
  description: >-
    Hair hypoplasia gives the disease the second half of its name and is one of
    the phenotypes that tracks the messenger-RNA cleavage arm rather than the
    ribosomal one. The hair is fine, sparse and silky, ranging from mildly sparse
    scalp hair to complete alopecia in the most affected. The hair follicle is
    another compartment defined by continuous rapid proliferation, so its
    involvement fits the proliferative-demand logic; the more specific
    explanation is that RMRP-derived small RNAs regulate hair development
    programmes directly, which the ribosome arm alone does not account for.
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."
    explanation: >-
      Establishes fine silky hair as a characteristic feature of the spectrum.
  - reference: PMID:17701897
    reference_title: "Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "reduced mRNA cleavage, and thus cell-cycle impairment, predicts the presence of hair hypoplasia, immunodeficiency, and hematological abnormalities and thus increased cancer risk"
    explanation: >-
      Assigns hair hypoplasia specifically to the messenger-RNA cleavage arm.
  - reference: PMID:24009312
    reference_title: "Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes."
    explanation: >-
      Provides the specific regulatory route to hair development that the
      ribosome arm does not supply.
  downstream:
  - target: Fine hair
    description: >-
      Follicular hypoplasia produces abnormally fine, silky hair.
  - target: Sparse hair
    description: >-
      Reduced follicular output produces sparse scalp and body hair.
- name: Gastrointestinal and Enteric Nervous System Involvement
  biological_scale: ORGANISM
  description: >-
    Hirschsprung disease is a well-established comorbidity, reported in roughly a
    tenth to a quarter of Finnish patients depending on era, and prolonged or
    recurrent diarrhoea with malabsorption is common independently of it. The
    mechanistic link between RNase MRP deficiency and failure of enteric neural
    crest colonization is genuinely unknown, which is unusual in this entry:
    every other arm has at least a candidate substrate. The zebrafish knockout
    shows a hypoplastic gut with reduced intestinal epithelial cell numbers and
    absent villi, consistent with a general proliferative defect in gut
    epithelium, but that is a different claim from aganglionosis. Hirschsprung
    disease is also one of the reported risk factors for early death, so this is
    not a cosmetic gap.
  evidence:
  - reference: PMID:32506568
    reference_title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."
    explanation: >-
      Establishes Hirschsprung disease as part of the characteristic CHH
      phenotype.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hirschsprung's disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown."
    explanation: >-
      Explicit statement that the mechanism is unknown, which is why this node
      does not assert one.
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."
    explanation: >-
      Quantifies the non-Hirschsprung gastrointestinal burden in a defined
      cohort.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hirschsprung disease (odds ratio (OR) 7.2, 95%CI = 1.04-55)"
    explanation: >-
      Establishes Hirschsprung disease as a mortality risk factor, which is why
      this arm matters prognostically; the confidence interval only just
      excludes unity.
  downstream:
  - target: Aganglionic megacolon
    description: >-
      Failure of enteric ganglion cell colonization produces Hirschsprung
      disease, by a route that remains unidentified.
  - target: Chronic diarrhea
    description: >-
      Enteropathy and malabsorption produce persistent or recurrent diarrhoea.
phenotypes:
- name: Disproportionate short-limb short stature
  category: Growth
  description: >-
    Disproportionate short stature with short extremities, largely established
    before birth and progressive during infancy and puberty. Median adult height
    is 131 cm for men and 123 cm for women. Individuals of normal height with
    genetically confirmed CHH have been reported, so short stature is
    characteristic but not obligatory.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Disproportionate short-limb short stature
    term:
      id: HP:0008873
      label: Disproportionate short-limb short stature
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CHH-AD spectrum disorders are characterized by severe disproportionate (short-limb) short stature that is usually recognized in the newborn, and occasionally prenatally because of the short extremities."
    explanation: >-
      Establishes short-limb disproportionate short stature as a defining and
      near-universal feature of the spectrum, supporting the VERY_FREQUENT band.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The growth failure is progressive, particularly during the first year of life and during puberty, resulting in the median adult height of 131 cm for males and 123 cm for females"
    explanation: >-
      Quantifies the adult height outcome described here.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While short stature was first thought to be invariably present in CHH patients, individuals with normal height have since been reported"
    explanation: >-
      Retained qualification: short stature is characteristic but not
      obligatory, which is why the band is VERY_FREQUENT rather than obligate.
- name: Metaphyseal chondrodysplasia
  category: Skeletal
  description: >-
    Metaphyseal dysplasia with flaring, cupping, widening, cysts, fragmentation
    and scalloping of the metaphyses, most marked at the knee. Changes may not be
    apparent in the first two years of life and some patients never show them, so
    normal radiographs do not exclude the diagnosis.
  phenotype_term:
    preferred_term: Metaphyseal chondrodysplasia
    term:
      id: HP:0005871
      label: Metaphyseal chondrodysplasia
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiologically, metaphyseal abnormalities included flaring, cupping, widening, cysts, fragmentation, and scalloping of metaphyses in the tubular bones, particularly at the knee."
    explanation: >-
      Describes the specific radiographic metaphyseal changes of CHH.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, metaphyseal changes may not be apparent in the first 2 years of life"
    explanation: >-
      Supports the diagnostic caveat that early radiographs may be
      uninformative.
- name: Joint hypermobility
  category: Musculoskeletal
  description: >-
    Generalized ligamentous laxity, present in the large majority of patients and
    coexisting paradoxically with restricted elbow extension.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)"
    explanation: >-
      Reports ligamentous laxity in 95% (81/85), which maps to the VERY_FREQUENT
      band (80-100%).
- name: Limited elbow extension
  category: Musculoskeletal
  description: >-
    Incomplete extension of the elbows, present in the great majority of patients
    despite generalized laxity elsewhere.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Limited elbow extension
    term:
      id: HP:0001377
      label: Limited elbow extension
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "incomplete extension of elbows (present in 92%, 79/86 patients) despite overall ligamentous laxity (95%, 81/85)"
    explanation: >-
      Reports incomplete elbow extension in 92% (79/86), which maps to the
      VERY_FREQUENT band (80-100%).
- name: Genu varum
  category: Skeletal
  description: >-
    Varus deformity of the lower limbs, frequently progressive and a common
    indication for corrective realignment surgery.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Genu varum
    term:
      id: HP:0002970
      label: Genu varum
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"
    explanation: >-
      Reports lower-limb varus deformity in 63% (54/86), which maps to the
      FREQUENT band (30-79%).
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The review of orthopedic data from 135 North American patients with CHH revealed that ~43% had required surgical realignment for the bowing of lower extremities"
    explanation: >-
      Quantifies the surgical burden arising from the deformity.
- name: Lumbar hyperlordosis
  category: Skeletal
  description: >-
    Exaggerated lumbar lordosis, part of the characteristic skeletal habitus.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Lumbar hyperlordosis
    term:
      id: HP:0002938
      label: Lumbar hyperlordosis
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"
    explanation: >-
      Reports lumbar lordosis in 85% (72/85), which maps to the VERY_FREQUENT
      band (80-100%).
- name: Scoliosis
  category: Skeletal
  description: >-
    Lateral spinal curvature, present in a minority of patients.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lower limbs varus deformity (63%, 54/86), chest deformity (68%, 57/84), as well as lumbar lordosis (85%, 72/85) and scoliosis (21%, 18/86)"
    explanation: >-
      Reports scoliosis in 21% (18/86), which maps to the OCCASIONAL band
      (5-29%).
- name: Short metacarpal
  category: Skeletal
  description: >-
    Marked shortening of the metacarpals, metatarsals and phalanges with
    metaphyseal cupping and cone-shaped epiphyses, giving the characteristically
    short, pudgy hands with striking laxity of the small joints. No frequency
    band is assigned because the orthopaedic series describes the finding
    qualitatively rather than counting it.
  phenotype_term:
    preferred_term: Short metacarpal
    term:
      id: HP:0010049
      label: Short metacarpal
  evidence:
  - reference: PMID:25764362
    reference_title: "Cartilage hair hypoplasia: characteristics and orthopaedic manifestations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is marked shortening of the metacarpals, metatarsals, and phalanges, with metaphyseal cupping"
    explanation: >-
      Directly describes the shortened metacarpals this phenotype records, in
      the largest reported orthopaedic series of CHH patients.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typical features in addition to short limbs include short hands"
    explanation: >-
      Independent confirmation that short hands are a typical feature, though
      stated clinically rather than at the level of the individual bone.
- name: Coxa vara
  category: Skeletal
  description: >-
    Reduced femoral neck-shaft angle on radiography, present in about a quarter
    of patients whose films were reviewed. Occasionally severe enough to warrant
    corrective osteotomy alongside the more common varus knee.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Coxa vara
    term:
      id: HP:0002812
      label: Coxa vara
  evidence:
  - reference: PMID:25764362
    reference_title: "Cartilage hair hypoplasia: characteristics and orthopaedic manifestations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In our series, 27 % of the cases where radiographs were reviewed (19/71) showed coxa vara radiographically."
    explanation: >-
      Reports coxa vara in 27% (19/71), which maps to the OCCASIONAL band
      (5-29%).
- name: Decreased specific antibody response to vaccination
  category: Immunologic
  description: >-
    Specific antibody deficiency after polysaccharide vaccination is common and
    may mark more severe disease. It matters mechanistically because it is the
    dominant humoral abnormality in CHH: total immunoglobulin levels are usually
    preserved and frank hypogammaglobulinemia is rare, so a normal
    immunoglobulin panel does not exclude a clinically meaningful antibody
    defect. Vaccine responses therefore need testing directly rather than being
    inferred from immunoglobulin concentrations.
  phenotype_term:
    preferred_term: Decreased specific antibody response to vaccination
    term:
      id: HP:0032140
      label: Decreased specific antibody response to vaccination
  evidence:
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients who agreed to receive Pneumovax"
    explanation: >-
      Marks the vaccine-challenge experiment in which seven of eight
      participants demonstrated specific antibody deficiency. No frequency band
      is assigned because only eight patients consented, so the proportion is
      not a population estimate.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While B cell counts are often decreased, hypogammaglobulinemia is rare in patients with CHH; moreover, some individuals have hypergammaglobulinemia"
    explanation: >-
      Establishes that total immunoglobulin concentration is usually preserved
      in CHH, which is why the humoral defect is curated here as an impaired
      specific antibody response rather than as decreased circulating
      immunoglobulin.
- name: Decreased total neutrophil count
  category: Hematologic
  description: >-
    Neutropenia occurs in single patients and may be intrinsic to the marrow
    defect or autoimmune in origin. It is reported alongside the anemia rather
    than instead of it, consistent with the multilineage colony-formation
    defect, but it is not a characteristic feature and no frequency band is
    assigned.
  phenotype_term:
    preferred_term: Decreased total neutrophil count
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Single patients also have neutropenia, either intrinsic or autoimmune"
    explanation: >-
      Establishes neutropenia as an occasional feature and names both candidate
      mechanisms; the single-patient framing is why no frequency is assigned.
  - reference: PMID:25764362
    reference_title: "Cartilage hair hypoplasia: characteristics and orthopaedic manifestations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CHH is associated with a broad spectrum of mild-to-moderate, cell-mediated immunodysfunction, including occasionally severe combined immune deficiency, neutropenia, lymphopenia, disordered erythrogenesis, and a predisposition to lymphoma"
    explanation: >-
      Independent listing of neutropenia among the recognized haematologic
      features of CHH.
- name: Fine hair
  category: Dermatologic
  description: >-
    Fine, silky hair, one of the two features that name the disease.
  phenotype_term:
    preferred_term: Fine hair
    term:
      id: HP:0002213
      label: Fine hair
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."
    explanation: >-
      Establishes fine silky hair as a characteristic feature.
- name: Sparse hair
  category: Dermatologic
  description: >-
    Hypoplastic, sparse scalp and body hair, ranging in severity up to complete
    alopecia in the most severely affected individuals.
  phenotype_term:
    preferred_term: Sparse hair
    term:
      id: HP:0008070
      label: Sparse hair
  evidence:
  - reference: PMID:32506568
    reference_title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunodeficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of immune dysfunction and increased incidence of anaemia, Hirschsprung disease and malignancy."
    explanation: >-
      Names hypotrichosis as a defining feature of the syndrome.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Historically, CHH-HD has been associated with more severe growth failure, complete alopecia, and severe anemia"
    explanation: >-
      Supports the severe end of the hair phenotype; PARTIAL because complete
      alopecia is described in the Hirschsprung subgroup rather than of CHH
      generally.
- name: Combined immunodeficiency
  category: Immunologic
  description: >-
    Clinical combined immunodeficiency, affecting roughly a quarter of patients
    in prospective follow-up. More than half manifest no symptoms of
    immunodeficiency at all, and a further fifth show humoral features only, so
    the label describes one end of a continuum rather than the disease as a
    whole. Onset may be in adulthood.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Combined immunodeficiency
    term:
      id: HP:0005387
      label: Combined immunodeficiency
  evidence:
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency."
    explanation: >-
      Reports symptomatic combined immunodeficiency in 24% of an 80-patient
      prospective cohort, which maps to the OCCASIONAL band (5-29%).
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We grouped patients as having: 1) no symptoms/signs of immunodeficiency (n=15, 27%), 2) features of humoral immunodeficiency only (n=26, 46%) and 3) features of combined immunodeficiency (CID, n=15, 27%)"
    explanation: >-
      Independent cohort reporting 27%, consistent with the same band.
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As mortality due to infections and malignancies is increased in CHH4, patients surviving into adulthood represent individuals with milder disease."
    explanation: >-
      Ascertainment caveat retained: cohorts of living patients probably
      understate severity in the disease as a whole.
- name: Decreased total T cell count
  category: Laboratory
  description: >-
    Reduced circulating T cells, with the deficit concentrated in recent thymic
    emigrants and naive subsets. Patients with clinically suggested combined
    immunodeficiency show lower CD3, CD8 and recent thymic emigrant counts.
  phenotype_term:
    preferred_term: Decreased total T cell count
    term:
      id: HP:0005403
      label: Decreased total T cell count
  evidence:
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with clinically suggested CID showed decreased median CD3+, CD8+ and RTE counts"
    explanation: >-
      Directly reports reduced T cell counts in the clinically affected
      subgroup.
- name: Recurrent respiratory infections
  category: Immunologic
  description: >-
    Recurrent sinopulmonary infection including rhinosinusitis, otitis media and
    pneumonia. A substantial share of patients nonetheless have a normal
    infection history, which is why no frequency band is assigned.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:33675005
    reference_title: "Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."
    explanation: >-
      Establishes the recurrent respiratory infection phenotype.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the clinical cohorts, 33-78% of the patients have normal infection history"
    explanation: >-
      Retained counterweight: a large fraction of patients are not clinically
      infection-prone, so no frequency band is assigned.
- name: Recurrent pneumonia
  category: Respiratory
  description: >-
    Repeated episodes of pneumonia. Pneumonia in the first year of life, or
    recurrently in adulthood, is a reported risk factor for early death.
  phenotype_term:
    preferred_term: Recurrent pneumonia
    term:
      id: HP:0006532
      label: Recurrent pneumonia
  evidence:
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pneumonia in the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3-43/2.6-140)"
    explanation: >-
      Establishes recurrent pneumonia as a prognostic risk factor rather than
      merely a manifestation.
  - reference: PMID:33675005
    reference_title: "Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with subtle signs of bronchiectasis on imaging tended to have low immunoglobulin M levels, as well as suffered from pneumonia during the follow-up."
    explanation: >-
      Links pneumonia during follow-up to the imaging changes in the same
      cohort.
- name: Bronchiectasis
  category: Respiratory
  description: >-
    Irreversible bronchial dilatation from recurrent airway infection, reported
    in about 29% of an unselected adult cohort and up to 52% of symptomatic
    patients, and detectable as early as the first decade.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  evidence:
  - reference: PMID:33675005
    reference_title: "Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with cartilage-hair hypoplasia are prone to recurrent respiratory tract infections, and the prevalence of bronchiectasis ranges from 29 to 52%."
    explanation: >-
      Reports a prevalence range of 29-52%, which sits in the FREQUENT band
      (30-79%) apart from its lowest reported value at the band boundary.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In an unselected cohort of 34 Finnish patients, aged 13-68 years, 10 (29%) had bronchiectasis on chest HRCT imaging"
    explanation: >-
      Gives the unselected-cohort figure anchoring the lower end of the range.
- name: Anemia
  category: Hematologic
  description: >-
    Anemia arising from defective erythroid colony formation, most severe in
    early childhood and typically absent in adults. A minority develop severe
    transfusion-dependent disease, usually presenting within the first months of
    life.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a cohort of 88 Finnish patients, low hemoglobin levels were common in childhood (54/74, 73%), in addition to macrocytosis (in 47%), but were not seen in adult subjects"
    explanation: >-
      Reports low haemoglobin in 73% (54/74) of children, which maps to the
      FREQUENT band (30-79%); the same source notes its absence in adults, which
      is why the description is age-qualified.
  - reference: PMID:10690856
    reference_title: "Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Retrospective analysis of hematological data of 114 patients showed that the severity of the anemia and macrocytosis in CHH varies with age. The anemia was most severe in early childhood."
    explanation: >-
      Independent confirmation of the age dependence of the anemia.
- name: Macrocytic anemia
  category: Hematologic
  description: >-
    The anemia of CHH is characteristically macrocytic, and macrocytosis occurs
    even in patients without anemia. Iron studies, vitamin B12 and folate are
    normal, so this is not a nutritional macrocytosis.
  phenotype_term:
    preferred_term: Macrocytic anemia
    term:
      id: HP:0001972
      label: Macrocytic anemia
  evidence:
  - reference: PMID:39321258
    reference_title: "Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group."
    explanation: >-
      Establishes the macrocytic character of the anemia across the published
      literature.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reticulocyte index and haptoglobin, iron and transferrin concentrations, as well as vitamin B12 and folate levels were normal."
    explanation: >-
      Excludes nutritional and haemolytic causes for the macrocytosis, which is
      what makes it a marker of the intrinsic marrow defect.
- name: Autoimmunity
  category: Immunologic
  description: >-
    Clinical autoimmune disease affects about one in ten patients, against
    roughly 5% in the general Finnish population, and spans an unusually broad
    range. Autoimmunity in adulthood is among the strongest reported risk factors
    for early death.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy)."
    explanation: >-
      Reports clinical autoimmunity in 10.6% (11/104), which maps to the
      OCCASIONAL band (5-29%).
- name: Autoimmune hemolytic anemia
  category: Immunologic
  description: >-
    Autoimmune haemolytic anemia is the most common autoimmune manifestation of
    CHH and is mechanistically distinct from the hypoplastic anemia of marrow
    origin.
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Apart from hypoplastic anemia, autoimmune hemolytic anemia (AIHA) has also been described in multiple patients and is the most common autoimmune phenomenon in CHH."
    explanation: >-
      Establishes AIHA as the leading autoimmune feature and distinguishes it
      from the hypoplastic anemia.
- name: Asthma
  category: Respiratory
  description: >-
    Asthma is substantially more prevalent than in the general population,
    reported in about a quarter of Finnish patients.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Asthma
    term:
      id: HP:0002099
      label: Asthma
  evidence:
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%)."
    explanation: >-
      Reports asthma in 23%, which maps to the OCCASIONAL band (5-29%).
- name: Allergic rhinitis
  category: Immunologic
  description: >-
    Allergic rhinoconjunctivitis is excessively prevalent, affecting roughly two
    in five patients. Notably, nasal cytology showed no eosinophils in the small
    subset tested despite the allergic history, so the mechanism may not be
    straightforwardly atopic.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Allergic rhinitis
    term:
      id: HP:0003193
      label: Allergic rhinitis
  evidence:
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%)."
    explanation: >-
      Reports allergic rhinoconjunctivitis in 39%, which maps to the FREQUENT
      band (30-79%).
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite the history of allergic rhinitis, no eosinophils were observed in nasal cytology in five tested patients."
    explanation: >-
      Retained negative finding qualifying the atopic interpretation; PARTIAL
      because only five patients were tested.
- name: Chronic diarrhea
  category: Gastrointestinal
  description: >-
    Persistent or recurrent diarrhoea affects about a third of patients, with
    chronic gastritis, peptic ulceration or duodenal villous atrophy found on
    endoscopy in some.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Chronic diarrhea
    term:
      id: HP:0002028
      label: Chronic diarrhea
  evidence:
  - reference: PMID:30410491
    reference_title: "A Wide Spectrum of Autoimmune Manifestations and Other Symptoms Suggesting Immune Dysregulation in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."
    explanation: >-
      Reports persistent diarrhoea in 31% (32/104), which maps to the FREQUENT
      band (30-79%).
- name: Aganglionic megacolon
  category: Gastrointestinal
  description: >-
    Hirschsprung disease, reported in 9% of a historical Finnish cohort and 25%
    of patients born in the 2000s, the rise probably reflecting earlier fatal
    cases going undiagnosed rather than a true increase.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Aganglionic megacolon
    term:
      id: HP:0002251
      label: Aganglionic megacolon
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of HD in the Finnish CHH cohort has increased from 9% (13/142) in the 20th century to 25% (8/32) in the 2000s"
    explanation: >-
      Both reported figures, 9% and 25%, fall within the OCCASIONAL band
      (5-29%).
- name: Non-Hodgkin lymphoma
  category: Oncologic
  description: >-
    Non-Hodgkin lymphoma is the dominant malignancy of CHH, with a standardized
    incidence ratio around 90, presenting in young adulthood, usually at advanced
    stage, and with high mortality. Diffuse large B-cell lymphoma is the most
    common subtype.
  phenotype_term:
    preferred_term: Non-Hodgkin lymphoma
    term:
      id: HP:0012539
      label: Non-Hodgkin lymphoma
  evidence:
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1)."
    explanation: >-
      Quantifies the non-Hodgkin lymphoma excess against population expectation.
  - reference: PMID:36211439
    reference_title: "Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lymphoma was diagnosed in young adulthood (median age 26.4 years, range from 6.4 to 69.5 years), mostly in advanced stage."
    explanation: >-
      Establishes the age at presentation and the advanced stage driving the
      poor outcome.
  - reference: PMID:36211439
    reference_title: "Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Altogether, eleven CHH patients died due to lymphomas (11/16, 69%)."
    explanation: >-
      Quantifies lymphoma mortality within the case series.
- name: Basal cell carcinoma
  category: Oncologic
  description: >-
    Basal cell carcinoma occurs at greatly elevated frequency and only on
    sun-exposed skin, which is why sun protection is emphasized in management.
  phenotype_term:
    preferred_term: Basal cell carcinoma
    term:
      id: HP:0002671
      label: Basal cell carcinoma
  evidence:
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61)."
    explanation: >-
      Quantifies the basal cell carcinoma excess against population expectation.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Skin cancer in CHH develops only on sun-exposed areas (95); therefore, enhanced sun protection should be emphasized."
    explanation: >-
      Supports the anatomical restriction to sun-exposed skin and the resulting
      management advice.
- name: Neoplasm
  category: Oncologic
  description: >-
    Overall malignancy risk is elevated roughly sevenfold over population
    expectation, concentrated in young adults, and is not confined to patients
    with clinically apparent immunodeficiency.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12)."
    explanation: >-
      Quantifies the overall cancer excess.
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nine of the 14 cancers were diagnosed in patients less than 45 years of age."
    explanation: >-
      Supports the concentration of malignancy in younger patients.
- name: Severe varicella zoster infection
  category: Immunologic
  description: >-
    Severe primary varicella was described as fatal in the original Amish series
    and remains a recognized risk, although most patients now clear varicella
    without complication. Low IgG2 has been associated with hospitalization for
    varicella.
  phenotype_term:
    preferred_term: Severe varicella zoster infection
    term:
      id: HP:0032170
      label: Severe varicella zoster infection
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "immediate high-dose intravenous acyclovir for varicella infection"
    explanation: >-
      The management recommendation presupposes varicella as a recognized severe
      risk in this population.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This has not been reported in later case series; vice versa, the majority of patients with CHH clear varicella without antiviral medications or any complications"
    explanation: >-
      Retained counterweight: severe varicella is a real but uncommon outcome,
      so no frequency band is assigned and the historical framing is qualified.
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lower median IgG2 concentrations (1.08 vs 1.96 g/l, p=0.016) were observed in patients who required hospitalization for VZV infection."
    explanation: >-
      Supports the IgG2 association described here.
- name: Short telomere length
  category: Laboratory
  description: >-
    Telomeres are shorter than in matched controls, most clearly in children, and
    telomerase activity is reduced in patient lymphocytes. Telomere length does
    not correlate with genotype or with any clinical or laboratory feature within
    CHH.
  phenotype_term:
    preferred_term: Short telomere length
    term:
      id: HP:0031413
      label: Short telomere length
  evidence:
  - reference: PMID:27986801
    reference_title: "Decreased telomere length in children with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In particular children (<18 years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008)."
    explanation: >-
      Directly measures the shortened telomere phenotype in children.
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH."
    explanation: >-
      Independent measurement in lymphocyte subsets, adding the telomerase
      activity deficit.
- name: Abnormal spermatogenesis
  category: Genitourinary
  description: >-
    Impaired spermatogenesis is a recognized feature of the spectrum, and
    pubertal maturation may require hormonal induction.
  phenotype_term:
    preferred_term: Abnormal spermatogenesis
    term:
      id: HP:0008669
      label: Abnormal spermatogenesis
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings include joint hypermobility, fine, silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis."
    explanation: >-
      Names impaired spermatogenesis as a feature of the spectrum.
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A generalized defect in cell proliferation has been speculated to explain several of the clinical manifestations, including disorganized growth-plate chondrocyte maturation, hair hypoplasia, immunodeficiency and impaired spermatogenesis"
    explanation: >-
      Supports routing this phenotype to the cell-cycle arm; PARTIAL because the
      authors present the proliferation explanation as speculation rather than
      as an established mechanism for spermatogenesis specifically.
genetic:
- name: RMRP
  gene_term:
    preferred_term: RMRP
    term:
      id: hgnc:10031
      label: RMRP
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  notes: >-
    Encodes the 269-nucleotide untranslated RNA component of RNase MRP, and was
    the first non-coding nuclear RNA gene implicated in a human disease.
    Biallelic variants cause the whole CHH-AD spectrum; CHH arises from allele
    combinations retaining more residual rRNA cleavage activity than anauxetic
    dysplasia but with substantially impaired messenger-RNA cleavage. The Finnish
    and Amish founder variant is n.71A>G, previously reported as n.70A>G and more
    recently as n.72A>G against a revised reference sequence, which is a live
    source of confusion when comparing papers across years. Two practical points
    follow from RMRP being non-coding: the gene may be missed on whole-exome
    sequencing, and standard ACMG variant-classification criteria apply poorly,
    since none of the four strong-evidence criteria is usable.
  evidence:
  - reference: PMID:11207361
    reference_title: "Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype."
    explanation: >-
      The original cosegregation evidence establishing RMRP as the CHH gene.
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RMRP was the first non-coding nuclear RNA gene implicated in a disease."
    explanation: >-
      Supports the historical significance noted here.
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The founder mutation n.71 A > G (NCBI reference sequence: NR_003051.3) has been detected in almost all previously reported Finnish patients with CHH either in homozygous or heterozygous state3."
    explanation: >-
      Specifies the founder allele and its reference sequence, and its dominance
      in the Finnish population.
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients were homozygous (n=43) or compound heterozygous (n=13) for the RMRP g.70A>G mutation."
    explanation: >-
      Demonstrates the dominance of the founder allele in a genetically
      confirmed cohort, using the older nomenclature noted above.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For example, the founder variant in the Finnish and Amish populations (n.71A>G) has been previously reported as n.70A>G and most recently as n.72A>G."
    explanation: >-
      Documents the nomenclature drift for the founder allele that this note
      warns about.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, pathogenic variants in RMRP may be missed on whole-exome sequencing; therefore, RMRP coverage should be specifically inquired for"
    explanation: >-
      Supports the diagnostic caveat that exome sequencing may not cover this
      non-coding gene.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As an example, of the four criteria of strong evidence of pathogenicity (PS1-4), none is applicable to RMRP variants"
    explanation: >-
      Supports the variant-interpretation difficulty specific to a non-coding
      disease gene.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genotype-phenotype correlation has not been consistently demonstrated in CHH. Siblings with identical pathogenic variants can exhibit dramatically different clinical course of immunodeficiency"
    explanation: >-
      Important limit on the substrate-dissociation model: the in vitro
      correlation does not translate into individual prediction, and identical
      genotypes diverge clinically.
diagnosis:
- name: Clinical and radiographic diagnosis
  description: >-
    Diagnosis is established in a proband with characteristic clinical and
    radiographic findings. Metaphyseal changes may be absent in the first two
    years of life and some patients never show them, so normal radiographs do not
    exclude CHH.
  diagnosis_term:
    preferred_term: skeletal radiography
    term:
      id: NCIT:C38101
      label: X-Ray Imaging
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis of a CHH-AD spectrum disorder is established in a proband with characteristic clinical and radiographic findings."
    explanation: >-
      States the clinical and radiographic basis of diagnosis.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some patients' radiographs show no signs of metaphyseal dysplasia despite evident short stature (19) or severe immunodeficiency"
    explanation: >-
      Supports the caveat that radiographic normality does not exclude the
      diagnosis.
- name: Molecular genetic testing
  description: >-
    Identification of biallelic RMRP variants confirms the diagnosis and enables
    family studies, carrier testing and prenatal or preimplantation testing.
    Testing must specifically cover the non-coding gene including its promoter
    region, since standard exome capture may miss it; whole-genome sequencing,
    targeted panels fully covering RMRP, or copy-number assessment are the
    reliable options.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identification of biallelic pathogenic variants in RMRP by molecular genetic testing can confirm the diagnosis and allow for family studies"
    explanation: >-
      Specifies the role of molecular testing relative to clinical diagnosis.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnostic approach can include whole-genome sequencing or targeted panels that fully capture the RMRP gene, including the promoter region, as well as copy number variation assessment"
    explanation: >-
      Specifies the testing strategies that reliably cover a non-coding gene and
      its promoter.
- name: Immunological assessment and surveillance
  description: >-
    Baseline and serial immunological assessment is recommended in all patients
    including asymptomatic ones, because laboratory abnormalities are common,
    correlate poorly with symptoms, and progress over time, with adult-onset
    immunodeficiency documented. Vaccine responses should be studied after
    infancy, since specific antibody deficiency is common and may mark more
    severe disease.
  diagnosis_term:
    preferred_term: laboratory assessment of immune function
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:32506568
    reference_title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regular follow-up by a multidisciplinary team should be implemented to address immune dysfunction in all patients with CHH, also in asymptomatic cases."
    explanation: >-
      Directly supports assessing asymptomatic patients rather than testing on
      symptoms alone.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In conclusion, patients with CHH may develop adult-onset immunodeficiency or malignancy without preceding clinical symptoms of immune defect, warranting careful follow-up."
    explanation: >-
      The prospective-cohort conclusion that makes lifelong surveillance the
      recommended model rather than symptom-triggered testing.
  - reference: PMID:28284971
    reference_title: "Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SAD may therefore be a marker of more severe disease and vaccine responses should be routinely studied after infancy."
    explanation: >-
      Supports routine vaccine-response testing as part of immunological
      assessment.
treatments:
- name: Hematopoietic stem cell transplantation
  description: >-
    Allogeneic HSCT is the only curative option for the immune and severe
    haematological manifestations of CHH. It corrects the marrow-derived arm
    while leaving growth failure untouched, which is the cleanest available
    demonstration that the skeletal phenotype is chondrocyte-autonomous rather
    than secondary to immune or haematological disease. In a European
    collaborative survey of 16 transplanted patients, 10 were long-term
    survivors, with normalization of T-lymphocyte numbers and function and
    resolution of autoimmunity in all survivors. Its role in mildly symptomatic
    patients remains debated; the argument for transplanting earlier is that
    outcomes worsen once severe infection, organ damage or malignancy has
    supervened.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Defective Lymphocyte Proliferation and Combined Immunodeficiency
    treatment_effect: RESTORES
    description: >-
      Replacing the haematopoietic compartment with donor cells carrying
      functional RMRP restores lymphocyte numbers and function.
    evidence:
    - reference: PMID:20375313
      reference_title: "Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors."
      explanation: >-
        Direct evidence that transplantation corrects the lymphoid arm modeled
        by this node.
  - target: Multilineage Bone Marrow Progenitor Failure
    treatment_effect: RESTORES
    description: >-
      Donor progenitors restore erythropoiesis, curing transfusion-dependent
      anemia.
    evidence:
    - reference: PMID:42170584
      reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The only curative option for severe anemia in CHH remains HSCT, with multiple case reports of successful resolution"
      explanation: >-
        Direct evidence that transplantation corrects the marrow arm modeled by
        this node.
  - target: Immune Dysregulation and Autoimmunity
    treatment_effect: RESTORES
    description: >-
      Autoimmunity resolved in all long-term survivors of transplantation,
      consistent with the dysregulation being intrinsic to the haematopoietic
      compartment.
    evidence:
    - reference: PMID:20375313
      reference_title: "Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors."
      explanation: >-
        Direct evidence of resolution of the autoimmune arm after
        transplantation.
  evidence:
  - reference: PMID:20375313
    reference_title: "Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected."
    explanation: >-
      Establishes both the efficacy for immunodeficiency and the failure to
      affect growth, the dissociation this entry rests on.
  - reference: PMID:20375313
    reference_title: "Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years."
    explanation: >-
      Quantifies long-term survival in the largest reported transplanted cohort.
  - reference: PMID:20375313
    reference_title: "Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients."
    explanation: >-
      Supports the timing argument for earlier transplantation.
  - reference: PMID:32506568
    reference_title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Haematopoietic stem cell transplantation can cure immune dysfunction, but its benefits in mildly symptomatic patients with CHH remain debatable."
    explanation: >-
      Retained qualification on patient selection; PARTIAL because it supports
      the curative claim while explicitly contesting the indication in mild
      disease.
- name: Immunoglobulin replacement therapy
  description: >-
    Immunoglobulin replacement is used for patients with humoral immunodeficiency
    and recurrent infection. Its limits should be stated plainly: progressive
    lung disease occurs in patients with and without hypogammaglobulinemia, and
    replacement is often insufficient to prevent deterioration, so it should not
    be treated as protective against bronchiectasis.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: immunoglobulin therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  target_mechanisms:
  - target: Defective Lymphocyte Proliferation and Combined Immunodeficiency
    treatment_effect: BYPASSES
    description: >-
      Passive antibody substitutes for what the patient's defective B cell
      compartment cannot reliably make, without correcting the underlying
      proliferation defect.
    evidence:
    - reference: PMID:22420014
      reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy"
      explanation: >-
        Establishes immunoglobulin replacement as recommended management for the
        immune defect.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypogammaglobulinemia is present in some, but not all, of these patients, and immunoglobulin replacement therapy (IGRT) is often insufficient to prevent deterioration."
    explanation: >-
      PARTIAL because it establishes the therapy's use while limiting the claim
      of benefit against progressive lung disease.
- name: Antimicrobial prophylaxis and treatment of infection
  description: >-
    Infections are treated according to type, location and severity, with
    prophylactic antibiotics considered in selected patients. Antimicrobial
    management is directed at the consequences of the immune defect rather than
    at the defect itself.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
  target_mechanisms:
  - target: Chronic Airway Infection and Bronchiectasis
    treatment_effect: INHIBITS
    description: >-
      Suppressing recurrent airway infection is the available lever on the
      infection-to-structural-damage sequence.
    evidence:
    - reference: PMID:22420014
      reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "treatment of underlying infections based on their type, location, and severity; immediate high-dose intravenous acyclovir for varicella infection; consideration of prophylactic antibiotic therapy and/or immunoglobulin replacement therapy"
      explanation: >-
        Establishes both treatment of infection and prophylaxis as recommended
        management.
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physiotherapy and other acute and long-term medical management for bronchiectasis per pulmonologist"
    explanation: >-
      Supports the specialist respiratory management arm alongside
      antimicrobials.
- name: High-dose intravenous acyclovir for varicella
  description: >-
    Varicella infection in CHH warrants immediate high-dose intravenous
    acyclovir, a recommendation inherited from the historically fatal varicella
    of the original Amish series. Most patients now clear varicella uneventfully,
    so this is a precaution proportionate to a severe but uncommon outcome rather
    than an expectation of severe disease.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antiviral therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: acyclovir
      term:
        id: CHEBI:2453
        label: acyclovir
  target_mechanisms:
  - target: Defective Lymphocyte Proliferation and Combined Immunodeficiency
    treatment_effect: BYPASSES
    description: >-
      Pharmacological suppression of viral replication substitutes for the
      cellular immunity the patient cannot mount.
    evidence:
    - reference: PMID:22420014
      reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "immediate high-dose intravenous acyclovir for varicella infection"
      explanation: >-
        States the specific antiviral recommendation for this population.
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "immediate high-dose intravenous acyclovir for varicella infection"
    explanation: >-
      The GeneReviews management recommendation this treatment records.
- name: Live viral vaccination, contraindicated when immune function is abnormal
  description: >-
    This is the principal drug-safety consideration in CHH, and the evidence
    points two ways, so it is recorded with both directions intact. GeneReviews
    lists administration of live vaccines as an agent to avoid when there are
    signs of abnormal immunologic function or severe combined immunodeficiency,
    and vaccine-strain rubella has caused skin granulomas in a CHH patient. Set
    against that, a Finnish cohort of 104 patients in which 38% received MMR and
    10% received varicella vaccine recorded no serious adverse events, with
    durable seropositivity and both humoral and cellular responses in a small
    prospective trial. The defensible position is the one the vaccine study
    itself takes: live vaccines may be considered in selected patients with no or
    clinically mild immunodeficiency, which makes immunological assessment before
    immunization the decisive step rather than a blanket rule either way.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: Administration of live vaccines when signs of abnormal immunologic function or SCID are present."
    explanation: >-
      The explicit GeneReviews agents-to-avoid warning, recorded verbatim.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "as well as vaccine-strain rubella virus-induced skin granulomas"
    explanation: >-
      Documents a realized live-vaccine complication in CHH, the concrete basis
      for the warning.
  - reference: PMID:32849667
    reference_title: "The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines."
    explanation: >-
      Direct counterweight to a blanket contraindication; PARTIAL because it is
      a single-population retrospective series plus a five-subject trial, and
      does not license live vaccination in patients with abnormal immune
      function.
  - reference: PMID:32849667
    reference_title: "The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunization with live vaccines may be considered in selected CHH patients with no or clinically mild immunodeficiency."
    explanation: >-
      The authors' own scoped conclusion, which is the position this entry
      adopts.
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early diagnosis of relatives at risk for the CHH-AD spectrum disorders allows for early management of manifestations that can be associated with significant morbidity (e.g., infections, immunization with live vaccines, malignancies)."
    explanation: >-
      Supports extending the same precaution to at-risk relatives before formal
      diagnosis.
- name: Red blood cell transfusion with iron chelation
  description: >-
    Severe anemia is managed with red cell transfusion, and iron chelation is
    recommended for those requiring repeated transfusion. Transfusion dependency
    typically presents in the first months of life and may remit spontaneously or
    recur after prolonged remission, so the requirement should be reassessed
    rather than assumed permanent.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: blood transfusion
    term:
      id: NCIT:C15192
      label: Blood Transfusion
  target_mechanisms:
  - target: Multilineage Bone Marrow Progenitor Failure
    treatment_effect: BYPASSES
    description: >-
      Transfused red cells substitute for the erythropoiesis the marrow cannot
      sustain, without correcting the progenitor defect.
    evidence:
    - reference: PMID:39321258
      reference_title: "Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Most authors have reported macrocytic anemia and blood transfusion as a common treatment approach in this patient group."
      explanation: >-
        Establishes transfusion as the standard supportive approach to the
        anemia.
  evidence:
  - reference: PMID:39321258
    reference_title: "Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recommended guidelines for managing anemia in CHH patients include iron chelation therapy for those requiring multiple blood transfusions, regular assessment of anemia symptoms, red blood cell parameters, and immune system function."
    explanation: >-
      States the chelation and monitoring recommendations recorded here.
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "red blood cell transfusions for severe anemia with iron chelation as needed"
    explanation: >-
      Independent statement of the same management pairing.
- name: Orthopedic surgical management
  description: >-
    Corrective osteotomy may be required for progressive varus deformity of the
    lower extremities, and roughly 43% of North American patients in one
    orthopedic review had required surgical realignment. Surgery addresses the
    consequences of the growth-plate lesion; it does not modify it.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_mechanisms:
  - target: Genu varum
    treatment_effect: INHIBITS
    description: >-
      Realignment osteotomy corrects the varus deformity produced by asymmetric
      metaphyseal growth.
    evidence:
    - reference: PMID:22420014
      reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "corrective osteotomies may be required for progressive varus deformity of the lower extremities"
      explanation: >-
        States the surgical indication for the deformity targeted here.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The review of orthopedic data from 135 North American patients with CHH revealed that ~43% had required surgical realignment for the bowing of lower extremities"
    explanation: >-
      Quantifies the proportion of patients requiring realignment surgery.
- name: Growth hormone therapy, generally not recommended
  description: >-
    This is a negative recommendation, and it is load-bearing for a disorder
    defined by short stature: growth hormone is the intervention families most
    often ask about, and it is mostly considered futile in CHH. Eight patients
    across several case reports had therapy that was ineffective or at best
    temporarily beneficial. The mechanism fits the failure, since the lesion is a
    chondrocyte-autonomous block in growth-plate differentiation rather than a
    deficiency of growth-promoting hormone, and the same futility is documented
    for the hypoplastic anemia. The one carve-out is real and should not be lost:
    where genuine growth hormone deficiency coexists, treatment may help, so the
    recommendation is against reflexive use rather than against ever testing for
    a treatable pituitary cause.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Growth Plate Chondrocyte Differentiation Failure
    treatment_effect: MODULATES
    description: >-
      Growth hormone acts on a growth plate whose defect is intrinsic to the
      chondrocyte, which is the mechanistic reason the intervention mostly
      fails; MODULATES rather than RESTORES because no durable correction of
      this node is demonstrated.
    evidence:
    - reference: PMID:42170584
      reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "Several case reports (altogether, of eight patients) have described GH therapy as ineffective or, at most, with temporary benefit"
      explanation: >-
        Direct negative evidence that growth hormone does not durably correct
        the growth-plate defect.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Growth hormone (GH) treatment in CHH is mostly considered futile."
    explanation: >-
      States the negative recommendation this treatment entry records.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, GH deficiency has also been reported in CHH patients, and for them, GH treatment might be beneficial"
    explanation: >-
      The exception that keeps this from being an absolute contraindication:
      coexisting growth hormone deficiency remains a treatable indication.
  - reference: PMID:10690856
    reference_title: "Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone marrow cultures obtained from six patients with CHH showed reduced or totally absent erythroid colony formation, which was not influenced by GH or IGF-I in vitro or by GH treatment in vivo."
    explanation: >-
      Independent negative result for the haematologic arm, showing growth
      hormone does not rescue the erythroid defect either in vitro or in vivo.
- name: Malignancy surveillance
  description: >-
    Lifelong malignancy surveillance is recommended, with clinical and laboratory
    examination annually in childhood and abdominal ultrasound every one to two
    years, continuing beyond paediatric age. The rationale is unusually strong:
    over half of non-skin cancers in prospective follow-up arose in patients with
    no preceding clinical symptoms of immune defect, and nearly all surviving
    lymphoma patients were diagnosed through routine screening or evaluation of
    mild non-specific symptoms rather than overt presentation.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: cancer screening
    term:
      id: NCIT:C15406
      label: Cancer Screening
  evidence:
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical and laboratory examination for manifestations of malignancy annually in children and as needed in adults; abdominal ultrasound every one to two years in children and as needed in adults."
    explanation: >-
      States the surveillance schedule recorded here.
  - reference: PMID:36211439
    reference_title: "Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In almost all surviving lymphoma patients, the diagnosis was made either during routine follow-up or after evaluation for non-specific mild symptoms."
    explanation: >-
      The strongest available argument for surveillance: survival was associated
      with detection during routine follow-up rather than clinical
      presentation.
  - reference: PMID:36211439
    reference_title: "Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other CHH-related manifestations poorly predicted lymphoma development, implying that all CHH patients should be regularly screened for malignancy."
    explanation: >-
      Supports universal rather than risk-stratified screening.
  - reference: PMID:18698627
    reference_title: "Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Careful follow-up, extending beyond pediatric age, is warranted for early diagnosis of malignancies."
    explanation: >-
      Supports continuing surveillance into adulthood.
clinical_trials:
- name: NCT02383797
  status: COMPLETED
  description: >-
    Prospective immunization of carefully selected CHH patients who lacked a
    varicella history and were seronegative for varicella zoster virus, with
    live attenuated VZV vaccine, assessing both humoral and cell-mediated
    responses. The design is the interesting part: participants were chosen by
    disease severity and degree of immunodeficiency including CD4 counts, and
    acyclovir was held ready for any vaccine-related symptoms, so it is a
    controlled test of exactly the contraindication that GeneReviews states.
    Trial participants developed humoral and cellular responses; one developed a
    post-immunization rash and knee swelling, both of which resolved without
    treatment.
  target_phenotypes:
  - preferred_term: Severe varicella zoster infection
    term:
      id: HP:0032170
      label: Severe varicella zoster infection
  - preferred_term: Decreased specific antibody response to vaccination
    term:
      id: HP:0032140
      label: Decreased specific antibody response to vaccination
  evidence:
  - reference: clinicaltrials:NCT02383797
    reference_title: "Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The investigators will verify the development of immune response to vaccination by testing for VZV antibodies and cell-mediated immunity."
    explanation: >-
      The registered protocol's stated objective, matching the immunization
      question this entry curates under live viral vaccination.
  - reference: PMID:32849667
    reference_title: "The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conducted a clinical trial (ClinicalTrials.gov identifier: NCT02383797) of live VZV vaccine on five subjects with CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and were seronegative for VZV"
    explanation: >-
      Ties the registered trial to its publication and states the enrolment
      criteria that scope its conclusion to mildly affected patients.
  - reference: PMID:32849667
    reference_title: "The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment."
    explanation: >-
      Reports the trial outcome including its single adverse event; PARTIAL
      because five participants cannot establish safety in patients with
      abnormal immune function.
differential_diagnoses:
- name: Anauxetic dysplasia
  disease_term:
    preferred_term: anauxetic dysplasia
    term:
      id: MONDO:0011773
      label: anauxetic dysplasia
  description: >-
    The severe end of the same RMRP spectrum, reached by allele combinations
    producing the greatest loss of rRNA cleavage activity. It shares the
    molecular lesion but is skeletally far more severe and may include
    atlantoaxial subluxation and cognitive deficiency, while the hair, immune and
    haematologic features characteristic of CHH are not assumed to be present.
  distinguishing_features:
  - Markedly more severe skeletal dysplasia, with the most pronounced short stature of the spectrum.
  - Atlantoaxial subluxation may be present in the newborn, which is not characteristic of CHH.
  - Cognitive deficiency may occur, which is not a feature of CHH.
  - Hair, immune and haematologic involvement is conditional rather than characteristic.
  evidence:
  - reference: PMID:17701897
    reference_title: "Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD)."
    explanation: >-
      Places CHH and anauxetic dysplasia at different points of one allelic
      spectrum.
  - reference: PMID:22420014
    reference_title: "Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most severe phenotype, AD, has the most pronounced skeletal phenotype, may be associated with atlantoaxial subluxation in the newborn, and may include cognitive deficiency."
    explanation: >-
      Names the features that separate anauxetic dysplasia from CHH clinically.
- name: Metaphyseal dysplasia without hypotrichosis
  disease_term:
    preferred_term: metaphyseal dysplasia without hypotrichosis
    term:
      id: MONDO:0009601
      label: metaphyseal dysplasia without hypotrichosis
  description: >-
    The mild end of the same RMRP spectrum, distinguished from CHH by absence of
    hair involvement. Its status as a separate entity is doubtful: longitudinal
    follow-up of such individuals has revealed late-onset immune abnormalities
    typical of CHH, so the distinction may reflect age at assessment rather than
    a different disease.
  distinguishing_features:
  - Absence of hypotrichosis, as reflected in the disease name.
  - Milder skeletal phenotype than CHH.
  - May be reclassified as CHH on longer follow-up once immune features emerge.
  evidence:
  - reference: PMID:17701897
    reference_title: "Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the RMRP gene lead to a wide spectrum of autosomal recessive skeletal dysplasias, ranging from the milder phenotypes metaphyseal dysplasia without hypotrichosis and cartilage hair hypoplasia (CHH) to the severe anauxetic dysplasia (AD)."
    explanation: >-
      Places metaphyseal dysplasia without hypotrichosis at the mild end of the
      same spectrum as CHH.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, the longitudinal follow-up of such individuals has revealed late-onset development of immune abnormalities typical for CHH."
    explanation: >-
      Supports treating the distinction as provisional rather than a firm
      diagnostic boundary.
- name: Schmid metaphyseal chondrodysplasia
  disease_term:
    preferred_term: metaphyseal chondrodysplasia, Schmid type
    term:
      id: MONDO:0007983
      label: Schmid metaphyseal chondrodysplasia
  description: >-
    An autosomal dominant COL10A1-related metaphyseal dysplasia sharing short
    stature, metaphyseal changes and genu varum with CHH but with no hair,
    immune, haematologic or malignancy involvement, and dominant rather than
    recessive inheritance. It is the differential that matters when radiographs
    are the presenting finding.
  distinguishing_features:
  - Autosomal dominant inheritance rather than autosomal recessive.
  - Caused by COL10A1 rather than RMRP.
  - No hair hypoplasia, immunodeficiency, anemia or cancer predisposition.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typical clinical manifestations of CHH include chondrodysplasia with short stature, hair hypoplasia, combined immunodeficiency, and anemia."
    explanation: >-
      PARTIAL because this establishes the extraskeletal features that separate
      CHH from an isolated metaphyseal dysplasia, but does not itself discuss
      the Schmid type.
- name: Shwachman-Diamond syndrome
  disease_term:
    preferred_term: Shwachman-Diamond syndrome
    term:
      id: MONDO:0009833
      label: Shwachman-Diamond syndrome
  description: >-
    The other classic metaphyseal dysplasia with marrow failure, and the closest
    mechanistic analogue: also a ribosome-related disorder combining skeletal
    dysplasia with cytopenias and malignancy risk. It is distinguished by
    exocrine pancreatic insufficiency, by neutropenia rather than anemia as the
    dominant cytopenia, and by myeloid rather than lymphoid malignancy.
  distinguishing_features:
  - Exocrine pancreatic insufficiency, absent in CHH.
  - Neutropenia is the characteristic cytopenia rather than macrocytic anemia.
  - Malignant risk is predominantly myelodysplasia and acute myeloid leukemia rather than non-Hodgkin lymphoma.
  - No hair hypoplasia.
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings, together with other known ribosomopathies affecting the skeleton (RPL13, SBDS, and NEPRO gene defects), emphasize the pivotal role of ribosomes in skeletal development"
    explanation: >-
      PARTIAL because it establishes SBDS-related disease as a fellow
      skeleton-affecting ribosomopathy, the basis for including it here, without
      itself enumerating the distinguishing clinical features.
- name: Dyskeratosis congenita
  disease_term:
    preferred_term: dyskeratosis congenita
    term:
      id: MONDO:0015780
      label: dyskeratosis congenita
  description: >-
    The prototypical telomere biology disorder, and a differential CHH earns by
    mechanism rather than by appearance: both combine bone marrow failure,
    immunodeficiency and cancer predisposition with measurably short telomeres.
    The skeletal dysplasia and hair hypoplasia of CHH, and the mucocutaneous
    triad of dyskeratosis congenita, separate them clinically.
  distinguishing_features:
  - Mucocutaneous triad of nail dystrophy, oral leukoplakia and reticular skin pigmentation.
  - No metaphyseal chondrodysplasia or disproportionate short-limb short stature.
  - Caused by telomere maintenance genes rather than by RMRP.
  evidence:
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The CHH disease phenotype has some overlap with dyskeratosis congenita, a well-known \"telomere disorder.\""
    explanation: >-
      Explicitly names the phenotypic overlap that makes this a mechanistically
      motivated differential.
experimental_models:
- name: Rmrp-deficient ATDC5 chondrogenic cell model
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  cell_source: Mouse ATDC5 chondrogenic cell line
  culture_system: Monolayer chondrogenic differentiation culture with Rmrp RNA interference
  conditions:
  - Rmrp knockdown
  - Control chondrogenic differentiation
  publication: PMID:28743979
  description: >-
    Rmrp interference in ATDC5 cells couples impaired pre-rRNA processing to a
    particularly strong defect in chondrocyte hypertrophy, the step this entry
    identifies as the skeletal bottleneck. It is a two-dimensional mouse-derived
    line and reproduces neither growth-plate architecture nor any extraskeletal
    feature.
  modeled_mechanisms:
  - target: Growth Plate Chondrocyte Differentiation Failure
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Measures chondrogenic differentiation and hypertrophy after Rmrp
      interference.
    limitations: >-
      A murine immortalized chondrogenic line in monolayer culture; it models
      the differentiation step but not growth-plate architecture, limb
      proportion, or any extraskeletal disease.
    readouts:
    - name: Chondrogenic differentiation and hypertrophy
      target: Growth Plate Chondrocyte Differentiation Failure
      direction: DECREASED
      interpretation: >-
        Cellular correlate of the growth-plate differentiation node.
      evidence:
      - reference: PMID:28743979
        reference_title: "Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."
        explanation: >-
          Directly demonstrates the differentiation and hypertrophy defect.
    evidence:
    - reference: PMID:28743979
      reference_title: "Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."
      explanation: >-
        Supports treating this model as informative for the growth-plate node.
  evidence:
  - reference: PMID:28743979
    reference_title: "Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Genetic interference with Rmrp RNA expression in ATDC5 cultures caused a deregulation of chondrogenic differentiation, with a prominent impact on hypertrophy and changes in pre-rRNA processing and rRNA levels."
    explanation: >-
      Establishes the model, perturbation, molecular readout and cellular
      phenotype.
- name: CHH patient-derived fibroblast cell-cycle and transcriptome model
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Primary dermal fibroblasts from patients with cartilage-hair hypoplasia and healthy controls
  culture_system: Monolayer culture with pulse-labeling, time-lapse microscopy and RNA sequencing
  conditions:
  - CHH patient fibroblasts
  - Healthy control fibroblasts
  publication: PMID:31551465
  description: >-
    The most direct human evidence for the cell-cycle arm. Combining
    transcriptomics with single-cell tracking in patient fibroblasts localizes
    the defect to the G2-to-mitosis passage specifically, rather than inferring a
    generic proliferation problem, and shows the affected gene programmes reach
    bone, cartilage and lymphocyte function. Fibroblasts are an accessible
    surrogate rather than a disease-target tissue, which is the main caveat.
  modeled_mechanisms:
  - target: Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Directly measures cell-cycle progression and transcriptome changes in
      patient-derived cells carrying the disease genotype.
    limitations: >-
      Dermal fibroblasts are not one of the tissues that fails clinically, so
      the model demonstrates the lesion is cell-intrinsic and general without
      showing why chondrocytes, lymphocytes and erythroid progenitors are the
      ones that decompensate.
    readouts:
    - name: G2-to-mitosis transit time
      target: Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
      direction: DECREASED
      interpretation: >-
        Delayed passage from G2 into mitosis is the specific cell-cycle lesion
        this node asserts.
      evidence:
      - reference: PMID:31551465
        reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."
        explanation: >-
          The direct measurement of the readout in patient cells.
    evidence:
    - reference: PMID:31551465
      reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We combined transcriptome analysis with single-cell analysis using fibroblasts from CHH patients and healthy controls."
      explanation: >-
        Establishes the model system and the two orthogonal measurement
        approaches.
  findings:
  - statement: >-
      Downregulated genes in CHH fibroblasts are significantly connected to the
      cell cycle, with additional effects on apoptosis, bone and cartilage
      formation and lymphocyte function.
    supporting_text: "The downregulated genes were significantly connected to the cell cycle."
    evidence:
    - reference: PMID:31551465
      reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle."
      explanation: >-
        The experimental result is quoted directly from the publication
        abstract.
  evidence:
  - reference: PMID:31551465
    reference_title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "To directly assess cell cycle progression, we followed CHH fibroblasts by pulse-labeling and time-lapse microscopy."
    explanation: >-
      Establishes the direct cell-cycle measurement rather than inference from
      static assays.
- name: Patient bone marrow progenitor colony-forming assay
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  cell_source: Bone marrow and peripheral blood from patients with cartilage-hair hypoplasia
  culture_system: Semi-solid colony-forming assay for erythroid, megakaryocyte and granulocyte-macrophage progenitors
  conditions:
  - Patient-derived progenitors
  - Normal progenitor controls
  - Standard versus more effectively stimulated culture
  publication: PMID:7895753
  description: >-
    The closest thing CHH has to a functional test of the marrow arm, and its
    value lies in a specific control: showing progenitor numbers are normal or
    increased while colony formation fails separates a proliferation defect from
    progenitor depletion. The limitation is that colony formation did not
    correlate with haemoglobin, platelet or neutrophil counts, so the assay
    reports the cellular lesion rather than predicting the clinical blood count.
  modeled_mechanisms:
  - target: Multilineage Bone Marrow Progenitor Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Measures colony formation across erythroid, megakaryocyte and
      granulocyte-macrophage lineages in patient-derived progenitors.
    limitations: >-
      Ex vivo culture in eight patients; the defect did not track peripheral
      blood counts, so it cannot serve as a severity readout for an individual
      patient.
    readouts:
    - name: Erythroid, megakaryocyte and granulocyte-macrophage colony formation
      target: Multilineage Bone Marrow Progenitor Failure
      direction: DECREASED
      interpretation: >-
        Functional demonstration of the multilineage progenitor defect in
        patient cells.
      evidence:
      - reference: PMID:7895753
        reference_title: "Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "All patients showed decreased erythroid and megakaryocyte colony formation. Only one patient had a normal granulocyte-macrophage growth, while the others showed decreased numbers of colonies."
        explanation: >-
          Reports the measured colony deficit across all three lineages.
    evidence:
    - reference: PMID:7895753
      reference_title: "Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The present study shows defective in vitro colony formation in all myeloid lineages in patients with CHH, which is in accordance with the suggestion of a common cell proliferation defect in CHH."
      explanation: >-
        Supports treating this assay as informative for the marrow-failure node.
  findings:
  - statement: >-
      Colony formation fails despite normal or increased progenitor numbers,
      identifying a functional proliferation defect rather than progenitor
      depletion.
    supporting_text: "The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures."
    evidence:
    - reference: PMID:7895753
      reference_title: "Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The impaired growth was not caused by a decreased number of progenitors as shown by erythroid cultures. The erythroid progenitors were incapable of colony formation in culture conditions sufficient for colony formation by normal progenitors."
      explanation: >-
        The experimental result is quoted directly from the publication
        abstract.
  evidence:
  - reference: PMID:7895753
    reference_title: "Defective in-vitro colony formation of haematopoietic progenitors in patients with cartilage-hair hypoplasia and history of anaemia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In the present study erythroid, megakaryocyte, and granulocyte-macrophage colony formation in vitro by progenitors from bone marrow and blood was investigated in eight patients with CHH."
    explanation: >-
      Establishes the model system, cell source and readout.
animal_models:
- name: rmrp knockout zebrafish
  species: Zebrafish
  genotype: rmrp knockout
  publication: PMID:31237961
  description: >-
    The only viable whole-organism model of RMRP deficiency, because mouse
    knockouts die before embryonic day 6.5. It reproduces disrupted chondrogenesis
    with altered ossification, links it to inhibited proliferation and increased
    apoptosis, and identifies upregulated canonical Wnt/beta-catenin signalling
    as a candidate effector that can be pharmacologically inhibited with partial
    rescue. That rescue is the only mechanistic handle on the skeletal phenotype
    anywhere in this entry, which makes the model disproportionately important
    and also disproportionately in need of mammalian confirmation.
  modeled_mechanisms:
  - target: Growth Plate Chondrocyte Differentiation Failure
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces dysregulated chondrogenesis and abnormal ossification, and
      implicates Wnt/beta-catenin as a reversible effector.
    limitations: >-
      Zebrafish cartilage development differs architecturally from the mammalian
      endochondral growth plate, and the primary readouts are pharyngeal arch
      patterning and skull and vertebral ossification rather than long-bone
      metaphyseal growth; ossification effects are directionally mixed, being
      inhibited in skull and promoted in vertebrae, which has no clean human
      counterpart.
    readouts:
    - name: Chondrogenesis and bone ossification
      target: Growth Plate Chondrocyte Differentiation Failure
      direction: ALTERED
      interpretation: >-
        Whole-organism correlate of the cartilage differentiation node;
        ALTERED rather than DECREASED because ossification changed in opposite
        directions in different skeletal elements.
      evidence:
      - reference: PMID:31237961
        reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis."
        explanation: >-
          Reports the cartilage and ossification phenotype, including its
          direction-dependence by skeletal element.
    evidence:
    - reference: PMID:31237961
      reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants."
      explanation: >-
        Pharmacological rescue supports the model being mechanistically
        informative rather than merely phenotypically similar.
  - target: Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces inhibited proliferation and increased apoptosis with
      dysregulation of cell-cycle and apoptosis genes.
    limitations: >-
      Gene-expression-level evidence in a whole zebrafish embryo; it does not
      resolve the specific G2-to-M step identified in human patient cells.
    readouts:
    - name: Cell proliferation and apoptosis
      target: Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
      direction: DECREASED
      interpretation: >-
        Whole-organism correlate of the proliferation defect.
      evidence:
      - reference: PMID:31237961
        reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."
        explanation: >-
          Reports the proliferation and apoptosis readouts in the model.
    evidence:
    - reference: PMID:31237961
      reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes."
      explanation: >-
        Supports treating the model as informative for the proliferation arm.
  evidence:
  - reference: PMID:31237961
    reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Currently, the pathogenesis of osteochondrodysplasia and extraskeletal manifestations in CHH patients remains incompletely understood; in addition, there are no viable animal models for CHH. We generated an rmrp KO zebrafish model to study the developmental mechanisms of CHH."
    explanation: >-
      Establishes both the model and the absence of any prior viable animal
      model, which is why it carries so much weight here.
discussions:
- discussion_id: gap_chh_hirschsprung_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    By what route does deficiency of a ubiquitously expressed non-coding RNA
    produce failure of enteric neural crest colonization, and why does this
    manifest as Hirschsprung disease in only a minority of patients?
  attaches_to:
  - pathophysiology#Gastrointestinal and Enteric Nervous System Involvement
  - pathophysiology#Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
  rationale: >-
    Hirschsprung disease is one of the best-established comorbidities of CHH,
    occurring far above population background, yet it is the single feature for
    which no candidate mechanism has been offered; the review literature states
    this absence explicitly. A proliferation defect is an attractive general
    explanation, since enteric neural crest colonization of the gut is a
    proliferation-and-migration process on a developmental deadline, but that
    account is untested and would predict far higher penetrance than the observed
    9% to 25%. The zebrafish knockout shows a hypoplastic gut, but that is
    epithelial hypoplasia rather than aganglionosis, so it does not fill the gap.
    Resolving this matters practically because Hirschsprung disease is itself a
    reported risk factor for early death, so a shared upstream determinant of
    severity may exist.
  proposed_experiments:
  - experiment_id: exp_chh_enteric_crest_colonization
    name: Enteric neural crest colonization under graded RMRP deficiency
    description: >-
      Track enteric neural crest cell proliferation, migration velocity and
      terminal colonization of the distal gut across a graded allelic series of
      RMRP deficiency, using the zebrafish model and patient-derived enteric
      neural crest-like cells, and test whether the colonization front fails to
      reach the hindgut within the developmental window. Measure Cyclin B2
      turnover in the migrating population to test the cell-cycle account
      specifically.
    decision_criterion: >-
      If colonization failure tracks the degree of cell-cycle impairment in
      enteric neural crest specifically, the proliferation account is supported;
      if colonization is normal despite comparable cell-cycle impairment, a
      distinct mechanism must be sought.
    supporting_outcome:
    - A generalized cell-cycle defect acting on migrating enteric neural crest explains the Hirschsprung association
    refuting_outcome:
    - Enteric neural crest colonization is unaffected by RMRP deficiency, implicating a separate mechanism
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hirschsprung's disease (HD) is a well-known comorbidity of CHH, although the pathogenetic link between RMRP deficiency and HD remains unknown."
    explanation: >-
      Explicit statement in the review literature that this mechanism is
      unknown, which is what makes it a knowledge gap rather than an omission.
- discussion_id: gap_chh_cancer_surveillance_versus_cell_autonomous
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Is the lymphoma excess in CHH driven by loss of immune surveillance, or by
    the cell-cycle and telomere lesions acting cell-autonomously within the
    transforming B-cell clone?
  attaches_to:
  - pathophysiology#Impaired Immune Surveillance and Lymphomagenesis
  - pathophysiology#Impaired Telomere Maintenance
  - pathophysiology#Impaired Cyclin B2 mRNA Cleavage and G2-to-M Delay
  rationale: >-
    The surveillance account is conventional and is how the original cohort
    studies framed their finding, but they offered it as probable rather than
    demonstrated. Three observations sit awkwardly with it. Over half of non-skin
    cancers in prospective follow-up arose in patients with no preceding clinical
    symptoms of immune defect, and other CHH manifestations poorly predict
    lymphoma. Every cell in the patient carries a cell-cycle lesion and shortened
    telomeres, both established routes to genomic instability in their own right.
    And the malignancy spectrum is narrow, dominated by B-cell lymphoma and basal
    cell carcinoma, which suggests specific lineage vulnerability more than a
    general failure to police tumours. The distinction is not academic: if the
    driver is substantially cell-autonomous, correcting immunity by
    transplantation would not be expected to abolish residual risk in the
    recipient's own surviving lymphoid tissue, and surveillance would still be
    needed after transplant.
  proposed_experiments:
  - experiment_id: exp_chh_lymphoma_clonal_origin
    name: Genomic and clonal characterization of CHH-associated lymphomas
    description: >-
      Sequence CHH-associated lymphomas for mutational signatures of replication
      stress and telomere crisis, quantify telomere length and cyclin
      dysregulation within the malignant clone against the patient's own
      non-malignant lymphocytes, and determine Epstein-Barr virus status
      systematically rather than opportunistically. Compare against sporadic
      diffuse large B-cell lymphoma and against lymphomas arising in non-CHH
      immunodeficiencies.
    decision_criterion: >-
      If CHH lymphomas carry genomic signatures of replication stress or telomere
      crisis exceeding those of immunodeficiency-associated lymphomas generally,
      a cell-autonomous contribution is supported; if they are indistinguishable
      from other immunodeficiency-associated lymphomas, the surveillance account
      suffices.
    supporting_outcome:
    - The cell-cycle and telomere lesions contribute cell-autonomously to lymphomagenesis
    refuting_outcome:
    - CHH lymphomas are genomically typical of immunodeficiency-associated lymphoma, supporting pure surveillance failure
  evidence:
  - reference: PMID:10064668
    reference_title: "Increased incidence of cancer in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study confirms an increased risk of cancer, especially non-Hodgkin's lymphoma, probably attributable to defective immunity, among patients with CHH."
    explanation: >-
      The surveillance attribution is offered as probable, not demonstrated,
      which is the opening this gap addresses.
  - reference: PMID:31379817
    reference_title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 15 patients with non-skin cancer, eight had no preceding clinical symptoms of immunodeficiency."
    explanation: >-
      The observation that makes a purely surveillance-based account
      uncomfortable: most cancers arose without clinical immune failure.
- discussion_id: gap_chh_telomerase_post_transcriptional_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    How does loss of RMRP reduce telomerase activity when telomerase gene
    transcript levels are normal?
  attaches_to:
  - pathophysiology#Impaired Telomere Maintenance
  rationale: >-
    This is a well-posed gap rather than a vague one, because the simplest
    explanation has already been excluded by measurement: telomerase activity is
    reduced in patient lymphocytes in a gene-dose-dependent manner, yet the
    transcript levels of the telomerase genes are normal relative to endogenous
    controls. The defect is therefore post-transcriptional, and the authors say
    outright that the mechanism is unidentified. Candidate routes exist and are
    testable, including the reported TERT-RMRP complex and its RNA-dependent RNA
    polymerase activity, and a general ribosome-synthesis ceiling limiting
    translation of telomerase components; distinguishing them would also
    determine whether the telomere arm is a genuinely separate mechanism or a
    downstream consequence of the ribosome arm.
  proposed_experiments:
  - experiment_id: exp_chh_telomerase_assembly_step
    name: Localizing the post-transcriptional telomerase defect in CHH lymphocytes
    description: >-
      In patient lymphocytes across an allelic series, quantify TERT protein
      abundance, TERC levels, telomerase holoenzyme assembly and trafficking, and
      TERT-RMRP complex formation, and test whether restoring TERT protein alone
      rescues telomerase activity. Run the same panel in cells where ribosome
      synthesis is limited independently of RMRP, to separate a specific
      TERT-RMRP effect from a general translational ceiling.
    decision_criterion: >-
      If telomerase activity tracks holoenzyme assembly or TERT protein
      abundance and is not reproduced by independent ribosome limitation, a
      specific RMRP-telomerase mechanism is supported; if independent ribosome
      limitation reproduces it, the telomere arm is downstream of the ribosome
      arm.
    supporting_outcome:
    - A specific post-transcriptional RMRP-telomerase mechanism independent of general ribosome limitation
    refuting_outcome:
    - Reduced telomerase activity is a downstream consequence of limited ribosome synthesis
  evidence:
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."
    explanation: >-
      Excludes the transcriptional explanation, which is what makes this gap
      specific rather than generic.
  - reference: PMID:28126377
    reference_title: "Defects in lymphocyte telomere homeostasis contribute to cellular immune phenotype in patients with cartilage-hair hypoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings suggest that telomere deficiency is implicated in the CHH disease phenotype through an as yet unidentified mechanism."
    explanation: >-
      The authors state directly that the mechanism is unidentified.
- discussion_id: gap_chh_hsct_effect_on_linear_growth
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does haematopoietic stem cell transplantation ever rescue linear growth in
    CHH, and if so, what distinguishes the patients in whom it does?
  attaches_to:
  - pathophysiology#Growth Plate Chondrocyte Differentiation Failure
  - pathophysiology#Multilineage Bone Marrow Progenitor Failure
  rationale: >-
    This entry treats the skeletal phenotype as chondrocyte-autonomous, and the
    strongest support for that is the observation that transplantation corrects
    immunity while growth failure remains unaffected. The literature is not
    unanimous. The same review that states skeletal features are not altered by
    transplantation also records two patients who normalized their growth
    afterwards, both carrying promoter-region duplications. That is a small
    number, but it is not obviously noise, because promoter variants act by
    reducing transcription rather than by perturbing RNA structure and might
    therefore behave differently. If growth rescue is real in any subgroup, the
    chondrocyte-autonomous framing needs qualifying and there would be a case
    for transplanting earlier on skeletal grounds, which is currently never an
    indication. The alternative reading, that these two patients reflect
    conditioning-era effects, catch-up from chronic illness, or ascertainment, is
    equally live and would leave the framing intact.
  proposed_experiments:
  - experiment_id: exp_chh_growth_trajectory_after_hsct
    name: Genotype-stratified growth trajectories before and after transplantation
    description: >-
      Assemble the transplanted CHH cohorts and plot height standard deviation
      scores against CHH-specific growth curves before and after
      transplantation, stratified by RMRP variant class (promoter-region versus
      transcribed-region) and by conditioning regimen and age at transplant.
      Include untransplanted genotype-matched patients as the comparison, since
      the question is whether transplant changes the trajectory rather than
      whether growth continues.
    decision_criterion: >-
      If post-transplant growth trajectories improve specifically in
      promoter-variant patients relative to genotype-matched untransplanted
      controls, growth rescue is real and variant-class dependent; if
      trajectories are indistinguishable once genotype and age are accounted
      for, the two reported cases are best read as ascertainment.
    supporting_outcome:
    - Transplantation rescues linear growth in a definable RMRP variant subgroup
    refuting_outcome:
    - Growth trajectories are unchanged by transplantation across all variant classes, upholding the chondrocyte-autonomous model
  evidence:
  - reference: PMID:20375313
    reference_title: "Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected"
    explanation: >-
      The observation this entry's chondrocyte-autonomous framing rests on.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Skeletal features are not altered by HSCT (68); however, two patients normalized their growth after HSCT, one homozygous and another compound heterozygous for promoter region duplications"
    explanation: >-
      Carries both sides of the discrepancy in one sentence, including the
      variant class shared by the two exceptional patients; PARTIAL because two
      cases cannot settle the question either way.
- discussion_id: mismatch_chh_no_viable_mouse_model
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Can conclusions about CHH pathogenesis be validated in a mammalian
    whole-organism system, given that Rmrp knockout mice die before embryonic day
    6.5 while heterozygotes are healthy?
  attaches_to:
  - pathophysiology#RMRP Non-Coding RNA Loss of Function
  - pathophysiology#Growth Plate Chondrocyte Differentiation Failure
  rationale: >-
    This is a structural, not incidental, gap in the evidence base. Complete loss
    of the RNA is embryonic lethal in mouse and lethal in yeast, while mice
    carrying one null allele are healthy with 50% expression, so the mouse offers
    neither a null nor a graded hypomorphic model in the range where human
    disease lives. Every mammalian result in this entry therefore comes from cell
    culture, and the only whole-organism data come from zebrafish, whose
    cartilage development is architecturally different from the mammalian
    endochondral growth plate and whose ossification phenotype is directionally
    mixed. The consequence is that the most therapeutically interesting claim
    available, partial rescue of chondrodysplasia by beta-catenin inhibition,
    rests on a single non-mammalian model and cannot currently be tested in a
    mammal at all.
  proposed_experiments:
  - experiment_id: exp_chh_hypomorphic_mouse_knockin
    name: Hypomorphic and conditional Rmrp mouse alleles reproducing patient variants
    description: >-
      Generate knock-in mice carrying the founder n.71A>G variant and a
      promoter-region insertion allele, plus a chondrocyte-conditional deletion,
      and characterize growth-plate architecture, limb proportion, immune
      reconstitution and erythropoiesis. Test whether beta-catenin inhibition
      rescues the skeletal phenotype in a mammalian growth plate as it partially
      does in zebrafish.
    decision_criterion: >-
      If a hypomorphic allele is viable and reproduces the skeletal and immune
      phenotype, mammalian mechanistic and preclinical work becomes possible; if
      all hypomorphic alleles are either lethal or normal, the murine dose window
      does not overlap the human one and non-mammalian models remain the only
      whole-organism option.
    supporting_outcome:
    - A graded mammalian model of RMRP deficiency is achievable and can validate the zebrafish rescue
    refuting_outcome:
    - The murine RMRP dose-response has no window corresponding to human disease
  evidence:
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mouse model for RMRP deficiency has never been established, as Rmrp knockout by insertion of DNA elements upstream the promoter was lethal early in embryonic development before embryonic day (E) 6.5"
    explanation: >-
      Establishes the absence of a viable mouse null, the core of this
      mismatch.
  - reference: PMID:42170584
    reference_title: "Cartilage-hair hypoplasia: A comprehensive review."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Hemizygous mice missing one RMRP allele showed 50% decrease of RMRP expression in embryonic fibroblasts and were healthy"
    explanation: >-
      Establishes that the surviving murine genotype is unaffected, so no graded
      mammalian model currently spans the human disease range.
  - reference: PMID:31237961
    reference_title: "Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in Zebrafish Model of Cartilage-Hair Hypoplasia via Enhanced Wnt/β-Catenin Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "in addition, there are no viable animal models for CHH"
    explanation: >-
      Independent statement of the same absence, from the group that built the
      zebrafish model in response to it.
references:
- reference: PMID:22420014
  title: "Cartilage-Hair Hypoplasia - Anauxetic Dysplasia Spectrum Disorders"
  tags:
  - GeneReviews
- reference: PMID:42170584
  title: "Cartilage-hair hypoplasia: A comprehensive review"
- reference: PMID:11207361
  title: "Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia"
- reference: PMID:35115551
  title: "A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis"
- reference: PMID:31551465
  title: "The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2"
- reference: PMID:31379817
  title: "A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia"
- reference: PMID:32506568
  title: "Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management"

📚

References & Deep Research

References

7

PMID:22420014

Cartilage-Hair Hypoplasia - Anauxetic Dysplasia Spectrum Disorders

No top-level findings curated for this source.

PMID:42170584

Cartilage-hair hypoplasia: A comprehensive review

No top-level findings curated for this source.

PMID:11207361

Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia

No top-level findings curated for this source.

PMID:35115551

A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis

No top-level findings curated for this source.

PMID:31551465

The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2

No top-level findings curated for this source.

PMID:31379817

A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia

No top-level findings curated for this source.

PMID:32506568

Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Cartilage-Hair Hypoplasia (CHH) — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-5[1m] 24 citations 2026-08-14T13:54:08.257756

Cartilage-Hair Hypoplasia (CHH) — Comprehensive Research Report

Prepared: 2026-08-14 · Target KB entry: kb/disorders/Cartilage-Hair_Hypoplasia.yaml

0. Evidence-verification status (read this first)

I pulled abstracts through Europe PMC. These I have verbatim and safe to quote:

PMID	Short handle
11207361	Ridanpää 2001 Cell — gene discovery
31379817	Vakkilainen 2019 Front Immunol — 30-yr follow-up, mortality
30410491	Vakkilainen 2018 Front Immunol — autoimmunity/allergy
35115551	Robertson 2022 Nat Commun — ribosomopathy
31551465	Vakkilainen 2019 Sci Rep — G2 cell-cycle delay
31237961	Sun 2019 JBMR — zebrafish rmrp model
28126377	Aubert 2017 JACI — telomere biology
33675005	Vakkilainen 2021 J Clin Immunol — lung imaging
32849667	Vakkilainen 2020 Front Immunol — live vaccines
20375313	Bordon 2010 Blood — EBMT HSCT cohort
42170584	Vakkilainen 2025 J Hum Immun — comprehensive review

These I have paraphrase only — re-fetch before quoting: 18698627, 17701897, 16252239, 16254002, 18804272, 24009312, 25764362, 8444246, 11391344, 37115363, 38862721, 34956076, 38676846, 38187867, 22420014 (GeneReviews — a book chapter, not abstract-shaped anyway).

Ontology IDs below are suggestions. Every one needs just validate-terms before it lands. I flag the shakier ones explicitly.

1. Disease Information

Overview

Cartilage-hair hypoplasia is what happens when you break the cell's ribosome factory in a way that's bad but not lethal. It's an autosomal recessive, multi-system disorder in which a single non-protein-coding RNA gene — RMRP — is disabled, and the fallout lands hardest on the tissues that need to divide fastest: growth-plate cartilage, hair follicles, the T-cell compartment, and the erythroid line. Hence the four-part clinical signature: short-limbed short stature, fine sparse hair, combined immunodeficiency, and macrocytic anemia. Layered on top are Hirschsprung disease, autoimmunity, and a genuinely alarming lymphoma risk.

The 2025 review states it cleanly (verbatim, PMID:42170584):

"Cartilage-hair hypoplasia (CHH) is a rare syndromic inborn error of immunity, caused by variants in the noncoding RNA gene RMRP. The effects of RMRP deficiency are pleiotropic, affecting the ribosomal RNA processing, cell cycle, and gene regulation. Typical clinical manifestations of CHH include chondrodysplasia with short stature, hair hypoplasia, combined immunodeficiency, and anemia. In addition, individuals with CHH have increased prevalence of malignancies, Hirschsprung's disease, and autoimmunity. The only curative option for immunodeficiency or severe anemia in CHH remains hematopoietic stem cell transplantation."

Historically it's McKusick's disease — described in 1965 in the Old Order Amish of Lancaster County, Pennsylvania (PMID:14284412, "DWARFISM IN THE AMISH. II. CARTILAGE-HAIR HYPOPLASIA").

Identifiers

Resource	ID	Confidence
MONDO	MONDO:0009595 — "cartilage-hair hypoplasia"	Verified via OLS4 this session
OMIM	250250 (CHH)	High
OMIM	157660 (RMRP* gene)	Medium — verify
OMIM	607095 (Anauxetic dysplasia 1)	Medium — verify
OMIM	250460 (Metaphyseal dysplasia without hypotrichosis)	Medium — verify
Orphanet	ORPHA:175	High (Orphanet blocked my fetch — cite via the cached `ORPHA:175` structured source instead)
ICD-10	Q78.5 (Metaphyseal dysplasia)	Medium
ICD-11	VERIFY — I could not confirm	Low
UMLS	C0175787	Medium — verify
HGNC	HGNC:10031 (RMRP) → dismech form `hgnc:10031`	Medium — verify

MONDO exact synonyms confirmed from OLS4: cartilage hair hypoplasia, metaphyseal chondrodysplasia, McKusick type, autosomal recessive metaphyseal chondrodysplasia, McKusick Type Metaphyseal Chondrodysplasia. Related: CHH.

Other names in the wild: metaphyseal chondrodysplasia McKusick type, McKusick-type metaphyseal dysplasia, CHH.

Sibling entities worth their own dismech entries or a Grouping: - Anauxetic dysplasia 1 (RMRP, severe end of the same allelic spectrum) - Metaphyseal dysplasia without hypotrichosis / MDWH (RMRP, mild end) - Anauxetic dysplasia 2 (POP1, PMID:27380734) — same holoenzyme, different subunit - Anauxetic dysplasia 3 (NEPRO, PMID:31250547, PMID:37294112) — likewise

There's a real modeling decision here: GeneReviews treats MDWH–CHH–AD as one "CHH–AD spectrum" (PMID:22420014). Given dismech's lump/split conventions, the cleanest shape is probably a separate Cartilage-Hair_Hypoplasia entry plus a Grouping (grouping_basis: SHARED_GENE_FAMILY + SHARED_MECHANISM) covering the RNase MRP holoenzyme disorders, with POP1/NEPRO entries as future members. Flagging it, not deciding it.

Data provenance

Nearly everything quantitative comes from aggregated disease-level cohort studies, not EHR. The Finnish national CHH cohort (Helsinki; Mäkitie, Taskinen, Vakkilainen) is the dominant source — ~80–123 genetically confirmed patients followed prospectively since 1985, cross-linked to the Finnish Cancer Registry and national Cause-of-Death Registry. That's why the epidemiology is unusually good for a disease this rare, and also why you should treat the numbers as Finnish-founder-population numbers rather than universal ones.

2. Etiology

Primary cause

Biallelic pathogenic variants in RMRP (9p13.3), which encodes the ~267–268 nt non-coding RNA subunit of the RNase MRP ribonucleoprotein. It's an RNA polymerase III transcript — no protein product, ever. This is the historically important bit: RMRP was the first nuclear non-coding RNA gene tied to a human disease (verbatim, PMID:31551465: "RMRP was the first non-coding nuclear RNA gene implicated in a disease.").

Ridanpää's original Cell paper, verbatim (PMID:11207361):

"The recessively inherited developmental disorder, cartilage-hair hypoplasia (CHH) is highly pleiotropic with manifestations including short stature, defective cellular immunity, and predisposition to several cancers. The endoribonuclease RNase MRP consists of an RNA molecule bound to several proteins. It has at least two functions, namely, cleavage of RNA in mitochondrial DNA synthesis and nucleolar cleaving of pre-rRNA. We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype. Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not. The association of protein subunits with RNA appears unaltered. We conclude that mutations in RMRP cause CHH by disrupting a function of RNase MRP RNA that affects multiple organ systems."

That last sentence is a genuinely good dismech evidence snippet for a top-level pathophysiology node.

Genetic risk factors

Not a susceptibility-locus disease — it's straight Mendelian recessive. Two functional classes of allele:

Transcribed-region variants (e.g. n.71A>G, the big one) — the RNA is made but works badly.
Promoter insertions/duplications — transcription is knocked down or silenced. Ridanpää: "Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not." Tan 2023 (PMID:37115363) showed homozygous promoter duplications cause severely reduced transcript abundance and, notably, SCID-level immunodeficiency.

No established modifier genes. No GWAS loci. Carriers are asymptomatic and — worth stating explicitly for counseling — not at increased cancer risk (GeneReviews, PMID:22420014). The one hint of a heterozygote effect is biochemical, not clinical: Aubert found telomerase activity varied by gene dose between carriers and patients (verbatim, PMID:28126377: "telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH.").

Environmental risk factors

None established for causation — this is a fully penetrant genetic disease. But there are real environmental modifiers of outcome, and dismech should model them as influences_mechanisms with environmental_effect: EXACERBATES rather than as causes:

Varicella-zoster exposure — potentially fatal in CHH with significant cellular immunodeficiency; historically a named cause of death. Prompts the "immediate high-dose IV acyclovir" rule.
Live attenuated vaccines, especially oral poliovirus — vaccine-associated paralytic poliomyelitis in a CHH child is one of the oldest reports in the literature (PMID:165279, 1975, "Combined immunodeficiency and vaccine-related poliomyelitis in a child with cartilage-hair hypoplasia"). Note this is now nuanced — see §13.
UV exposure — a plausible modifier of the basal-cell / squamous-cell carcinoma excess, though I found no CHH-specific dose-response study. Treat as inferred, not evidenced.
Respiratory pathogen burden — recurrent pneumonia is one of the strongest mortality predictors (§11).

Protective factors

Consanguinity avoidance / outbreeding in founder populations — mechanically obvious, no CHH-specific study.
No protective alleles reported.
No dietary or lifestyle protective factor with evidence. Growth hormone specifically does not help (GeneReviews: "no sustained benefit, not recommended").

Gene–environment interaction

The clean, well-evidenced one: genotype sets immune competence, and immune competence sets the consequence of pathogen and vaccine exposure. Vakkilainen 2020 (PMID:32849667) is the direct test — live viral vaccines turned out to be tolerated in Finnish CHH patients with mild/absent clinical immunodeficiency, with no serious adverse events across 40 MMR and 10 VZV recipients, while remaining contraindicated at the SCID end. That's a genotype→immune-phenotype→exposure-outcome chain, and it's exactly the shape dismech's influences_mechanisms slot wants.

3. Phenotypes

Frequencies below are mostly from GeneReviews (PMID:22420014) and the Finnish cohorts. Every frequency: you curate needs its own quantitative snippet — most of these come from the GeneReviews summary rather than from a quotable abstract sentence, so per the frequency-evidence SOP, omit the band rather than manufacture support.

Skeletal (near-universal)

Phenotype	Suggested HP	Freq	Notes
Disproportionate short-limb short stature	HP:0003026 (Short long bone) / HP:0008873 (Disproportionate short-limb short stature)	100%	Recognizable at birth, sometimes prenatally
Metaphyseal dysplasia	HP:0002980 (Femoral bowing) + HP:0000944 (Abnormal metaphysis morphology)	100% (75/75 with films, PMID:25764362)	Flaring, cupping, marginal serration, fragmentation, scalloping; cystic radiolucencies extending into diaphysis
Genu varum / bowed legs	HP:0002970 (Genu varum)	87% (85/96)	Commonest reason for orthopaedic referral
Short metacarpals/phalanges, "short pudgy hands"	HP:0010049 (Short metacarpal)	100%	Bullet-shaped middle phalanges; cone-shaped epiphyses
Joint hypermobility	HP:0001382 (Joint hypermobility)	100%	Rarely symptomatic
Limited elbow extension	HP:0001377 (Limited elbow extension)	81% (56/69)	Radial head subluxation/dislocation; "not a single patient had any issues of consequence"
Coxa vara	HP:0002812 (Coxa vara)	27% (19/71)
Lumbar lordosis	HP:0002938 (Lumbar hyperlordosis)	common	Rarely needs treatment
Scoliosis	HP:0002650 (Scoliosis)	variable	Observation → bracing → fusion
Atlantoaxial instability	HP:0003318? VERIFY — better: HP:0003468 (Atlantoaxial instability)	AD >> CHH	Prominent in anauxetic dysplasia; PMID:25764362 found no surgical cases in 12 CHH C-spines

Adult height (PMID:25764362, n=135): males median 131.1 cm (110.7–149.0), females median 122.5 cm (103.7–137.4). GeneReviews gives the spectrum range as 104–151 cm for CHH, versus <85 cm for anauxetic dysplasia. Growth: short at birth, further deceleration in the first 2 years, and a "very weak or absent pubertal growth spurt." Model this as clinical_course: PROGRESSIVE on a growth-failure node with onset_category: CONGENITAL_ONSET.

Craniofacial (PMID:34956076, 17 patients vs 34 controls): significantly decreased length of upper jaw, lower jaw, and clivus. Basilar invagination not observed. Midfacial hypoplasia, macroglossia, and dental anomalies are AD-predominant features.

Hair and skin

Hypotrichosis — HP:0001006 (Hypotrichosis) or HP:0002212 (Fine hair) + HP:0002213 (Fine hair)/HP:0008070 (Sparse hair). Fine, silky, sparse, often light-colored; eyebrows and eyelashes involved. Classic old-literature finding: reduced hair shaft diameter with absent or small pigment core (PMID:5533438, PMID:4787841).
Complete alopecia — HP:0002293 (Alopecia of scalp) — ~15%, involving scalp, eyelashes and body hair (GeneReviews).
Neonatal erythroderma — HP:0001019 (Erythroderma) — an emerging, under-recognized presentation (PMID:40110983, PMID:41616907). Nice detail for a "diagnostic pitfall" note.
Hypopigmentation / light hair — common in the Finnish cohort.

Immunologic

The heart of the disease. GeneReviews: cellular immune deficiency in ~88%, clinical infections in 35–65%, mostly infancy and childhood.

Feature	Suggested HP	Freq / detail
Combined immunodeficiency	HP:0005387 (Combined immunodeficiency)	24% symptomatic in the Finnish prospective cohort
Humoral immunodeficiency alone	HP:0004313 (Decreased circulating antibody level)	19%
Asymptomatic	—	57% (46/80) — critical for framing
T-cell lymphopenia	HP:0005403 (Decreased T cell count)	Near-universal on labs
CD8 lymphocytopenia	HP:0005407? VERIFY	Novel phenotype flagged by Kavadas 2008 (PMID:18804272)
Impaired lymphocyte proliferation	HP:0031381 (Abnormal lymphocyte proliferation) VERIFY	9/12 severe in Kavadas
SCID	HP:0004430 (Severe combined immunodeficiency)	Minority; associated with promoter duplications (PMID:37115363)
Recurrent respiratory infections	HP:0002205 (Recurrent respiratory infections)
Bronchiectasis	HP:0002110 (Bronchiectasis)	29–52% (PMID:33675005, verbatim)
Recurrent pneumonia	HP:0006532 (Recurrent pneumonia)	Major mortality driver
Severe varicella	HP:0004429? VERIFY	Historically fatal
Neutropenia	HP:0001875 (Neutropenia)	Reported since 1970 (PMID:4188537)

The Finnish 30-year data (verbatim, PMID:31379817) is the single best structured source here:

"Half of the patients (57%, n = 46) manifested no symptoms of immunodeficiency during follow-up while 19% (n = 15) and 24% (n = 19) demonstrated symptoms of humoral or combined immunodeficiency, including six cases of adult-onset immunodeficiency. In a significant proportion of patients (17/79, 22%), clinical features of immunodeficiency progressed over time."

That "22% progressed over time" plus "six cases of adult-onset immunodeficiency" is the clinically load-bearing insight: CHH immunodeficiency is not a fixed congenital deficit you can rule out once. It creeps.

Immune dysregulation / autoimmunity / allergy

From verbatim PMID:30410491 (n=104, median age 39.2 y):

"Clinical autoimmunity was common (11/104, 10.6%) and included conditions previously undescribed in subjects with CHH (narcolepsy, psoriasis, idiopathic thrombocytopenic purpura, and multifocal motor axonal neuropathy). Patients with autoimmunity more often had recurrent pneumonia, sepsis, high immunoglobulin (Ig) E and/or undetectable IgA levels. The mortality rates were higher in subjects with AI diseases (χ(2)2 = 14.056, p = 0.0002). ... We confirmed the high prevalence of asthma (23%) and allergic rhinoconjunctivitis (39%). Gastrointestinal complaints, mostly persistent diarrhea, were also frequently reported (32/104, 31%)."

So: autoimmunity 10.6%, asthma 23% (HP:0002099), allergic rhinoconjunctivitis 39% (HP:0003193/HP:0000509), chronic diarrhea 31% (HP:0002028, temporality: CHRONIC). And a lovely mechanistic oddity worth a notes: line — "Despite the history of allergic rhinitis, no eosinophils were observed in nasal cytology in five tested patients." The allergy phenotype may not be conventionally eosinophilic.

Also: serum autoantibody positivity frequently occurs without matching clinical disease (Biggs 2017, PMID:28631025). Don't curate autoantibody positivity as an autoimmune phenotype.

Granulomas (cutaneous/systemic, including lymphomatoid granulomatosis, PMID:29744913) occur and drive anti-TNF-α or HSCT decisions.

Hematologic

Mild macrocytic anemia — HP:0001889 (Macrocytic anemia) — ~80% of CHH, typically resolves in childhood.
Severe persistent anemia — ~6%, phenocopying Diamond-Blackfan anemia; 50–75% of those needed transfusion or transplant (GeneReviews).
Neutropenia and lymphopenia as above.

The DBA resemblance isn't a coincidence — it's the ribosomopathy family showing its hand (PMID:20194897, Blood ribosomopathy review, which explicitly names CHH).

Gastrointestinal

Hirschsprung disease — HP:0002251 — 7–8% of CHH, concentrated in severe phenotypes (Mäkitie 2001, PMID:11391344, "Hirschsprung disease is associated especially with severe cartilage-hair hypoplasia" — paraphrase, re-fetch). Massively enriched over the ~1/5000 population baseline (PMID:11694544). It is not reported in AD or MDWH.
Malabsorption — secondary to infection in the first two years.
Chronic diarrhea — 31% (above).

Reproductive

Males: impaired spermatogenesis — reduced sperm concentration, motility, and morphology; testicular volume below age norms with normal gonadotropins/testosterone (GeneReviews). HP:0000798 (Abnormal spermatogenesis) VERIFY.
Females: possible hypogonadotropic or normogonadotropic hypogonadism with absent puberty; a dedicated gynecologic series exists (PMID:30445974, PMID:30561899) and pregnancies do occur (14 women, 42 pregnancies — Holopainen preprint).

Malignancy

Treated in §11 — it's a prognostic feature more than a "phenotype," but for HP purposes: HP:0002665 (Lymphoma), HP:0002671 (Basal cell carcinoma), HP:0001909 (Leukemia).

Quality of life

Genuinely thin. I found no EQ-5D, SF-36, or PROMIS study in CHH. Per-phenotype QoL statements would be speculation. What is documented: 43% undergo lower-limb realignment surgery (PMID:25764362); the elbow contracture and joint laxity are radiographically striking but functionally near-silent ("not a single patient had any issues of consequence with that loss of motion"); and adult stature ~122–131 cm carries the accessibility burdens common to skeletal dysplasia. This is a real knowledge gap — worth a discussions entry with kind: KNOWLEDGE_GAP.

4. Genetic/Molecular Information

The gene

RMRP — RNA component of mitochondrial RNA processing endoribonuclease. Chromosome 9p13.3. Single-exon, non-protein-coding, RNA polymerase III transcript, ~267–268 nt. Suggested hgnc:10031 (verify).

The clinically decisive practical consequence: it's non-coding, so standard exome pipelines miss it. Multiple sources say this outright. This belongs in the diagnostics section of the entry as a first-class fact, not a footnote.

Variant landscape

The dominant allele. The founder variant is written several ways across the literature — n.71A>G, g.70A>G, 70A→G, c.70A>G, n.72A>G — because numbering conventions for this transcript have shifted. Pick one and note the aliases; this is a classic curation trap. GeneReviews reports it as g.71A>G and gives its distribution:

100% of Old Order Amish CHH alleles
92% of Finnish CHH alleles
48% of non-Finnish CHH alleles

Ancient shared founder haplotype across populations (Nature EJHG worldwide mutation spectrum study — "ancient founder origin of the major 70A→G mutation").

Other recurrent alleles: - n.262G>T — historically cited as an Amish-associated allele (verify against current sources; GeneReviews now emphasizes 71A>G at 100% in Amish) - n.197C>T — Brazilian founder effect on a shared haplotype of predominantly European ancestry (PMID:38862721) - n.64C>T — homozygous, reported in Italy (PMID:33444820) - Promoter insertions/duplications — the transcription-silencing class. GeneReviews notes the mechanism precisely: they increase the spacing of regulatory elements, and insertions of 24–26 bp reduce transcription efficiency. Homozygous promoter duplications → severely reduced transcript → SCID (PMID:37115363).

Variant classes: point substitutions in the transcribed region; promoter insertions/duplications; rarely whole-gene deletions. Sequence analysis detects ~100%; deletion/duplication analysis is a low-yield add-on (GeneReviews).

Origin: germline, biallelic. No somatic CHH. (RMRP is separately over-expressed as an oncogenic lncRNA in various sporadic cancers — PMID:33996836 — which is a completely different biology and should not be conflated in the entry.)

Functional consequence: loss of function / hypomorphic. Complete null is presumed non-viable — no human has been reported with two true null alleles, and RNase MRP is essential in yeast. Suggested functional_impact_category: PARTIAL_LOSS_OF_FUNCTION for most transcribed-region alleles, LOSS_OF_FUNCTION for promoter-silencing ones.

Allele frequency: gnomAD coverage of RMRP is poor (non-coding, short, historically excluded from exome capture). The carrier frequencies below come from population studies, not gnomAD.

Genotype–phenotype correlation — the good bit

This is unusually well worked out, and it maps beautifully onto a two-branch dismech pathograph. Thiel 2007 (PMID:17701897, paraphrase — re-fetch):

rRNA cleavage impairment (ribosome assembly) → severity of bone dysplasia
mRNA cleavage impairment (cell-cycle regulation) → presence of hair hypoplasia, immunodeficiency, and hematologic abnormality

GeneReviews adds that anauxetic dysplasia arises from variants that severely impair both, particularly 5.8S rRNA cleavage and cyclin B1 mRNA processing.

So the entry should carry two parallel mechanism branches from a shared upstream node, not one linear chain. That's the structurally interesting thing about this disease.

Modifier genes

None established. Kavadas 2008 documented "significant, even intrafamilial, phenotypic heterogeneity" — siblings with identical genotypes diverging clinically — which is strong evidence that modifiers (genetic or stochastic) exist without any being identified. Good KNOWLEDGE_GAP candidate.

Epigenetics

No CHH-specific methylation or chromatin study found. Not available.

Chromosomal abnormalities

None. Not a CNV/aneuploidy disorder (rare whole-gene deletions aside).

5. Environmental Information

Short section, honestly. CHH is not an environmental disease.

Environmental factors: no toxin, radiation, or occupational exposure implicated in causation. CTD has no CHH entry of substance.
Lifestyle: no evidence of dietary or behavioral modification of disease course. GH therapy explicitly unhelpful.
Infectious agents: no infectious cause, but infection is the dominant complication. Named organisms/entities across the literature: varicella-zoster virus (severe/fatal disease), vaccine-derived poliovirus (PMID:165279), Epstein-Barr virus (EBV-positive Hodgkin lymphoma in CHH-AD siblings, PMID:41460196), and the usual recurrent bacterial respiratory pathogens driving bronchiectasis. EBV is the most mechanistically interesting — it links the immunodeficiency node to the lymphoma node.

For the pathograph: model infections as influences_mechanisms targeting the immunodeficiency node with environmental_effect: EXACERBATES, and remember the CLAUDE.md guidance that only TRIGGERS/EXACERBATES count as causal for compliance scoring — don't inflate.

6. Mechanism / Pathophysiology

Here's the causal architecture. I'd build it as one upstream lesion fanning into two mechanistic arms that reconverge on tissue-specific outcomes.

The enzyme

RNase MRP is a nucleolar ribonucleoprotein — one catalytic RNA (RMRP) wrapped in ~10 protein subunits: POP1, POP4 (RPP29), POP5, RPP14, RPP20 (POP7), RPP21, RPP25, RPP30, RPP38, RPP40, plus NEPRO. It's an evolutionary sibling of RNase P — same architectural family, different substrate menu. Think of it as a pair of molecular scissors that got repurposed for several unrelated jobs over evolutionary time, which is exactly why breaking it produces such a scattered, pleiotropic mess.

Structural work exists: RPP20–RPP25 in complex with the P3 domain of the RNA (PMID:33571640) — useful if the entry wants a protein-structure claim.

Critically, Ridanpää showed the CHH mutations don't stop the proteins binding: "The association of protein subunits with RNA appears unaltered." Robertson 2022 refines this — the 70AG allele reduces the amount of intact complex, rather than making a mis-assembled one.

Known catalytic functions (i.e. the fan-out)

Pre-rRNA processing. Cleaves internal transcribed spacer 1 (ITS1, site A3 in yeast) during ribosome biogenesis, feeding 5.8S rRNA maturation. This is the arm that makes CHH a ribosomopathy.
Cell-cycle control via cyclin mRNA cleavage. Degrades cyclin B2 (and per GeneReviews, cyclin B1) mRNA at mitotic exit. Break this and you break the G2→M transition.
Mitochondrial DNA replication. Processes the RNA primer at the mtDNA heavy-strand origin — the "MRP" in the name.
Telomere biology. RMRP associates with TERT; the TERT–RMRP complex has RNA-dependent RNA polymerase activity producing double-stranded RMRP RNA processed into siRNA (Rogler 2014 lineage).
Small-RNA gene silencing. RMRP is processed into RMRP-S1 and RMRP-S2, which act as miRNAs (PMID:24009312).

Arm A — the ribosomopathy arm (→ skeleton, growth)

Verbatim, PMID:35115551 (this is the single best mechanistic snippet available):

"RMRP encodes a non-coding RNA forming the core of the RNase MRP ribonucleoprotein complex. Mutations cause Cartilage Hair Hypoplasia (CHH), characterized by skeletal abnormalities and impaired T cell activation. Yeast RNase MRP cleaves a specific site in the pre-ribosomal RNA (pre-rRNA) during ribosome synthesis. CRISPR-mediated disruption of RMRP in human cells lines caused growth arrest, with pre-rRNA accumulation. Here, we analyzed disease-relevant primary cells, showing that mutations in RMRP impair mouse T cell activation and delay pre-rRNA processing. Patient-derived human fibroblasts with CHH-linked mutations showed similar pre-rRNA processing delay. Human cells engineered with the most common CHH mutation (70AG in RMRP) show specifically impaired pre-rRNA processing, resulting in reduced mature rRNA and a reduced ratio of cytosolic to mitochondrial ribosomes. Moreover, the 70AG mutation caused a reduction in intact RNase MRP complexes. Together, these results indicate that CHH is a ribosomopathy."

Chain: biallelic RMRP lesion → reduced intact RNase MRP complex → delayed/impaired pre-rRNA cleavage at ITS1 → reduced mature cytosolic rRNA → reduced cytosolic:mitochondrial ribosome ratio → reduced translational capacity → impaired proliferation of growth-plate chondrocytes → metaphyseal dysplasia and short-limb short stature.

That ribosome-ratio finding is unusually specific and quotable. Also worth an attaches_to link: Hermanns 2005 (PMID:16254002) showed the 70A>G allele shifts the 5.8S rRNA ratio in yeast — i.e. it's not just less rRNA, it's the wrong mixture of 5.8S isoforms.

The p53 connection completes the arm: ribosome biogenesis stress activates p53, and "this pathway appears to be a critical mediator of many of the clinical features of ribosomopathies" (PMID:20194897, needs re-fetch to quote).

Arm B — the cell-cycle arm (→ hair, immunity, blood, cancer)

Verbatim, PMID:31551465:

"Transcriptome analysis identified 35 significantly upregulated and 130 downregulated genes in CHH fibroblasts. The downregulated genes were significantly connected to the cell cycle. Multiple other pathways, involving regulation of apoptosis, bone and cartilage formation, and lymphocyte function, were also affected, as well as PI3K-Akt signaling. Cell-cycle studies indicated that the CHH cells were delayed specifically in the passage from G2 phase to mitosis."

Chain: RMRP lesion → impaired cyclin B1/B2 mRNA cleavage → dysregulated mitotic cyclin turnover → G2→M transition delay → reduced proliferative output in high-turnover lineages (T cells, erythroid progenitors, hair follicle matrix keratinocytes) → combined immunodeficiency + macrocytic anemia + hypotrichosis.

Hermanns adds a transcriptional flavor: upregulation of cytokine and cell-cycle genes, linking altered ribosomal processing to "modified cytokine signaling and cell cycle progression in lymphocytic and chondrocytic lineages" (paraphrase — re-fetch).

Arm C — telomere maintenance (→ immune senescence, cancer)

Verbatim, PMID:28126377:

"Lymphocyte cultures from patients with CHH display growth defects in vitro, which is consistent with an immune deficiency cellular phenotype. Here we show that telomere length and telomerase activity are impaired in primary lymphocyte subsets from patients with CHH. Notably, telomerase activity is affected in a gene dose-dependent manner when comparing heterozygote RMRP carriers with patients with CHH. Telomerase deficiency in patients with CHH is not mediated by abnormal telomerase gene transcript levels relative to those of endogenous genes."

That last sentence is a genuinely nice piece of negative evidence — the telomerase defect is post-transcriptional, which rules out the simplest explanation. The mechanism remains unidentified ("through an as yet unidentified mechanism") — perfect KNOWLEDGE_GAP material.

Note the phenotypic overlap with dyskeratosis congenita this creates. Worth a differential_diagnosis entry.

Arm D — small-RNA gene silencing (→ tissue-specific programs)

Rogler 2014 (PMID:24009312, paraphrase — re-fetch): RMRP yields RMRP-S1/S2, which are significantly reduced in CHH patient fibroblasts and a CHH B-cell line. Over 900 genes were regulated (~75% down), with pathway enrichment in skeletal development, hair development, and hematopoietic differentiation, naming PTCH2 (hedgehog) and SOX4. This is the most direct mechanistic bridge to the hair phenotype specifically, which the ribosome arm alone doesn't explain well.

Arm E — Wnt/β-catenin in cartilage (from the zebrafish)

Verbatim, PMID:31237961:

"We found that rmrp is required for the patterning and shaping of pharyngeal arches. Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis. Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell-cycle- and apoptosis-related genes. We also demonstrate that rmrp mutation upregulates canonical Wnt/β-catenin signaling; the pharmacological inhibition of Wnt/β-catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants."

The pharmacological rescue is the payload — it identifies Wnt/β-catenin as a druggable node. Tag evidence_source: MODEL_ORGANISM and, per dismech policy, don't let it stand alone for a human phenotype.

Complementary chondrocyte work: RMRP expression is dynamically regulated during chondrocyte hypertrophy and determines chondrogenic differentiation (PMID:28743979); CHH fibroblast chondrogenic-differentiation pathway analysis in PMID:34988338.

Cellular / molecular annotations

Suggested GO biological processes (all VERIFY): - rRNA processing — GO:0006364 - maturation of 5.8S rRNA — GO:0000460 VERIFY - ribosome biogenesis — GO:0042254 - mRNA cleavage — GO:0006379 VERIFY - G2/M transition of mitotic cell cycle — GO:0000086 - regulation of cell cycle — GO:0051726 - telomere maintenance via telomerase — GO:0007004 - canonical Wnt signaling pathway — GO:0060070 (modifier: INCREASED per the zebrafish) - endochondral ossification — GO:0001958 - chondrocyte differentiation — GO:0002062 - T cell activation — GO:0042110 (modifier: DECREASED) - mitochondrial DNA replication — GO:0006264 - gene silencing by miRNA — GO:0035195

Suggested GO molecular functions: - ribonuclease activity / endoribonuclease activity — GO:0004521 / GO:0004519

Suggested GO cellular components: - nucleolus — GO:0005730 (primary site of RNase MRP action) - mitochondrion — GO:0005739 - cytosolic ribosome — GO:0022626

Suggested CL cell types (VERIFY): - chondrocyte — CL:0000138 - growth plate chondrocyte / hypertrophic chondrocyte — VERIFY - T cell — CL:0000084; CD8-positive alpha-beta T cell — CL:0000625 - erythroid progenitor cell — CL:0000038 VERIFY - hair follicle keratinocyte / matrix cell — VERIFY - fibroblast — CL:0000057 (the workhorse of the in-vitro literature) - enteric neuron / neural crest cell — CL:0007011 VERIFY (for the Hirschsprung branch)

Molecular profiling summary

Transcriptomics: yes — CHH fibroblast RNA-seq, 35 up / 130 down, cell cycle + PI3K-Akt (PMID:31551465). Rogler's >900 small-RNA-regulated genes (PMID:24009312). Hermanns' cytokine/cell-cycle upregulation (PMID:16254002).
Proteomics: none CHH-specific found.
Metabolomics / lipidomics: none found. Not available.
Single-cell / spatial: none found. Not available — and a legitimate gap given the tissue-specific ribosome-ratio finding practically begs for it.
Functional genomics: CRISPR disruption of RMRP in human cell lines → growth arrest with pre-rRNA accumulation (PMID:35115551); targeted CRISPR disruption revealing a role for RNase MRP RNA (Goldfarb & Cech, PMID:28115465).

7. Anatomical Structures Affected

Primary organs / systems:

Structure	Suggested UBERON	Involvement
Long bone metaphysis	UBERON:0002225 (bone metaphysis) VERIFY	Primary — femur, tibia especially
Epiphyseal/growth plate cartilage	UBERON:0006255? VERIFY (epiphyseal plate)	Primary lesion site
Femur / tibia	UBERON:0000981 / UBERON:0000979	Bowing, varus
Vertebral column	UBERON:0000955? no — UBERON:0002240 (spinal cord) is wrong; use UBERON:0000956? VERIFY — want vertebral column UBERON:0002412	Lordosis, scoliosis; AD cervical instability
Hair follicle	UBERON:0002073	Hypoplastic
Thymus / T-cell compartment	UBERON:0002370	Impaired T-cell output
Bone marrow	UBERON:0002371	Macrocytic anemia, neutropenia
Lung / bronchus	UBERON:0002048 / UBERON:0002185	Secondary — bronchiectasis
Large intestine / colon	UBERON:0001155	Hirschsprung (aganglionic segment)
Enteric nervous system	UBERON:0002005 VERIFY	Absent ganglion cells
Testis / ovary	UBERON:0000473 / UBERON:0000992	Impaired spermatogenesis; hypogonadism
Skin	UBERON:0002097	BCC/SCC; granulomas; neonatal erythroderma
Mandible / maxilla / clivus	UBERON:0001684 / UBERON:0002397 / VERIFY	Shortened (PMID:34956076)

Body systems: skeletal, immune, hematopoietic, integumentary, gastrointestinal, respiratory (secondary), reproductive.

Subcellular: nucleolus (GO:0005730) is the star — that's where the ribosome-biogenesis lesion lives. Mitochondrion (GO:0005739) for the mtDNA primer function. Cytosolic ribosome (GO:0022626) for the depleted product.

Lateralization: bilateral and symmetric throughout. Metaphyseal changes, bowing, and hair involvement are symmetric. Asymmetry should prompt reconsideration of the diagnosis.

8. Temporal Development

Onset: congenital. Short limbs are recognizable at birth and increasingly prenatally — there's now a whole small literature on it (PMID:41525162 narrative review of prenatal diagnosis; PMID:41720498 familial prenatal ultrasound; PMID:33567347 early prenatal presentation of the CHH/AD spectrum). GeneReviews notes ultrasound may detect severe cases at 16–18 weeks. Suggested onset_category: CONGENITAL_ONSET (with ANTENATAL_ONSET for the severe end).

Course by domain — and they diverge, which is the key structural point:

Domain	Course
Growth	Progressive deceleration through the first 2 years, then proportionate tracking with a weak/absent pubertal spurt. Final height reached in adolescence.
Immunodeficiency	Variable and often progressive. 22% progressed over follow-up; adult-onset immunodeficiency documented in 6 patients (PMID:31379817). Not a static congenital deficit.
Anemia	Usually remitting — mild macrocytic anemia typically resolves during childhood. ~6% persist severely.
Infections	Peak burden in infancy and childhood (35–65%), then generally decreasing.
Bronchiectasis	Prevalence high (29–52%) but progression is slow or absent — see below.
Malignancy	Late and progressive risk — cumulative, rising with age (41% by age 65).
Autoimmunity	Adult-onset and mortality-associated.

That bronchiectasis finding deserves its own mention because it overturned an assumption (verbatim, PMID:33675005):

"We determined the rate and correlates of progression of structural lung changes in a prospectively followed cohort of 16 patients with cartilage-hair hypoplasia. ... Imaging findings remained identical or improved due to disappearance of inflammatory changes in all evaluated patients. ... In conclusion, our results suggest slow if any development of bronchiectasis in selected subjects with cartilage-hair hypoplasia."

Disease duration: chronic, lifelong. No spontaneous remission of the underlying disorder. The only "remission" available is treatment-induced — HSCT resets the immune and hematologic arms (and only those arms).

Critical intervention windows: 1. Newborn screening period — TREC-based SCID screening can catch the severe end before first infection (PMID:41831046, PMID:41727503). 2. Before major organ damage — Bordon's central argument: transplant "before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome." 3. Late childhood/adolescence — timing for corrective osteotomy. 4. Lifelong — malignancy surveillance never stops, because 8 of 15 non-skin cancers occurred in patients with no preceding clinical immunodeficiency symptoms.

9. Inheritance and Population

Epidemiology

Population	Figure	Source
Finland	Incidence 1:23,000; carrier frequency 1:76	GeneReviews (PMID:22420014)
Old Order Amish	Prevalence 1–2:1,000; carrier frequency 1:10	GeneReviews
Global	~700 individuals documented in the literature	GeneReviews
Anauxetic dysplasia	<10 reported cases	GeneReviews

For a dismech prevalence block, normalizing: Finland 1:23,000 → rate_per_100000 ≈ 4.3, measure_type: ANNUAL_INCIDENCE (it's stated as incidence), prevalence_class: BAND_1_9_PER_100000. Amish 1–2:1,000 → rate_per_100000 = 100–200, prevalence_class: ABOVE_1_IN_1000. Global rarity elsewhere: ULTRA_RARE. Note these are wildly different populations — do not collapse them into one record.

Inheritance

Autosomal recessive, HP:0000007. Recurrence risk 25% affected / 50% carrier / 25% unaffected non-carrier per pregnancy.
Penetrance: essentially complete for the skeletal phenotype. Markedly incomplete/variable for the extraskeletal features — 57% of the Finnish cohort never manifested clinical immunodeficiency. This is the single most important counseling nuance in the disease.
Expressivity: highly variable, including intrafamilial variability among identical genotypes (PMID:18804272).
Anticipation: not applicable — no repeat expansion.
Germline mosaicism: not reported.
Founder effects: yes, prominently — Amish, Finnish, and Brazilian (n.197C>T, PMID:38862721). The 71A>G allele traces to an ancient shared founder haplotype.
Consanguinity: contributory in non-founder populations (Turkish, Pakistani, Moroccan case reports). PMID:27740950 documents the Finnish founder allele appearing in a Pakistani family — nice illustration that "founder" ≠ "confined to that population."

Demographics

Ethnic distribution: highest in Old Order Amish and Finns; described worldwide (Brazil, Turkey, Korea, Japan, Italy, Spain, Pakistan, India). First Korean cases reported only in 2024 (PMID:38787970) — ascertainment, not absence.
Sex ratio: ~1:1, as expected for autosomal recessive. No reported skew. (Sex-specific manifestations differ — spermatogenic failure vs. hypogonadism — but incidence does not.)
Age distribution: diagnosed in infancy/early childhood classically; increasingly prenatally; and mild cases can be diagnosed late — PMID:28094436 reports CHH with normal height in childhood, and PMID:31413121 reports MDWH presenting with late-onset manifestations. Median age in the Finnish adult cohort was 39.2 years, with a range to 73.6 — people do reach old age with this.

10. Diagnostics

The one thing that matters most

RMRP is non-coding, so exome sequencing does not cover it. A negative WES does not exclude CHH. This is the most consequential practical fact in the whole diagnostic section, and it should be prominent in the entry (a definitions note or a notes: line on the genetic block).

Diagnostic pathway

Clinical + radiographic suspicion: short-limb disproportionate short stature; metaphyseal dysplasia on skeletal survey; bowed femora/tibiae; bullet-shaped middle phalanges; joint hypermobility with limited elbow extension; fine silky hair; ± infections, anemia, GI dysfunction.
Confirmatory: direct Sanger sequencing of RMRP (including the promoter — don't sequence only the transcribed region, or you'll miss the promoter duplication class). Detects ~100% of variants. Deletion/duplication analysis as a low-yield adjunct.
Panel testing: skeletal dysplasia panels and IEI panels that explicitly include the RMRP locus. Check the panel design.
WGS: works (covers non-coding regions) where WES does not.
Karyotype/CMA/FISH/mtDNA/repeat testing: not indicated.

Laboratory / immunologic workup

CBC with indices — macrocytic anemia (↑MCV), neutropenia, lymphopenia
Lymphocyte subsets — CD3/CD4/CD8 (CD8 lymphocytopenia is the Kavadas signature), naive vs memory
TRECs — newborn SCID screening detects the severe end
Lymphocyte proliferation to mitogens/antigens
Immunoglobulins IgG/IgA/IgM/IgE — note the association of high IgE and/or undetectable IgA with autoimmunity and mortality (PMID:30410491); low IgM associated with subtle bronchiectasis (PMID:33675005)
Vaccine antibody titers
Autoantibody panel — with the caveat that positivity often has no clinical correlate (PMID:28631025)
Erythrocyte adenosine deaminase — normal in CHH; historically used to separate it from DBA (PMID:1151542, PMID:23252420)

Imaging

Skeletal survey (diagnostic)
Lower-limb alignment films (surgical planning)
Cervical spine films — mandatory in AD, annual; lower yield in classic CHH
Chest HRCT or MRI for bronchiectasis. Vakkilainen's imaging study supports MRI and argues against frequent repeat imaging given the slow progression — a radiation-sparing point worth curating.
Abdominal ultrasound every 1–2 years in children for malignancy surveillance

Histopathology

Growth plate: hypoplastic, disorganized chondrocyte columns, reduced proliferative zone
Hair shaft: reduced diameter, absent/small pigment core
Rectal suction biopsy: absent ganglion cells in the Hirschsprung subset
Skin/nodes: granulomas, lymphomatoid granulomatosis in a subset

Differential diagnosis

Condition	Gene	Discriminator
Schmid metaphyseal chondrodysplasia	COL10A1	No extraskeletal features at all — no hair, immune, or anemia involvement
Shwachman-Diamond syndrome	SBDS	Pancreatic exocrine insufficiency + neutropenia dominate; milder skeletal disease
Diamond-Blackfan anemia	ribosomal proteins	Severe anemia dominates; normal erythrocyte ADA in CHH, elevated in DBA
Omenn syndrome	RAG1/2 etc.	Ichthyosiform erythroderma, septicemia, more acutely severe (and note CHH itself can present with neonatal erythroderma — real overlap)
Schimke immuno-osseous dysplasia	SMARCAL1	Nephropathy, spondyloepiphyseal (not metaphyseal) dysplasia, hyperpigmented macules (PMID:18627050)
Dyskeratosis congenita	DKC1, TERT etc.	Overlapping telomere biology, but nail dystrophy/leukoplakia/reticular pigmentation
Anauxetic dysplasia 2	POP1	Skeletal phenotype without clinical immunodeficiency (reduced lymphocyte proliferation on labs only)
Anauxetic dysplasia 3	NEPRO	Sparse hair but no immunodeficiency
EXTL3-related	EXTL3	Spondyloepimetaphyseal dysplasia + developmental delay + liver cysts

Screening

Newborn SCID/TREC screening — catches severe CHH, and GeneReviews notes it may carry prognostic information. Multiple recent papers put CHH in the syndromic-IEI-detected-by-TREC bucket (PMID:41831046, PMID:41727503).
Carrier screening — high value in Amish and Finnish populations given 1:10 and 1:76 carrier frequencies.
Cascade testing of at-risk relatives once family variants are known.
Prenatal / PGT — available once the familial variants are identified; ultrasound detects severe cases from 16–18 weeks.

11. Outcome / Prognosis

Mortality — the headline numbers

From verbatim PMID:31379817, the 30-year Finnish prospective cohort (n=80):

"Altogether 20 patients had deceased (SMR = 7.0, 95%CI = 4.3-11); most commonly from malignancy (n = 7, SMR = 10, 95%CI = 4.1-21) and lung disease (n = 4, SMR = 46, 95%CI = 9.5-130)."

So: overall standardized mortality ratio 7.0 against the Finnish national rate. Lung disease carries an SMR of 46 — the highest single ratio in the study, and the reason pulmonary follow-up gets its own literature.

Validated risk factors for early death (same source, verbatim):

"Mortality associated with birth length below -4 standard deviation (compared to normal, SMR/SMR ratio = 5.4, 95%CI = 1.5-20), symptoms of combined immunodeficiency (compared to asymptomatic, SMR/SMR ratio = 3.9, 95%CI = 1.3-11), Hirschsprung disease (odds ratio (OR) 7.2, 95%CI = 1.04-55), pneumonia in the first year of life or recurrently in adulthood (OR = 7.6/19, 95%CI = 1.3-43/2.6-140) and autoimmunity in adulthood (OR = 39, 95%CI = 3.5-430)."

These were subsequently validated in an independent analysis (PMID:38676846) — and separately, shorter birth length plus decreased T-cell production/function predicted severe infections in non-SCID CHH children (PMID:38187867). Birth length below −4 SD is a beautifully simple, universally measured prognostic marker; it deserves to be a first-class item in the entry.

The paper's own conclusion is the clinical takeaway (verbatim):

"In conclusion, patients with CHH may develop adult-onset immunodeficiency or malignancy without preceding clinical symptoms of immune defect, warranting careful follow-up."

Malignancy

Taskinen 2008 (PMID:18698627, n=123 Finnish patients, 2,365 person-years — paraphrase, re-fetch before quoting): 14 cancers observed vs. 2 expected. Non-Hodgkin lymphoma most frequent (n=9), SIR 90.2 (CI 39.0–180). Conclusion: significantly increased risk of NHL and basal cell carcinoma at early age, with poor overall prognosis.

GeneReviews adds: ~11% developed malignancy over 39-year follow-up (14/123); Kaplan-Meier estimate 41% probability by age 65; commonest are NHL, squamous cell carcinoma, and leukemia; median survival after cancer diagnosis: 3 months (9 of 14 died). A separate series of 16 CHH lymphoma patients: DLBCL predominant, 69% mortality (11/16).

An SIR of 90 for NHL is one of the highest in any inherited condition. This should be a prominent, well-evidenced node.

The countercurrent worth curating: PMID:41460196 reports two CHH-AD siblings with relapsed/refractory EBV-positive Hodgkin lymphoma achieving durable (30-month) remission with gemcitabine/vinorelbine + brentuximab vedotin without transplant — evidence that targeted consolidation may change this grim picture.

Morbidity and function

Adult height 122–131 cm median with associated accessibility burden
~43% undergo lower-limb realignment surgery
Bronchiectasis in 29–52%, though slowly progressive
Chronic diarrhea in 31%
Subfertility in both sexes
Recurrent infection burden in the symptomatic 43%

Formal QoL instrument data: not available. Flag as a gap.

Prognostic factors — summary table

Factor	Direction	Evidence
Birth length < −4 SD	↑ mortality (SMR ratio 5.4)	PMID:31379817
Symptomatic combined immunodeficiency	↑ mortality (SMR ratio 3.9)	PMID:31379817
Hirschsprung disease	↑ mortality (OR 7.2)	PMID:31379817
Pneumonia, first year of life	↑ mortality (OR 7.6)	PMID:31379817
Recurrent pneumonia in adulthood	↑ mortality (OR 19)	PMID:31379817
Adult autoimmunity	↑ mortality (OR 39)	PMID:31379817, PMID:30410491
Undetectable IgA and/or high IgE	↑ autoimmunity, ↑ mortality	PMID:30410491
Decreased T-cell production/function	↑ severe infection	PMID:38187867
Malignancy (esp. NHL)	catastrophic — median 3 mo survival	GeneReviews / PMID:18698627
Asymptomatic status at follow-up (57%)	favorable — but not protective against later cancer	PMID:31379817

That last row matters: 8 of 15 patients with non-skin cancer had no preceding clinical immunodeficiency symptoms. Being asymptomatic does not earn you a pass on surveillance.

12. Treatment

No disease-modifying therapy exists. Management is complication-directed, with one curative option that fixes exactly half the disease.

Hematopoietic stem cell transplantation

The only curative option for the immune and hematologic arms. It does not correct growth failure. Bordon 2010 (verbatim, PMID:20375313):

"Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected. ... we performed a European collaborative survey reporting on 16 patients with CHH and immunodeficiency who underwent HSCT. Immune dysregulation, lymphoid malignancy, and autoimmunity were important features in this cohort. Thirteen patients were transplanted in early childhood (approximately 2.5 years). The other 3 patients were transplanted at adolescent age. Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years. T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors. HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients."

GeneReviews puts overall survival at 63–80% and notes normalization of T cells, resolution of autoimmunity, and catch-up growth in some series — worth flagging as a discrepancy with Bordon's "growth failure remains unaffected." Curate the discrepancy honestly rather than picking a side; it might be a KNOWLEDGE_GAP or a real difference in conditioning era.

Suggested annotation: treatment_term NCIT:C15431 (Hematopoietic Cell Transplantation) verify; therapeutic_modality: CELL_THERAPY (per the CLAUDE.md mechanical-backfill table, C15431 → CELL_THERAPY); target_mechanisms pointing at the immunodeficiency and anemia nodes with treatment_effect set appropriately.

Immunologic / infectious management

Intervention	Detail	Suggested NCIT
Immunoglobulin replacement	For documented hypogammaglobulinemia / impaired specific antibody	NCIT:C15986 Pharmacotherapy + agent verify
Antibiotic prophylaxis	For recurrent infections	NCIT:C15986
High-dose IV acyclovir	Immediately on varicella exposure/infection — potentially life-saving	NCIT:C15986 + CHEBI:2453 (aciclovir) verify
Airway clearance physiotherapy	Bronchiectasis, per pulmonologist	NCIT:C15302 Physical Therapy → `BEHAVIORAL`
Anti-TNF-α therapy	For granulomas — carries a rare fatal PML risk, per GeneReviews	NCIT:C15986 + NCIT:C20401 Monoclonal Antibody

Hematologic

Red cell transfusion with iron chelation for severe persistent anemia
HSCT for transfusion-dependent anemia (rarely needed)

Skeletal / orthopaedic

Corrective osteotomy for varus deformity — late childhood/adolescence; 43% of patients, mean age ~11.7–14.5 years (PMID:25764362). NCIT:C16186 Orthopedic Surgical Procedure → SURGERY.
Scoliosis: observation → bracing → fusion by curve magnitude
AD-specific: cervical fusion for atlantoaxial instability; special anaesthetic precautions for airway/neck manipulation; kyphoscoliosis surgery if lung function is compromised
Growth hormone: not recommended — no sustained benefit (GeneReviews). Curate this as an explicit negative treatment recommendation; it's the kind of thing families ask about.

Gastrointestinal

Surgical management of Hirschsprung disease (pull-through). Note the poor prognosis association (PMID:11391344) — HSCR in CHH is a mortality marker, not just a surgical problem.

Endocrine / reproductive

Hormonal induction of puberty where indicated
Fertility counseling for both sexes

Malignancy

Standard protocols; NHL carries poor prognosis with conventional cytotoxic regimens
Emerging: brentuximab vedotin + gemcitabine/vinorelbine achieved 30-month HSCT-free remission in refractory Hodgkin lymphoma in CHH-AD (PMID:41460196)
Caution warranted with cytotoxic intensity given the underlying proliferation defect and marrow reserve — inferred, not directly evidenced

Pharmacogenomics

No CHH-specific pharmacogenomic data found. Not available.

Experimental / future directions

Wnt/β-catenin inhibition — pharmacological inhibition partially rescued chondrodysplasia and vertebral mineralization in the zebrafish model (PMID:31237961). The only mechanism-directed lead with in-vivo rescue data. Preclinical only.
PI3K-Akt — flagged as affected in CHH fibroblast transcriptomics (PMID:31551465); the authors explicitly note the findings "indicate possible pathways for therapeutic intervention."
L-leucine / mTOR activation — established as a ribosomopathy strategy in DBA and del(5q) MDS (PMID:22734070). Not tested in CHH. Speculative, but a defensible proposed_experiments item.
RNA-based replacement/correction — conceptually attractive for a single non-coding RNA gene. No published program found.
ClinicalTrials.gov: the only CHH trial I identified is NCT02383797, the live VZV vaccine safety trial (5 subjects) in PMID:32849667. Worth a clinical_trials entry with phase as an enum value and target phenotypes bound to HP terms.

13. Prevention

Primary prevention of the disease itself isn't possible — it's a congenital genetic disorder. What's available:

Genetic counseling (NCIT:C15240 Genetic Counseling → the entry's treatments or a prevention block): 25% recurrence risk; carrier testing for relatives; special weight in Amish and Finnish communities where carrier frequency is 1:10 and 1:76.
Carrier screening in founder populations.
Prenatal diagnosis / PGT once familial variants are known; ultrasound from 16–18 weeks for severe phenotypes.

Secondary prevention (early detection):

Newborn TREC/SCID screening — identifies the severe immunodeficient end pre-symptomatically.
Immune function testing at diagnosis in every patient, including the asymptomatic — because 57% look fine and 22% will progress.

Tertiary prevention (complication avoidance) — this is where most of the value is:

GeneReviews' surveillance schedule, which maps cleanly onto a dismech management block:

Domain	Frequency
Growth (CHH-specific curves)	Annually through childhood
Immune function	At diagnosis; interval by initial result
Joints and spine (clinical + radiographic)	Annually in childhood
Spine radiographs (AD)	Annually
Respiratory assessment	By infection frequency; HRCT/MRI if bronchiectasis suspected
CBC (if prior anemia)	Annually
Malignancy screening — exam, CBC, LDH, uric acid	Annually
Abdominal ultrasound (children)	Every 1–2 years
Pubertal assessment	Annually through adolescence

Plus: immediate high-dose IV acyclovir on varicella exposure — the single highest-yield prophylactic rule in the disease.

Immunization — the nuanced one

Default: live vaccines contraindicated in SCID; inactivated vaccines safe and encouraged. But Vakkilainen 2020 (verbatim, PMID:32849667) genuinely moved this:

"A large proportion of patients have been immunized with live viral vaccines, including measles-mumps-rubella (MMR) (n = 40, 38%) and VZV (n = 10, 10%) vaccines, with no serious adverse events. ... Patients with CHH demonstrated seropositivity rates of 96%/75%/91% to measles, mumps and rubella, respectively, measured at a medium of 24 years post-immunization. Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment. Conclusion: No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines. Immunization with live vaccines may be considered in selected CHH patients with no or clinically mild immunodeficiency."

Curate that as a conditional recommendation gated on immune phenotype, not a blanket one. And keep the historical vaccine-associated poliomyelitis case (PMID:165279) as the counterweight — it's why the rule existed.

Public health / environmental interventions: not applicable beyond general infection control and, plausibly, sun protection given the BCC/SCC excess (inferred).

14. Other Species / Natural Disease

Thin section, and honestly interesting for what's absent.

Taxonomy: human — NCBITaxon:9606. No naturally occurring CHH homolog reported in companion animals or wildlife.
OMIA: I found no OMIA entry for an RMRP disorder in any species. Not available.
Breed (VBO): not applicable.
Orthologs: RMRP is conserved across eukaryotes — RNase MRP is present in yeast (NME1), where it's essential. Mouse Rmrp, zebrafish rmrp. The yeast work is where the ITS1/A3 cleavage function was originally defined, and Hermanns 2005 used yeast to show the 70A>G allele shifts 5.8S rRNA ratios. That's a genuinely useful piece of evolutionary conservation evidence — the disease-causing base change breaks the enzyme the same way a billion years of divergence apart.
Zoonotic potential / cross-species transmission: not applicable (genetic disorder).
Comparative biology: the deep conservation of RNase MRP's rRNA-processing role is the strongest cross-species claim available. The divergent bits — the miRNA-generating and telomerase-associating functions — appear more vertebrate/human-specific, which is worth noting as a limitation on how far yeast data can carry a human mechanistic claim.

15. Model Organisms

Zebrafish — the workhorse

rmrp knockout zebrafish (PMID:31237961) is the best-characterized whole-organism model, and the paper explicitly frames itself as filling a void: "there are no viable animal models for CHH."

Recapitulates: dysregulated chondrogenesis, abnormal endochondral ossification, inhibited intramembranous skull ossification, pharyngeal arch patterning defects, reduced proliferation, increased apoptosis, upregulated canonical Wnt/β-catenin.

Does not capture: hair (fish don't have any), the adaptive immune phenotype, anemia, Hirschsprung disease, malignancy predisposition. Also promotes vertebral ossification — a direction opposite to the general hypo-ossification story, which the authors themselves flag as variable.

Applications: skeletal development mechanism; and crucially it's the only system with a pharmacological rescue (Wnt inhibition), making it the natural platform for drug screening.

Suggested dismech shape: animal_models entry, species: Zebrafish, modeled_mechanisms with target: <chondrodysplasia node>, relationship: PARTIALLY_RECAPITULATES, fidelity: MODERATE, limitations naming the missing hair/immune/hematologic arms, and readouts for chondrogenesis and vertebral mineralization. The Wnt-inhibitor arm gets a RESTORED readout.

Mouse

No viable germline Rmrp knockout mouse exists — constitutive loss is presumed embryonic lethal (RNase MRP is essential). What does exist:

Mouse primary T cells carrying Rmrp mutations — Robertson 2022 (PMID:35115551) showed "mutations in RMRP impair mouse T cell activation and delay pre-rRNA processing." This is the model for the immune arm specifically.
Rogler 2014 (PMID:24009312) used transgenic/knockdown approaches for the small-RNA silencing work.

relationship: RECAPITULATES for the T-cell activation node only; fidelity: MODERATE; limitations: cell-level, not organismal; doesn't address skeletal or hair phenotype.

Human cellular models — the strongest evidence base

This is where CHH is actually best modeled, which makes sense for a disease this developmentally embedded.

System	Findings	PMID
Patient-derived fibroblasts	Delayed pre-rRNA processing; G2→M delay; 35 up/130 down transcriptome; reduced RMRP-S1/S2	35115551, 31551465, 24009312
*CRISPR RMRP* disruption, human cell lines**	Growth arrest with pre-rRNA accumulation	35115551, 28115465
Engineered 70AG human cells	Specifically impaired pre-rRNA processing; reduced mature rRNA; reduced cytosolic:mitochondrial ribosome ratio; reduced intact RNase MRP complexes	35115551
Patient B-cell line	Reduced RMRP-S1/S2	24009312
CHH patient lymphocyte cultures	In-vitro growth defect; short telomeres; reduced telomerase activity	28126377
CHH fibroblast chondrogenic differentiation	Pathway dissection of chondrogenesis	34988338
Chondrocyte hypertrophy models	RMRP expression dynamically regulated; determines chondrogenic differentiation	28743979
*Yeast (S. cerevisiae)*	70A>G alters 5.8S rRNA ratio	16254002

For dismech, most of these belong in experimental_models: (non-animal systems) with modeled_mechanisms links, per the CLAUDE.md distinction. The engineered 70AG human cell line is the single highest-fidelity model of the causal mechanism available and deserves fidelity: HIGH for the pre-rRNA processing node.

Notably absent: iPSC-derived chondrocytes or organoids from CHH patients; no CHH entry in DepMap-style functional-genomics resources beyond the CRISPR growth-arrest observation. Real opportunity, real gap.

Model limitations, collectively

Nothing available reproduces the full pleiotropy. The skeleton has a fish, the immune system has mouse T cells and human lymphocytes, the ribosome mechanism has engineered human cells — and nothing at all models the hair phenotype, the Hirschsprung association, or the lymphoma predisposition in vivo. If the entry carries a HUMAN_MODEL_MISMATCH discussion, that's the shape of it: the models are each faithful to one arm and blind to the others, so no single system can test a claim about the disease as a whole.

Suggested dismech pathograph skeleton

Sketching the node/edge structure since that's the actual deliverable target:

Biallelic RMRP loss-of-function                      [MOLECULAR]
  ├─▸ Reduced intact RNase MRP complex               [MOLECULAR]
  │     ├─▸ Impaired pre-rRNA ITS1 cleavage          [MOLECULAR]   ← Arm A
  │     │     └─▸ Reduced mature cytosolic rRNA / ribosome deficit [CELLULAR]
  │     │           ├─▸ Impaired chondrocyte proliferation [CELLULAR]
  │     │           │     └─▸ Metaphyseal dysplasia   [TISSUE]
  │     │           │           └─▸ Short-limb short stature [ORGANISM]
  │     │           └─▸ Impaired erythroid progenitor proliferation [CELLULAR]
  │     │                 └─▸ Macrocytic anemia       [ORGANISM]
  │     ├─▸ Impaired cyclin B1/B2 mRNA cleavage       [MOLECULAR]   ← Arm B
  │     │     └─▸ G2→M transition delay               [CELLULAR]
  │     │           ├─▸ Impaired T-cell proliferation/activation [CELLULAR]
  │     │           │     └─▸ Combined immunodeficiency [ORGANISM]
  │     │           │           ├─▸ Recurrent infection → bronchiectasis [TISSUE]
  │     │           │           └─▸ Immune dysregulation → autoimmunity [ORGANISM]
  │     │           └─▸ Impaired hair follicle keratinocyte proliferation [CELLULAR]
  │     │                 └─▸ Hypotrichosis           [ORGANISM]
  │     ├─▸ Impaired telomerase activity / telomere shortening [MOLECULAR] ← Arm C
  │     │     └─▸ Lymphocyte replicative exhaustion   [CELLULAR]
  │     └─▸ Reduced RMRP-S1/S2 small RNAs             [MOLECULAR]   ← Arm D
  │           └─▸ Dysregulated PTCH2/SOX4 developmental programs [CELLULAR]
  └─▸ (zebrafish) Upregulated canonical Wnt/β-catenin [CELLULAR]    ← Arm E

Combined immunodeficiency + telomere dysfunction ──▸ Lymphomagenesis (NHL) [ORGANISM]

Candidate module conformance: this entry is a natural conformer for a ribosomopathy module if one gets built (alongside Diamond-Blackfan, Shwachman-Diamond, Treacher Collins — note pharyngeal_arch_patterning_serial_homology already covers the TCOF1 ribosome-biogenesis→neural-crest route, and the zebrafish pharyngeal arch finding here is a suggestive but not sufficient link — don't wire it without evidence). Also plausibly myelosuppression-adjacent for the cytopenia arm, though that module is scoped to drug toxicity, so probably not.

Gaps and cautions for curation

Ontology IDs above are suggestions. Run just validate-terms before any of them land. I flagged the ones I'm least sure of; the vertebral-column and hair-follicle-keratinocyte ones especially.
Variant nomenclature is genuinely inconsistent across the literature (n.71A>G / g.70A>G / n.72A>G / c.70A>G for the same allele). Pick one canonical form, record aliases in notes:, and don't let two forms coexist in the entry as if they were different variants.
Most frequency figures come from GeneReviews prose, not from quotable abstract sentences. Per the frequency-evidence SOP, omit the band rather than attach a snippet that only supports the association.
The Finnish cohort dominates the quantitative literature. Prevalence, mortality, autoimmunity, and cancer figures are all Finnish-founder-population estimates. Say so in population: fields rather than presenting them as global.
Genuine knowledge gaps worth discussions entries: the mechanism of the telomerase defect ("as yet unidentified"); the absence of identified modifier genes despite documented intrafamilial variability; the HSCT-and-growth discrepancy between Bordon and GeneReviews; no QoL instrument data; no metabolomic/proteomic/single-cell data; no model of the hair, Hirschsprung, or lymphoma arms.
Don't conflate germline RMRP loss-of-function (this disease) with RMRP over-expression as an oncogenic lncRNA in sporadic cancers. Same gene, opposite direction, unrelated biology.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	63
Resolved	63
Unresolved (possible confabulation)	0
Unverifiable	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Cartilage-Hair Hypoplasia (CHH) — Comprehensive Research Report

0. Evidence-verification status (read this first)

1. Disease Information

Overview

Identifiers

Data provenance

2. Etiology

Primary cause

Genetic risk factors

Environmental risk factors

Protective factors

Gene–environment interaction

3. Phenotypes

Skeletal (near-universal)

Hair and skin

Immunologic

Immune dysregulation / autoimmunity / allergy

Hematologic

Gastrointestinal

Reproductive

Malignancy

Quality of life

4. Genetic/Molecular Information

The gene

Variant landscape

Genotype–phenotype correlation — the good bit

Modifier genes

Epigenetics

Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

The enzyme

Known catalytic functions (i.e. the fan-out)

Arm A — the ribosomopathy arm (→ skeleton, growth)

Arm B — the cell-cycle arm (→ hair, immunity, blood, cancer)

Arm C — telomere maintenance (→ immune senescence, cancer)

Arm D — small-RNA gene silencing (→ tissue-specific programs)

Arm E — Wnt/β-catenin in cartilage (from the zebrafish)

Cellular / molecular annotations

Molecular profiling summary

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

Epidemiology

Inheritance

Demographics

10. Diagnostics

The one thing that matters most

Diagnostic pathway

Laboratory / immunologic workup

Imaging

Histopathology

Differential diagnosis

Screening

11. Outcome / Prognosis

Mortality — the headline numbers

Malignancy

Morbidity and function

Prognostic factors — summary table

12. Treatment